Impax Laboratories (IPXL) 10-K 26 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 13, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	IMPAX LABORATORIES INC
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		71,330,034
Entity Public Float			$1,794,555,000
Amendment Flag	FALSE
Entity Central Index Key	1003642
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$214,873,000	$184,612,000
Short-term investments	199,983,000	228,521,000
Accounts receivable, net	146,490,000	112,993,000
Inventory, net	80,570,000	70,107,000
Deferred income taxes	54,825,000	50,788,000
Prepaid expenses and other current assets	33,710,000	12,721,000
Total current assets	730,451,000	659,742,000
Property, plant and equipment, net	188,169,000	188,191,000
Other assets	64,455,000	57,820,000
Deferred income taxes	41,837,000	33,926,000
Intangible assets, net	26,711,000	29,670,000
Goodwill	27,574,000	27,574,000
Total assets	1,079,197,000	996,923,000
Current liabilities:
Accounts payable	31,976,000	26,824,000
Accrued expenses	110,470,000	111,523,000
Accrued profit sharing and royalty expenses	15,346,000	11,560,000
Deferred revenue	907,000	3,983,000
Total current liabilities	158,699,000	153,890,000
Deferred revenue	3,403,000	4,267,000
Other liabilities	29,218,000	28,563,000
Total liabilities	191,320,000	186,720,000
Commitments and contingencies (Notes 18 and 19)
Stockholders’ equity:
Preferred Stock, $0.01 par value, 2,000,000 shares authorized, no shares outstanding at December 31, 2014 and 2013
Common stock, $0.01 par value, 90,000,000 shares authorized and 71,470,802 and 69,927,609 shares issued at December 31, 2014 and 2013, respectively	714,000	699,000
Additional paid-in capital	364,103,000	336,648,000
Treasury stock - 243,729 shares	-2,157,000	-2,157,000
Accumulated other comprehensive (loss) income	-6,009,000	1,140,000
Retained earnings	531,226,000	473,873,000
Total stockholders’ equity	887,877,000	810,203,000
Total liabilities and stockholders’ equity	$1,079,197,000	$996,923,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, par value (in Dollars per share)	$0.01	$0.01
Preferred Stock, shares authorized	2,000,000	2,000,000
Preferred Stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	71,470,802	69,927,609
Treasury stock, shares	243,729	243,729

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Revenues	$596,049,000	$511,502,000	$581,692,000
Cost of revenues	283,396,000	312,202,000	299,138,000
Gross profit	312,653,000	199,300,000	282,554,000
Operating expenses:
Research and development	79,114,000	68,854,000	81,320,000
Patent litigation	5,333,000	16,545,000	9,772,000
Selling, general and administrative	139,390,000	120,288,000	108,470,000
Total operating expenses	223,837,000	205,687,000	199,562,000
Income (loss) from operations	88,816,000	-6,387,000	82,992,000
Other income (expense), net	313,000	152,447,000	-138,000
Interest income	1,473,000	1,299,000	1,089,000
Interest expense	-43,000	-419,000	-632,000
Income before income taxes	90,559,000	146,940,000	83,311,000
Provision for income taxes	33,206,000	45,681,000	27,438,000
Net income	57,353,000	101,259,000	55,873,000
Net Income per share:
Basic (in Dollars per share)	$0.84	$1.51	$0.85
Diluted (in Dollars per share)	$0.81	$1.47	$0.82
Weighted average common shares outstanding:
Basic (in Shares)	68,185,552	66,921,181	65,660,271
Diluted (in Shares)	70,530,349	68,655,038	68,404,551
Global Division [Member]
Revenues:
Revenues	549,082,000	398,340,000	448,682,000
Cost of revenues	260,459,000	253,836,000	229,355,000
Operating expenses:
Research and development	40,927,000	41,384,000	48,604,000
Patent litigation	5,333,000	16,545,000	9,772,000
Selling, general and administrative	17,144,000	17,684,000	15,377,000
Income before income taxes	225,219,000	68,891,000	145,574,000
Impax Division [Member]
Revenues:
Revenues	46,967,000	113,162,000	133,010,000
Cost of revenues	22,937,000	58,366,000	69,783,000
Operating expenses:
Research and development	38,187,000	27,470,000	32,716,000
Selling, general and administrative	43,307,000	44,915,000	37,896,000
Income before income taxes	($57,464,000)	($17,589,000)	($7,385,000)

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net income	$57,353,000	$101,259,000	$55,873,000
Currency translation adjustments	-7,149,000	-4,104,000	3,520,000
Comprehensive income	$50,204,000	$97,155,000	$59,393,000

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Total
Balance at December 31 at Dec. 31, 2011	$667,000	$285,966,000	($2,157,000)	$1,724,000	$316,741,000	$602,941,000
Balance at December 31, Shares (in Shares) at Dec. 31, 2011	66,504,000
2012
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP	18,000	7,746,000				7,764,000
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP, Shares (in Shares)	1,768,000
Share-based compensation expense		16,303,000				16,303,000
Tax benefit related to exercise of stock options and restricted stock		4,702,000				4,702,000
Currency translation adjustments				3,520,000		3,520,000
Net income					55,873,000	55,873,000
Balance at December 31 at Dec. 31, 2012	685,000	314,717,000	-2,157,000	5,244,000	372,614,000	691,103,000
Balance at December 31, Shares (in Shares) at Dec. 31, 2012	68,272,000
2012
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP	14,000	3,538,000				3,552,000
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP, Shares (in Shares)	1,412,000
Share-based compensation expense		17,644,000				17,644,000
Tax benefit related to exercise of stock options and restricted stock		749,000				749,000
Currency translation adjustments				-4,104,000		-4,104,000
Net income					101,259,000	101,259,000
Balance at December 31 at Dec. 31, 2013	699,000	336,648,000	-2,157,000	1,140,000	473,873,000	810,203,000
Balance at December 31, Shares (in Shares) at Dec. 31, 2013	69,684,000
2012
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP	15,000	3,255,000				3,270,000
Exercise of stock options, issuance of restricted stock and sale of common stock under ESPP, Shares (in Shares)	1,544,000
Share-based compensation expense		20,883,000				20,883,000
Tax benefit related to exercise of stock options and restricted stock		3,317,000				3,317,000
Currency translation adjustments				-7,149,000		-7,149,000
Net income					57,353,000	57,353,000
Balance at December 31 at Dec. 31, 2014	$714,000	$364,103,000	($2,157,000)	($6,009,000)	$531,226,000	$887,877,000
Balance at December 31, Shares (in Shares) at Dec. 31, 2014	71,228,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$57,353	$101,259	$55,873
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	34,026	36,006	77,934
Intangible asset impairment	2,876	13,906
Provision for inventory reserves	7,964	12,476	-372
In-process research and development charge	2,000		1,550
Accretion of interest income on short-term investments	-774	-659	-639
Deferred income taxes – net and uncertain tax positions	-11,810	-21,132	-23,561
Tax benefit related to the exercise of employee stock options	-3,317	-749	-4,702
Deferred revenue			2,278
Deferred product manufacturing costs			-2,823
Recognition of deferred revenue	-3,939	-4,390	-29,099
Amortization of deferred product manufacturing costs			11,669
Accrued profit sharing and royalty expense	52,208	61,118	72,106
Payments of profit sharing and royalty expense	-48,422	-54,494	-107,935
Share-based compensation expense	20,883	17,644	16,303
Changes in certain assets and liabilities:
Accounts receivable	-33,497	-20,744	61,524
Inventory	-24,302	7,095	-33,692
Prepaid expenses and other assets	-9,952	-7,646	-22,301
Accounts payable and accrued expenses	-8,980	4,698	28,462
Other liabilities	500	5,552	3,254
Net cash provided by operating activities	32,817	149,940	105,829
Cash flows from investing activities:
Purchase of short-term investments	-366,092	-357,092	-210,688
Maturities of short-term investments	395,404	285,986	296,566
Purchases of property, plant and equipment	-29,913	-32,785	-66,900
Payments for product licensing rights, net	-13,000	-12,000	-104,760
Investment in cash surrender value of insurance	-3,000
Net cash used in investing activities	-16,601	-115,891	-85,782
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP	11,097	8,213	12,614
Tax benefit related to the exercise of employee stock options and restricted stock	3,317	749	4,702
Net cash provided by financing activities	14,414	8,962	17,316
Effect of exchange rate changes on cash and cash equivalents	-369	-561	380
Net increase in cash and cash equivalents	30,261	42,450	37,743
Cash and cash equivalents, beginning of year	184,612	142,162	104,419
Cash and cash equivalents, end of year	$214,873	$184,612	$142,162

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Supplemental disclosure of non-cash investing and financing activities:
		Years Ended December 31,
		2014		2013		2012
	(in $000s)
	Cash paid for interest	$	17	$	89	$	546
	Cash paid for income taxes, net	$	72,174	$	34,272	$	55,356
	Unpaid vendor invoices of approximately $1,932,000, $6,210,000 and $10,017,000 which were accrued as of December 31, 2014, 2013 and 2012, respectively, are excluded from the purchase of property, plant, and equipment and the change in accounts payable and accrued expenses.

Note_1_The_Company

Note 1 - The Company	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. THE COMPANY
	Impax Laboratories, Inc. (“Impax” or “Company”) is a technology-based, specialty pharmaceutical company. The Company has two reportable segments, referred to as the Global Pharmaceuticals Division (“Global Division”) and the Impax Pharmaceuticals Division (“Impax Division”).
	The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products primarily through four sales channels: the “Global products” sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the “Private Label” sales channel, for generic pharmaceutical over-the-counter (“OTC”) and prescription products the Company sells to unrelated third-party customers who in-turn sell the product under their own label; the “Rx Partner” sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under their own label pursuant to alliance and collaboration agreements; and the “OTC Partner” sales channel, for generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under their own label pursuant to alliance, collaboration and supply agreements. Revenues from the “Global Products” sales channel and the “Private Label” sales channel are reported under the caption “Global Product sales, net” in “Note 20 - Supplementary Financial Information.” The Company also generates revenue from research and development services provided under a joint development agreement with an unrelated third party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 20 - Supplementary Financial Information.” The Company provides these services through the research and development group in the Global Division.
	The Impax Division is engaged in the development of proprietary brand pharmaceutical products through improvements to already-approved pharmaceutical products to address central nervous system (“CNS”) disorders. The Impax Division currently has one internally developed branded pharmaceutical product, RYTARY™ (IPX066), an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015. The Company currently plans to fully launch its sales and marketing efforts for the product in early April 2015. The Impax Division is also currently engaged, through its specialty direct sales force, in the product sales and promotion of Zomig® (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations pursuant to the terms of a Distribution, License, Development and Supply Agreement (the “AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”). The Impax Division has a number of product candidates that are in varying stages of development. Additionally, the Company generates revenue in the Impax Division from research and development services provided under a development and license agreement with another unrelated third-party pharmaceutical company.
	In California, the Company utilizes a combination of owned and leased facilities mainly located in Hayward. The Company’s primary properties in California consist of a leased office building used as the Company’s corporate headquarters, in addition to five properties it owns, including a research and development center facility and a manufacturing facility. Additionally, the Company leases three facilities in Hayward, utilized for additional research and development, administrative services, equipment storage and quality assurance support. In Pennsylvania, the Company owns a packaging, warehousing, and distribution center located in Philadelphia and leases a facility in New Britain used for sales and marketing, finance, and administrative personnel, as well as used for additional warehouse space. Outside the United States, in Taiwan, R.O.C., the Company owns a manufacturing facility and leases an office in the Netherlands.
	CEO transition
	On June 25, 2013, the Company announced that Dr. Larry Hsu planned to retire as President and Chief Executive Officer of Impax and on April 21, 2014, Dr. Hsu retired from those positions at Impax. Dr. Hsu currently remains as a member of the Board of Directors. In connection with his retirement, Dr. Hsu entered into a Separation Agreement with the Company dated June 24, 2013 (the “Separation Agreement”). Pursuant to the Separation Agreement, the Company provided Dr. Hsu with certain termination benefits and payments. The Company recorded $5.0 million in costs associated with Dr. Hsu’s retirement in the three month period ended June 30, 2013, comprised of $2.7 million of separation pay and benefits and $2.3 million of accelerated expense related to Dr. Hsu’s outstanding stock options and restricted stock. Refer to “Note 14 – Share-based Compensation” for more information on the acceleration of Dr. Hsu’s equity awards.
	On April 21, 2014, the board of directors of the Company announced that it had appointed Fred Wilkinson as the Company’s new President and Chief Executive Officer effective as of April 29, 2014. Mr. Wilkinson succeeds Larry Hsu, Ph.D. who retired from his positions as President and Chief Executive Officer of the Company. In connection with Mr. Wilkinson’s appointment, Mr. Wilkinson and the Company entered into an Employment Agreement dated April 21, 2014 (the “Employment Agreement”). The Company will provide certain compensation and benefits as set forth in the Employment Agreement.
	Management changes
	During the three month period ended March 31, 2014, the Company announced a management change. The Company’s then Senior Vice President, Global Operations announced plans to retire and a Senior Vice President, Technical Operations was appointed. The Company’s then Senior Vice President, Global Operations subsequently retired from the Company in July 2014. In conjunction with the transition, the Company recorded $0.9 million in separation charges and accelerated share-based compensation expense in the six month period ended June 30, 2014.
	On October 22, 2014, the Company announced that Carole S. Ben-Maimon, M.D., President of the Company’s Global Pharmaceuticals Division, informed the Company of her decision to retire from her position effective November 3, 2014. In connection with her retirement, Dr. Ben-Maimon entered into a Separation Agreement with the Company dated October 22, 2014 which provided Dr. Ben-Maimon with $1.9 million of certain termination benefits and payments that were recorded during the fourth quarter of 2014.
	Workforce reductions
	On June 4, 2013, the Company committed to a reduction in the Company’s workforce, eliminating approximately 110 positions, with the majority of these positions at the Company’s Hayward, California manufacturing facility. The reduction in workforce is part of the Company’s efforts to streamline its operations in response to the need to reduce expenses and adapt to changing market conditions. The Company recorded an accrual for severance and related termination costs of $3.0 million in the three month period ended June 30, 2013 as a result of this workforce reduction. As of December 31, 2013, all accrued severance and related termination costs had been paid.
	On October 30, 2014, the Company committed to a reduction in the Company’s workforce, eliminating approximately 41 positions, including 35 positions in the Company’s research and development (“R&D”) organization. The reduction in workforce is part of the Company’s reorganization of its R&D organizations by consolidating the product development and analytical functions of the generic and brand R&D organizations. The workforce reduction resulted in charges of $2.1 million for severance and related termination costs, of which $1.8 million was paid during the quarter ended December 31, 2014. The Company expects the remaining balance to be paid during the first quarter of 2015.
	Acquisition of Tower Holdings, Inc. and Lineage Therapeutics Inc.
	On October 8, 2014, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which the Company will acquire all the outstanding shares of common stock of Tower Holdings, Inc. (“Tower”), including its operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC, and of Lineage Therapeutics Inc. (“Lineage”), (the “Transaction”) for a purchase price of $700.0 million in cash, subject to customary adjustments for working capital, net debt and transaction expenses. The closing of the Transaction is subject to the satisfaction or waiver of certain customary closing conditions, including approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the accuracy of the representations and warranties, and performance of covenants. The privately-held companies to be acquired in the Transaction specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. Following the closing of the Transaction, which is expected to occur during the first quarter of 2015, Tower and Lineage will become wholly owned subsidiaries of the Company. The Company expects to finance the Transaction from cash on hand and borrowings under a new credit facility, as discussed in “Note 11 – Revolving Line of Credit.”

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the U.S. Securities & Exchange Commission (“SEC”) requires the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant judgments are employed in estimates used in determining values of tangible and intangible assets, legal contingencies, tax assets and tax liabilities, fair value of share-based compensation related to equity incentive awards issued to employees and directors, and estimates used in applying the Company’s revenue recognition policy including those related to accrued chargebacks, rebates, product returns, Medicare, Medicaid, and other government rebate programs, shelf-stock adjustments, and the timing and amount of deferred and recognized revenue and deferred and amortized product manufacturing costs related to alliance and collaboration agreements. Actual results may differ from estimated results. Certain prior year amounts have been reclassified to conform to the presentation for the year ended December 31, 2014.
	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of the operating parent company, Impax Laboratories, Inc., its wholly owned subsidiaries, including Impax Laboratories (Taiwan) Inc., and an equity investment in Prohealth Biotech, Inc. (“Prohealth”), in which the Company held a 57.54% majority ownership interest at December 31, 2014. All significant intercompany accounts and transactions have been eliminated.
	Cash and Cash Equivalents
	The Company considers all short-term investments with maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which, for cash equivalents, approximates fair value due to their short-term maturity. The Company is potentially subject to financial instrument concentration of credit risk through its cash and cash equivalents. The Company maintains cash and cash equivalents with several major financial institutions. Such amounts frequently exceed Federal Deposit Insurance Corporation (“FDIC”) limits.
	Short-Term Investments
	Short-term investments represent investments in fixed rate financial instruments with maturities of greater than three months but less than 12 months at the time of purchase. The Company’s short-term investments are held in U.S. Treasury securities, corporate bonds, and high grade commercial paper, which are not insured by the FDIC. They are stated at amortized cost, which approximates fair value due to their short-term maturity, generally based upon observable market values of similar securities.
	Fair Value of Financial Instruments
	The Company’s deferred compensation liability is carried at the value of the amount owed to participants, and is derived from observable market data by reference to hypothetical investments. The carrying values of other financial assets and liabilities such as accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.
	Contingencies
	In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, covering a wide range of matters, including, among others, patent litigation, stockholder lawsuits, and product and clinical trial liability. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards CodificationTM (“ASC”) Topic 450, "Contingencies", the Company records accruals for such loss contingencies when it is probable a liability will been incurred and the amount of loss can be reasonably estimated. The Company, in accordance with FASB ASC Topic 450, does not recognize gain contingencies until realized. The Company records an accrual for legal costs in the period incurred. A discussion of contingencies is included in the “Commitments and Contingencies,” and “Legal and Regulatory Matters” footnotes below.
	Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers; these allowances are for specific amounts on certain accounts based on facts and circumstances determined on a case-by-case basis.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are cash, cash equivalents, short-term investments, and accounts receivable. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with high quality money market funds, corporate debt, and short-term commercial paper and in securities backed by the U.S. Government. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers.
	The following tables present the percentage of total accounts receivable and gross revenues represented by the Company’s five largest customers as of and for the years ended December 31, 2014, 2013 and 2012:
	Percent of Total Accounts Receivable		2014			2013			2012
	Customer #1			36.9	%		28.8	%		23.3	%
	Customer #2			28.2	%		35.1	%		31.9	%
	Customer #3			19.6	%		18.5	%		18.4	%
	Customer #4			1.8	%		2.9	%		--	%
	Customer #5			1.7	%		--	%		--	%
	Customer #6			--	%		--	%		3.7	%
	Customer #7			--	%		--	%		3.1	%
	Customer #8			--	%		1	%		--	%
	Total five largest customers			88.2	%		86.3	%		80.4	%
	Percent of Gross Revenues		2014			2013			2012
	Customer #1			36	%		30.6	%		21.8	%
	Customer #2			20.7	%		25.1	%		25.2	%
	Customer #3			19.3	%		20.3	%		15.1	%
	Customer #4			2.5	%		2.5	%		--	%
	Customer #5			1.9	%		--	%		--	%
	Customer #6			--	%		--	%		9.2	%
	Customer #7			--	%		2.4	%		2.9	%
	Total five largest customers			80.4	%		80.9	%		74.2	%
	During the years ended December 31, 2014, 2013 and 2012, the Company’s top ten generic products accounted for 62%, 68% and 70%, respectively, of Global Product sales, net. In the Impax Division, revenue from sales of branded Zomig® products pursuant to the AZ Agreement with AstraZeneca accounted for 100% of the Company’s Impax Product sales, net. Refer to “Note 20 - Supplemental Financial Information” for more information.
	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined using a standard cost method, and the cost flow assumption is first in, first out (“FIFO”) flow of goods. Standard costs are revised annually, and significant variances between actual costs and standard costs are apportioned to inventory and cost of goods sold based upon inventory turnover. Costs include materials, labor, quality control, and production overhead. Inventory is adjusted for short-dated, unmarketable inventory equal to the difference between the cost of inventory and the estimated value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Consistent with industry practice, the Company may build pre-launch inventories of certain products which are pending required approval from the FDA and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to prepare for the anticipated commercial launch and FDA approval is expected in the near term and/or the related litigation will be resolved in the Company’s favor. The Company accounts for all costs of idle facilities, excess freight and handling costs, and wasted materials (spoilage) as a current period charge in accordance with GAAP.
	Property, Plant and Equipment
	Property, plant and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Costs incurred in connection with the construction or major renovation of facilities, including interest directly related to such projects, are capitalized as construction in progress. Depreciation is recognized using the straight-line method based on the estimated useful lives of the related assets, which are generally 40 years for buildings, 10 to 15 years for building improvements, eight to 10 years for equipment, and four to 10 years for office furniture and equipment. Land and construction-in-progress are not depreciated.
	Goodwill
	In accordance with FASB ASC Topic 350, "Goodwill and Other Intangibles", rather than recording periodic amortization, goodwill is subject to an annual assessment for impairment by applying a fair value based test. Under FASB ASC Topic 350, if the fair value of the reporting unit exceeds the reporting unit’s carrying value, including goodwill, then goodwill is considered not impaired, making further analysis not required. The Company considers the Global Division and the Impax Division operating segments to each be a reporting unit. The Company attributes the entire carrying amount of goodwill to the Global Division.
	The Company concluded the carrying value of goodwill was not impaired as of December 31, 2014 and 2013 as the fair value of the Global Division exceeded its carrying value at each date. The Company performs its annual goodwill impairment test in the fourth quarter of each year. The Company estimated the fair value of the Global Division using a discounted cash flow model for both the reporting unit and the enterprise. In addition, on a quarterly basis, the Company performs a review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. If such events or changes in circumstances were deemed to have occurred, the Company would perform an interim impairment analysis, which may include the preparation of a discounted cash flow model, or consultation with one or more valuation specialists, to determine the impact, if any, on the Company’s assessment of the reporting unit’s fair value. The Company has not to date deemed there to have been any significant adverse changes in the legal, regulatory, or general economic environment in which the Company conducts its business operations.
	Revenue Recognition
	The Company recognizes revenue when the earnings process is complete, which under SEC Staff Accounting Bulletin No. 104, Topic No. 13, “Revenue Recognition” (“SAB 104”), is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Company accounts for material revenue arrangements which contain multiple deliverables in accordance with FASB ASC Topic 605-25, revenue recognition for arrangements with multiple elements, which addresses the determination of whether an arrangement involving multiple deliverables contains more than one unit of accounting. A delivered item within an arrangement is considered a separate unit of accounting only if both of the following criteria are met:
		●	the delivered item has value to the customer on a stand-alone basis; and
		●	if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor.
	Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. Revenue recognition for arrangements with multiple deliverables constituting a single unit of accounting is recognized generally over the greater of the term of the arrangement or the expected period of performance, either on a straight-line basis or on a modified proportional performance method.
	The Company accounts for milestones related to research and development activities in accordance with FASB ASC Topic 605-28, milestone method of revenue recognition. FASB ASC Topic 605-28 allows for the recognition of consideration, which is contingent on the achievement of a substantive milestone, in its entirety in the period the milestone is achieved. A milestone is considered to be substantive if all of the following criteria are met: the milestone is commensurate with either: (1) the performance required to achieve the milestone, or (2) the enhancement of the value of the delivered items resulting from the performance required to achieve the milestone; the milestone relates solely to past performance; and, the milestone payment is reasonable relative to all of the deliverables and payment terms within the agreement.
	Global Product sales, net, and Impax Product sales, net:
	The Global Product sales, net and Impax Product sales, net include revenue recognized related to shipments of generic and branded pharmaceutical products to the Company’s customers, primarily drug wholesalers and retail chains. Gross sales revenue is recognized at the time title and risk of loss passes to the customer, which is generally when product is received by the customer. Global and Impax Product revenue, net may include deductions from the gross sales price related to estimates for chargebacks, rebates, distribution service fees, returns, shelf-stock, and other pricing adjustments. The Company records an estimate for these deductions in the same period when revenue is recognized. A summary of each of these deductions is as follows:
	Chargebacks
	The Company has agreements establishing contract prices for certain products with certain indirect customers, such as managed care organizations, hospitals and government agencies who purchase products from drug wholesalers. The contract prices are lower than the prices the customer would otherwise pay to the wholesaler, and the price difference is referred to as a chargeback, which generally takes the form of a credit memo issued by the Company to reduce the invoiced gross selling price charged to the wholesaler. An estimated accrued provision for chargeback deductions is recognized at the time of product shipment. The primary factors considered when estimating the provision for chargebacks are the average historical chargeback credits given, the mix of products shipped, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual chargebacks granted and compares them to the estimated provision for chargebacks to assess the reasonableness of the chargeback reserve at each quarterly balance sheet date.
	Rebates
	The Company maintains various rebate programs with its customers in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebates generally take the form of a credit memo to reduce the invoiced gross selling price charged to a customer for products shipped. An estimated accrued provision for rebate deductions is recognized at the time of product shipment. The primary factors the Company considers when estimating the provision for rebates are the average historical experience of aggregate credits issued, the mix of products shipped and the historical relationship of rebates as a percentage of total gross product sales, the contract terms and conditions of the various rebate programs in effect at the time of shipment, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual rebates granted and compares them to the estimated provision for rebates to assess the reasonableness of the rebate reserve at each quarterly balance sheet date.
	Distribution Service Fees
	The Company pays distribution service fees to several of its wholesaler customers related to sales of its Impax Products. The wholesalers are generally obligated to provide the Company with periodic outbound sales information as well as inventory levels of the Company’s Impax Products held in their warehouses. Additionally, the wholesalers have agreed to manage the variability of their purchases and inventory levels within specified days on hand limits. An accrued provision for distribution service fees is recognized at the time products are shipped to wholesalers.
	Returns
	The Company allows its customers to return product if approved by authorized personnel in writing or by telephone with the lot number and expiration date accompanying any request and if such products are returned within six months prior to or until twelve months following, the products’ expiration date. The Company estimates and recognizes an accrued provision for product returns as a percentage of gross sales based upon historical experience. The product return reserve is estimated using a historical lag period, which is the time between when the product is sold and when it is ultimately returned, and estimated return rates which may be adjusted based on various assumptions including changes to internal policies and procedures, changes in business practices, and commercial terms with customers, competitive position of each product, amount of inventory in the wholesaler supply chain, the introduction of new products, and changes in market sales information. The Company also considers other factors, including significant market changes which may impact future expected returns, and actual product returns. The Company monitors actual returns on a quarterly basis and may record specific provisions for returns it believes are not covered by historical percentages.
	Shelf-Stock Adjustments
	Based upon competitive market conditions, the Company may reduce the selling price of certain Global Division products. The Company may issue a credit against the sales amount to a customer based upon their remaining inventory of the product in question, provided the customer agrees to continue to make future purchases of product from the Company. This type of customer credit is referred to as a shelf-stock adjustment, which is the difference between the sales price and the revised lower sales price, multiplied by an estimate of the number of product units on hand at a given date. Decreases in selling prices are discretionary decisions made by the Company in response to market conditions, including estimated launch dates of competing products and declines in market price. The Company records an estimate for shelf-stock adjustments in the period it agrees to grant such a credit memo to a customer.
Medicaidand Other Government Pricing Programs
As required by law, the Company provides a rebate on drugs dispensed under the Medicaid program, Medicare Part D, TRICARE, and other U.S. government pricing programs. The Company determines its estimated government rebate accrual primarily based on historical experience of claims submitted by the various states and other jurisdictions and any new information regarding changes in the various programs which may impact the Company’s estimate of government rebates. In determining the appropriate accrual amount, the Company considers historical payment rates and processing lag for outstanding claims and payments. The Company records estimates for government rebates as a deduction from gross sales, with a corresponding adjustment to accrued liabilities.
Cash Discounts
The Company offers cash discounts to its customers, generally 2% of the gross selling price, as an incentive for paying within invoice terms, which generally range from 30 to 90 days. An estimate of cash discounts is recorded in the same period when revenue is recognized.
Rx Partner and OTC Partner:
The Rx Partner and OTC Partner contracts include revenue recognized under alliance and collaboration agreements between the Company and unrelated third-party pharmaceutical companies. The Company has entered into these alliance agreements to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform.
The Rx Partners and OTC Partners alliance agreements obligate the Company to deliver multiple goods and/or services over extended periods. Such deliverables include manufactured pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development services. In exchange for these deliverables the Company receives payments from its agreement partners for product shipments and research and development services, and may also receive other payments including royalty, profit sharing, upfront, and periodic milestone payments. Revenue received from the alliance agreement partners for product shipments under these agreements is not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments. Royalty and profit sharing amounts the Company receives under these agreements are calculated by the respective agreement partner, with such royalty and profit share amounts generally based upon estimates of net product sales or gross profit which include estimates of deductions for chargebacks, rebates, product returns, and other adjustments the alliance agreement partners may negotiate with their respective customers. The Company records the agreement partner's adjustments to such estimated amounts in the period the agreement partner reports the amounts to the Company.
The Company applies the updated guidance of ASC 605-25 “Multiple Element Arrangements” to the Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited (“Teva Agreement”). The Company looks to the underlying delivery of goods and/or services which give rise to the payment of consideration under the Teva Agreement to determine the appropriate revenue recognition. The Company initially defers consideration received as a result of research and development-related activities performed under the Teva Agreement. The Company recognizes deferred revenue on a straight-line basis over the expected period of performance for such services. Consideration received as a result of the manufacture and delivery of products under the Teva Agreement is recognized at the time title and risk of loss passes to the customer which is generally when product is received by Teva. The Company recognizes profit share revenue in the period earned.
OTC Partner revenue is related to agreements with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”) and L. Perrigo Company (“Perrigo”) with respect to the supply of over-the-counter pharmaceutical products. The OTC Partner sales channel is no longer a core area of the business, and the over-the-counter pharmaceutical products the Company sells through this sales channel are older products which are only sold to Pfizer and Perrigo. The Company is currently only required to manufacture the over-the-counter pharmaceutical products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
Research Partner:
The Research Partner contract includes revenue recognized under development agreements with unrelated third-party pharmaceutical companies. The development agreements generally obligate the Company to provide research and development services over multiple periods. In exchange for this service, the Company received upfront payments upon signing of each development agreement and is eligible to receive contingent milestone payments, based upon the achievement of contractually specified events. Additionally, the Company may also receive royalty payments from the sale, if any, of a successfully developed and commercialized product under one of these development agreements. The Company recognizes revenue received from the achievement of contingent research and development milestones in the period such payment is earned. Royalty fee income, if any, will be recognized as current period revenue when earned.
Promotional Partner:
The Promotional Partner contract includes revenue recognized under a promotional services agreement with an unrelated third-party pharmaceutical company. The promotional services agreement obligated the Company to provide physician detailing sales calls services to promote certain of the unrelated third-party company’s branded drug products. The Company received service fee revenue in exchange for providing this service. The Company recognized revenue from providing physician detailing sales calls services as the services were provided. The Company’s obligation to provide physician detailing sales calls under the promotional services agreement ended on June 30, 2012.
Shipping and Handling Fees and Costs
Shipping and handling fees related to sales transactions are recorded as selling expense. Shipping costs were $2,382,000, $1,890,000 and $1,425,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Research and Development
Research and development activities are expensed as incurred and consist of self-funded research and development costs and costs associated with work performed by other participants under collaborative research and development agreements.
Derivatives
The Company does not engage in hedging transactions for trading or speculative purposes or to hedge exposure to currency or interest rate fluctuations. From time to time, the Company may engage in transactions that result in embedded derivatives (e.g., convertible debt securities). In accordance with FASB ASC Topic 815, “Derivatives and Hedging”, the Company records the embedded derivative at fair value on the balance sheet and records any related gains or losses in current earnings in the statement of operations.
Share-Based Compensation
The Company accounts for stock-based employee compensation arrangements in accordance with provisions of FASB ASC Topic 718, ”Stock Compensation”. Under FASB ASC Topic 718, the Company recognizes the grant date fair value of stock-based employee compensation as expense on a straight-line basis over the vesting period of the grant. The Company uses the Black Scholes option pricing model to determine the grant date fair value of employee stock options; the fair value of restricted stock awards is equal to the closing price of the Company’s stock on the date such award was granted.
Income Taxes
The Company provides for income taxes using the asset and liability method as required by FASB ASC Topic 740, “Income Taxes”. This approach recognizes the amount of federal, state, local taxes, and foreign taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequences of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates in the period during which they are signed into law. Under FASB ASC Topic 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.
FASB ASC Topic 740, Sub-topic 10, ”Tax Positions”, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with generally accepted accounting principles. Under FASB ASC Topic 740, Sub-topic 10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not the tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Additionally, FASB ASC Topic 740, Sub-topic 10 provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. In accordance with the disclosure requirements of FASB ASC Topic 740, Sub-topic 10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.
Earnings per Share
Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares adjusted for the dilutive effect of common stock equivalents outstanding during the period.
Other Comprehensive Income
The Company follows the provisions of FASB ASC Topic 220, ”Comprehensive Income”, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive income is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company recorded foreign currency translation gains and losses, which are reported as comprehensive income. Foreign currency translation gains (losses) for the years ended December 31, 2014, 2013 and 2012 were $(7,149,000), $(4,104,000) and $3,520,000 respectively.
Deferred Financing Costs
The Company capitalizes direct costs incurred with obtaining debt financing, which are included in other assets on the consolidated balance sheet. Deferred financing costs, including costs incurred in obtaining debt financing, are amortized to interest expense over the term of the underlying debt on a straight-line basis, which approximates the effective interest method. The Company recognized amortization of $30,000, $30,000 and $30,000 in the years ended December 31, 2014, 2013 and 2012, respectively.
Foreign Currency Translation
The Company translates the assets and liabilities of the Taiwan dollar functional currency of its majority-owned affiliate Prohealth Biotech, Inc. and its wholly-owned subsidiary Impax Laboratories (Taiwan), Inc. into the U.S. dollar reporting currency using exchange rates in effect at the end of each reporting period. The revenue and expense of these entities are translated using an average of the rates in effect during the reporting period. Gains and losses from these translations are recorded as currency translation adjustments included in the consolidated statements of comprehensive income and the consolidated statements of changes in stockholders’ equity.

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3. RECENT ACCOUNTING PRONOUNCEMENTS
	In March 2013, the FASB issued updated guidance on foreign currency matters. The update applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within a foreign entity. The Company adopted this guidance on January 1, 2014 and the adoption did not have a material effect on its consolidated financial statements.
	In July 2013, the FASB issued updated guidance related to presentation of an unrecognized tax benefit. The guidance requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss, or tax credit carryforward, rather than as a liability under certain circumstances. The Company adopted this guidance on January 1, 2014 and the adoption did not have a material effect on its consolidated financial statements.
	In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition. The update provides a single comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. This guidance will be the same for both U.S. GAAP and International Financial Reporting Standards (IFRS) and is effective for annual and interim periods beginning after December 15, 2016. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements.
	In July 2014, the IRS issued final regulations related to the branded pharmaceutical drug (BPD) annual fee under the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010. The final regulations indicate that an entity’s obligation to pay its portion of the BPD fee in any given calendar year is not triggered by the first qualifying sale in that calendar year but instead by the qualifying sales in the previous year. As a result, during the three month period ended September 30, 2014, the Company recorded a charge of $0.7 million in connection with the implementation of this updated guidance.

Note_4_Investments

Note 4 - Investments	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Investment [Text Block]	4. INVESTMENTS
	Investments consist of commercial paper and corporate bonds. The Company’s policy is to invest in only high quality “AAA-rated” or investment-grade securities. Investments in debt securities are accounted for as “held-to-maturity” and are recorded at amortized cost, which approximates fair value, generally based upon observable market values of similar securities. The Company has historically held all investments in debt securities until maturity, and has the ability and intent to continue to do so. All of the Company’s investments have remaining contractual maturities of less than 12 months and are classified as short-term. Upon maturity, the Company uses a specific identification method.
	A summary of short-term investments as of December 31, 2014 and December 31, 2013 follows:
				Gross		Gross
	(in $000’s)	Amortized		Unrecognized		Unrecognized			Fair
	31-Dec-14	Cost		Gains		Losses			Value
	Commercial paper	$	68,972	$	17	$	--		$	68,989
	Corporate bonds		131,011		--		(101	)		130,910
	Total short-term investments	$	199,983	$	17	$	(101	)	$	199,899
				Gross		Gross
	(in $000’s)	Amortized		Unrecognized		Unrecognized			Fair
	31-Dec-13	Cost		Gains		Losses			Value
	Commercial paper	$	91,480	$	26	$	--		$	91,506
	Corporate bonds		137,041		13		(21	)		137,033
	Total short-term investments	$	228,521	$	39	$	(21	)	$	228,539

Note_5_Accounts_Receivable

Note 5 - Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	5. ACCOUNTS RECEIVABLE
	The composition of accounts receivable, net is as follows:
		December 31,			December 31,
	(in $000’s)	2014			2013
	Gross accounts receivable	$	287,362		$	246,319
	Less: Rebate reserve		(88,812	)		(88,449	)
	Less: Chargeback reserve		(43,125	)		(37,066	)
	Less: Other deductions		(8,935	)		(7,811	)
	Accounts receivable, net	$	146,490		$	112,993
	A roll forward of the chargeback and rebate reserves activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
	(in $000’s)	December 31,			December 31,			December 31,
	Rebate reserve	2014			2013			2012
	Beginning balance	$	88,449		$	46,011		$	29,164
	Provision recorded during the period		260,747			193,288			111,099
	Credits issued during the period		(260,384	)		(150,850	)		(94,252	)
	Ending balance	$	88,812		$	88,449		$	46,011
	(in $000’s)	December 31,			December 31,			December 31,
	Chargeback reserve	2014			2013			2012
	Beginning balance	$	37,066		$	18,410		$	22,161
	Provision recorded during the period		487,377			389,707			209,452
	Credits issued during the period		(481,318	)		(371,051	)		(213,203	)
	Ending balance	$	43,125		$	37,066		$	18,410
	Other deductions include allowance for cash discounts and uncollectible amounts. The Company maintains an allowance for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers, with such allowances for specific amounts on certain accounts. The Company had an allowance for uncollectible amounts of $515,000 and $539,000 at December 31, 2014 and 2013, respectively.

Note_6_Inventory

Note 6 - Inventory	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. INVENTORY
	Inventory, net of carrying value reserves at December 31, 2014 and 2013 consisted of the following:
		December 31,		December 31,
	(in $000’s)	2014		2013
	Raw materials	$	34,681	$	27,981
	Work in process		2,447		1,434
	Finished goods		55,102		47,416
	Total inventory		92,230		76,831
	Less: Non-current inventory		11,660		6,724
	Total inventory-current	$	80,570	$	70,107
	Inventory carrying value reserves were $25,639,000 and $17,702,000 at December 31, 2014 and 2013, respectively. During the three month period ended March 31, 2013, the Company decided to discontinue the manufacture and distribution of certain unprofitable products after the Company conducted a strategic review of its currently manufactured generic product portfolio. As a result of this decision, the Company recorded an inventory reserve of $6,700,000 related to the discontinued products. In addition, upon receipt of the Complete Response Letter from the FDA for RYTARY™ in January 2013, the Company evaluated the impact of the expected delay of FDA approval on its ability to sell the associated inventory. The Company determined that a reserve of $5,000,000 was appropriate and recorded this amount in the three month period ended March 31, 2013. The Company subsequently received FDA approval for RYTARY™ on January 7, 2015. During the three month period ended March 31, 2013, the Company also recorded a $6,400,000 reserve for pre-launch inventory of a product manufactured for another third-party pharmaceutical company due to the anticipated delayed launch of such product as a result of the warning letter related to our Hayward, California manufacturing facility. The carrying value of unapproved inventory less reserves was $7,312,000 and $6,462,000 at December 31, 2014 and 2013, respectively.
	The Company recognizes pre-launch inventories at the lower of its cost or the expected net selling price. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Costs of unapproved products are the same as approved products and include materials, labor, quality control, and production overhead. When the Company concludes FDA approval is expected within approximately six months, the Company will generally begin to schedule manufacturing process validation studies as required by the FDA to demonstrate the production process can be scaled up to manufacture commercial batches. Consistent with industry practice, the Company may build quantities of pre-launch inventories of certain products pending required final FDA approval and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to prepare for the anticipated commercial launch, FDA approval is expected in the near term, and/or the related litigation will be resolved in the Company’s favor. The capitalization of unapproved pre-launch inventory involves risks, including, among other items, FDA approval of product may not occur; approvals may require additional or different testing and/or specifications than used for unapproved inventory; and, in cases where the unapproved inventory is for a product subject to litigation, the litigation may not be resolved or settled in favor of the Company. If any of these risks were to materialize and the launch of the unapproved product delayed or prevented, then the net carrying value of unapproved inventory may be partially or fully reserved. Generally, the selling price of a generic pharmaceutical product is at discount from the corresponding brand product selling price. Typically, a generic drug is easily substituted for the corresponding brand product, and once a generic product is approved, the pre-launch inventory is typically sold within the next three months. If the market prices become lower than the product inventory carrying costs, then the pre-launch inventory value is reduced to such lower market value. If the inventory produced exceeds the estimated market acceptance of the generic product and becomes short-dated, a carrying value reserve will be recorded. In all cases, the carrying value of the Company's pre-launch product inventory is lower than the respective estimated net selling prices.
	To the extent inventory is not scheduled to be utilized in the manufacturing process and/or sold within twelve months of the balance sheet date, it is included as a component of other non-current assets. Amounts classified as non-current inventory consist of raw materials, net of valuation reserves. Raw materials generally have a shelf life of approximately three to five years, while finished goods generally have a shelf life of approximately two years.

Note_7_Property_Plant_and_Equi

Note 7 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment, net consisted of the following:
		December 31,			December 31,
	(in $000’s)	2014			2013
	Land	$	5,773		$	5,773
	Buildings and improvements		154,374			139,657
	Equipment		122,184			114,950
	Office furniture and equipment		12,623			11,523
	Construction-in-progress		9,404			15,910
	Property, plant and equipment, gross	$	304,358		$	287,813
	Less: Accumulated depreciation		(116,189	)		(99,622	)
	Property, plant and equipment, net	$	188,169		$	188,191
	Depreciation expense was $20,353,000, $16,782,000 and $15,982,000 for the years ended December 31, 2014, 2013 and 2012, respectively.

Note_8_Goodwill_and_Intangible

Note 8 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	8. GOODWILL AND INTANGIBLE ASSETS
	Goodwill was $27,574,000 at December 31, 2014 and 2013, and the Company attributes the entire carrying amount of goodwill to the Global Division. Goodwill is tested at least annually for impairment or whenever events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. The Company concluded the carrying value of goodwill was not impaired as of December 31, 2014 and 2013.
	Intangible assets consisted of the following:
	(in $000’s)	Initial		Accumulated						Carrying
	31-Dec-14	Cost		Amortization			Impairment			Value
	Intangible assets:
	Zomig® product rights	$	41,783	$	(31,561	)	$	---		$	10,222
	Tolmar product rights		33,450		(10,801	)		(16,032	)		6,617
	Perrigo product rights		1,000		(297	)		---			703
	Ursodiol product rights		3,000		(331	)		---			2,669
	Other product rights		7,250		---			(750	)		6,500
	Total intangible assets	$	86,483	$	(42,990	)	$	(16,782	)	$	26,711
	(in $000’s)	Initial		Accumulated						Carrying
	31-Dec-13	Cost		Amortization			Impairment			Value
	Intangible assets:
	Zomig® product rights	$	41,783	$	(28,641	)	$	---		$	13,142
	Tolmar product rights		31,450		(3,266	)		(13,156	)		15,028
	Other product rights		2,250		---			(750	)		1,500
	Total intangible assets	$	75,483	$	(31,907	)	$	(13,906	)	$	29,670
	The Zomig® product rights under the AZ Agreement with AstraZeneca were amortized on a straight-line basis over a period of 14 months starting in April 2012 and ending upon the expiration of the underlying patent for the tablet and over a period of 11 months starting in July 2012 and ending upon the expiration of the underlying patent for the orally disintegrating tablet. The Zomig® product rights under the AZ Agreement are also being amortized over a period of 72 months starting in July 2012 for the nasal spray.
	In June 2012, the Company entered into a Development, Supply and Distribution Agreement (the “Tolmar Agreement”) with TOLMAR, Inc. (“Tolmar”). Under the terms of the Tolmar Agreement, Tolmar granted to the Company an exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and manufacturing the products, and the Company is responsible for the marketing and sale of the products. During the three month period ended September 30, 2013, as a result of the most recent market share data obtained by the Company and the Company’s revised five year projections for the Tolmar product lines, the Company performed an intangible asset impairment test on the Tolmar products. Based on the results of the impairment analysis, the Company recorded a $13.2 million impairment charge to cost of revenues for the Global Division in the three month period ended September 30, 2013. During the three month period ended March 31, 2014, as a result of a further decline in pricing, the Company revised its projections and performed an intangible asset impairment analysis. Based on the results of this analysis, the Company recorded a $2.9 million charge to cost of revenues for the Global Pharmaceuticals Division, which was 100% of the remaining net book value of this asset. The remaining carrying value of the Tolmar product rights are being amortized over the remaining estimated useful lives of the underlying products over a period ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the year ended December 31, 2012. During the fourth quarter of 2014, the Company paid a $2.0 million milestone related to the Diclofenac Sodium Gel 3% product to Tolmar pursuant to the Tolmar Agreement in accordance with the terms thereof. This milestone payment was capitalized as an intangible asset. Information concerning the AZ Agreement and the Tolmar Agreement can be found in “Note 12 - Alliance and Collaboration Agreements.”
	During the three month period ended June 30, 2014, the Company paid a $1.0 million milestone payment to Perrigo Company, plc (“Perrigo”) in conjunction with its launch of a generic version of Astepro nasal spray pursuant to a development agreement between the Company and an affiliate of Perrigo. The milestone was capitalized as an intangible asset acquisition and will be amortized over the expected cash flows of the product.
	During the three month period ended September 30, 2014, the Company acquired from Actavis plc two generic products including one product marketed under an existing ANDA, the Ursodiol tablet, and one approved product that was not yet then marketed, the Lamotrigine orally disintegrating tablet. The entire purchase price of $8.0 million was allocated to identifiable intangible assets and the Ursodiol intangible will be amortized over an eight year period. As of the year ended December 31, 2014, the Lamotrigine product was considered in-process research and development and will begin amortizing when commercialized. Other product rights consist of ANDAs which have been filed with the FDA. During the three month period ended September 30, 2013, as a result of a decision by management to withdraw one of these ANDAs and no longer seek FDA approval, the Company recorded an intangible asset impairment charge of $0.8 million in research and development expense, representing the full carrying value of the ANDA. For the remaining ANDAs, the Company will either commence amortization upon FDA approval and commercialization over the estimated useful life of the product rights, or will expense the related costs immediately upon failure to obtain FDA approval.
	Amortization expense is included as a component of Cost of Revenues on the Company’s consolidated statements of operations and was $11,083,000, $13,061,000 and $18,846,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	The following schedule shows the expected amortization of the Zomig®, Tolmar, Perrigo and Ursodiol product rights for the next five years and thereafter:
		Amortization
	(in $000’s)	Expense
	2015	$	5,846
	2016		4,618
	2017		4,230
	2018		2,625
	2019		1,005
	Thereafter		1,887
	Total	$	20,211

Note_9_Accrued_Expenses

Note 9 - Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities Disclosure [Abstract]
Accrued Liabilities Disclosure [Text Block]	9. ACCRUED EXPENSES
	The following table sets forth the Company’s accrued expenses:
	(in $000’s)	December 31,			December 31,
		2014			2013
	Payroll-related expenses	$	33,812		$	27,985
	Product returns		27,174			28,089
	Government rebates		18,272			23,351
	Legal and professional fees		9,497			3,162
	Income taxes payable		40			21,186
	Physician detailing sales force fees		2,336			1,512
	Litigation accrual		12,750			--
	Other		6,589			6,238
	Total accrued expenses	$	110,470		$	111,523
	Product Returns
	The Company maintains a return policy to allow customers to return product within specified guidelines. The Company estimates a provision for product returns as a percentage of gross sales based upon historical experience for sales made through its Global Products and Impax Products sales channels. Sales of product under the Private Label, Rx Partner and OTC Partner alliance, collaboration and supply agreements are not subject to returns. A roll forward of the return reserve activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
	(in $000's)	December 31,			December 31,			December 31,
	Returns Reserve	2014			2013			2012
	Beginning balance	$	28,089		$	23,440		$	24,101
	Provision related to sales recorded in the period		12,016			11,015			3,003
	Credits issued during the period		(12,931	)		(6,366	)		(3,664	)
	Ending balance	$	27,174		$	28,089		$	23,440

Note_10_Income_Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	10. INCOME TAXES
	The Company is subject to federal, state and local income taxes in the United States, and income taxes in Taiwan, R.O.C. and the Netherlands. The provision for income taxes is comprised of the following:
		For the Years Ended December 31,
	(in $000’s)	2014			2013			2012
	Current:
	Federal taxes	$	42,635		$	67,407		$	49,636
	State taxes		2,467			2,569			1,721
	Foreign taxes		832			742			453
	Total current tax expense		45,934			70,718			51,810
	Deferred:
	Federal taxes	$	(9,039	)	$	(21,050	)	$	(21,650	)
	State taxes		(3,597	)		(1,965	)		(2,537	)
	Foreign taxes		(92	)		(2,022	)		(185	)
	Total deferred tax (benefit) expense		(12,728	)		(25,037	)		(24,372	)
	Provision for income taxes	$	33,206		$	45,681		$	27,438
	A reconciliation of the difference between the tax provision at the federal statutory rate and actual income taxes on income before income taxes, which includes federal, state, and other income taxes, is as follows:
		For the Years Ended December 31,
	(in $000’s)	2014						2013					2012
	Income before income taxes	$	90,559					$	146,940				$	83,311
	Tax provision at the federal statutory rate		31,696			35	%		51,429		35	%		29,159		35	%
	Increase (decrease) in tax rate resulting from:
	Tax rate differential and permanent items on foreign income		2,285			2.5	%		383		0.3	%		(1,259	)	(1.5	)%
	State income taxes, net of federal benefit		887			1	%		1,616		1.1	%		1,906		2.3	%
	State research and development credits		(2,133	)		(2.4	)%		(1,787	)	(1.2	)%		(1,560	)	(1.9	)%
	Federal research and development credits		(2,401	)		(2.6	)%		(1,900	)	(1.3	)%		---		--	%
	Share-based compensation		189			0.2	%		92		0.1	%		326		0.4	%
	Executive compensation		1,552			1.7	%		336		0.2	%		825		1	%
	Domestic manufacturing deduction		(679	)		(0.7	)%		(1,666	)	(1.1	)%		(2,010	)	(2.4	)%
	Other permanent book/tax differences		170			0.2	%		(967	)	(0.7	)%		(185	)	(0.2	)%
	Provision for uncertain tax positions		952			1.1	%		1,718		1.1	%		801		0.9	%
	Revision of prior years’ estimates		664			0.7	%		(1,150	)	(0.8	)%		(392	)	(0.5	)%
	Prior year Federal research and development credits		---			--	%		(1,950	)	(1.3	)%		---		--	%
	Other, net		24			0	%		(473	)	(0.3	)%		(173	)	(0.2	)%
	Provision for income taxes	$	33,206			36.7	%	$	45,681		31.1	%	$	27,438		32.9	%
	On January 3, 2013, the research and development credit (the “R&D credit”) was reinstated retroactively as a part of The American Taxpayer Relief Act of 2012 for expenses paid or incurred from January 1, 2012 through December 31, 2012. Due to the fact that this legislation was not enacted prior to the Company’s 2012 year-end, no tax benefit related to potential R&D credits was reflected within the 2012 year-end tax provision. The 2012 R&D credit was reflected within the Company’s first quarter tax provision for the year ended December 31, 2013.
	Deferred income taxes result from temporary differences between the financial statement carrying values and the tax bases of the Company’s assets and liabilities. Deferred tax assets principally result from deferred revenue related to certain of the Company’s alliance and collaboration agreements (see “Note 12 – Alliance and Collaboration Agreements” below for a discussion of the Company's alliance and collaboration agreements), certain accruals and reserves currently not deductible for tax purposes, acquired product rights and intangibles, capitalized legal and share based compensation expense. Deferred tax liabilities principally result from the use of accelerated depreciation methods for income tax purposes. The components of the Company’s deferred tax assets and liabilities are as follows:
		December 31,
	(in $000’s)	2014			2013
	Deferred tax assets:
	Deferred revenues	$	1,550		$	2,961
	Accrued expenses		46,206			44,404
	Inventory reserves		10,223			6,681
	Net operating loss carryforwards		46			61
	Depreciation and amortization		284			275
	Acquired product rights and intangibles		18,788			15,147
	Capitalized legal fees		12,829			11,245
	R&D credit carryforwards		4,331			3,238
	Share based compensation expense		4,397			4,786
	Other		1,048			745
	Deferred tax assets	$	99,702		$	89,543
	Deferred tax liabilities:
	Tax depreciation and amortization in excess of book amounts	$	1,028		$	2,592
	Deferred manufacturing costs		65			65
	Other		1,947			2,172
	Deferred tax liabilities	$	3,040		$	4,829
	Deferred tax assets, net	$	96,662		$	84,714
	The breakdown between current and long-term deferred tax assets and tax liabilities is as follows:
		December 31,
	(in $000’s)	2014			2013
	Current deferred tax assets	$	56,772		$	52,959
	Current deferred tax liabilities		(1,947	)		(2,171	)
	Current deferred tax assets, net		54,825			50,788
	Non-current deferred tax assets		42,930			36,583
	Non-current deferred tax liabilities		(1,093	)		(2,657	)
Non-current deferred tax assets, net		41,837			33,926
Deferred tax assets, net	$	96,662		$	84,714
A rollforward of unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 is as follows:
	For the Years Ended December 31,
(in $000’s)	2014			2013			2012
Unrecognized tax benefits beginning of year	$	5,292		$	2,920		$	1,791
Gross change for current year positions		1,089			797			249
Gross change for prior period positions		310			1,575			1,231
Decrease due to settlements and payments		(174	)		--			(351	)
Unrecognized tax benefits end of year	$	6,517		$	5,292		$	2,920
The amount of unrecognized tax benefits at December 31, 2014, 2013 and 2012 was $6.5 million, $5.3 million and $2.9 million respectively, of which $5.0 million, $4.1 million and $2.3 million would impact the Company’s effective tax rate, respectively, if recognized. The Company currently does not believe that the total amount of unrecognized tax benefits will increase or decrease significantly over the next twelve months. Interest expense related to income taxes is included in “Interest expense” on the consolidated statement of operations. Net interest expense related to unrecognized tax benefits for the year ended December 31, 2014 was $5,000 principally due to the settlement of the 2007-2009 California audit, compared to $299,000 in 2013. Accrued interest expense as of December 31, 2014 and 2013 was $597,000 and $602,000, respectively. Income tax penalties are included in “Other income (expense)” on the consolidated statements of operations. Accrued tax penalties are not significant.
The Company is currently not under audit for its federal income tax, but is currently under audit by the State of California Franchise Tax Board for the tax years ended December 31, 2010 and 2011. No provision has been made for U.S. federal deferred income taxes on accumulated earnings on foreign subsidiaries since it is the current intention of management to indefinitely reinvest the undistributed earnings in the foreign subsidiary.

Note_11_Revolving_Line_of_Cred

Note 11 - Revolving Line of Credit	12 Months Ended
	Dec. 31, 2014
Line Of Credit Facilities [Abstract]
Line Of Credit Facilities [Text Block]	11. REVOLVING LINE OF CREDIT
	As of December 31, 2014, the Company had a Credit Agreement, as amended (the “Credit Agreement”) with Wells Fargo Bank, N.A., as a lender and as administrative agent (the “Administrative Agent”). The Credit Agreement provided the Company with a revolving line of credit in the aggregate principal amount of up to $50,000,000 (the “Revolving Credit Facility”). Under the Revolving Credit Facility, up to $10,000,000 was available for letters of credit, the outstanding face amounts of which reduced availability under the Revolving Credit Facility on a dollar for dollar basis. Proceeds under the Credit Agreement could be used for working capital, general corporate and other lawful purposes. The Credit Agreement matured in accordance with the terms therein on February 11, 2015. The Company did not borrow any amounts under the Revolving Credit Facility.
	The Company’s borrowings under the Credit Agreement were secured by substantially all of the personal property assets of the Company pursuant to a Security Agreement (the “Security Agreement”) entered into by the Company and the Administrative Agent. As further security, the Company also pledged to the Administrative Agent, 65% of the Company’s equity interest in its wholly owned subsidiary Impax Laboratories (Taiwan), Inc., all of the Company’s equity interests in its wholly owned domestic subsidiaries and must similarly pledge all or a portion of its equity interest in future subsidiaries. Under the Credit Agreement, among other things:
		●	The outstanding principal amount of all revolving credit loans, together with accrued and unpaid interest thereon, was due and payable on the maturity date, which occurred on February 11, 2015. There were no balances outstanding under the credit facility as of December 31, 2014.
		●	Borrowings under the Revolving Credit Facility bore interest, at the Company’s option, at either an Alternate Base Rate (as defined in the Credit Agreement) plus the applicable margin in effect from time to time ranging from 0.5% to 1.5%, or a LIBOR Rate (as defined in the Credit Agreement) plus the applicable margin in effect from time to time ranging from 1.5% to 2.5%. The Company was also required to pay an unused commitment fee ranging from 0.25% to 0.45% per annum based on the daily average undrawn portion of the Revolving Credit Facility. The applicable margin described above and the unused commitment fee in effect at any given time were determined based on the Company’s Total Net Leverage Ratio (as defined in the Credit Agreement), which was based upon the Company’s consolidated total debt, net of unrestricted cash in excess of $100 million, compared to Consolidated EBITDA (as defined in the Credit Agreement) for the immediately preceding four quarters.
		●	The Company could prepay any outstanding loan under the Revolving Credit Facility without premium or penalty.
		●	The Company was required under the Credit Agreement and the Security Agreement to comply with a number of affirmative, negative and financial covenants. Among other things, these covenants (i) required the Company to provide periodic reports, notices of material events and information regarding collateral, (ii) restricted the Company’s ability, subject to certain exceptions and baskets, to incur additional indebtedness, grant liens on assets, undergo fundamental changes, change the nature of its business, make investments, undertake acquisitions, sell assets, make restricted payments (including the ability to pay dividends and repurchase stock) or engage in affiliate transactions, and (iii) required the Company to maintain a Total Net Leverage Ratio (which was, generally, total funded debt, net of unrestricted cash in excess of $100 million, over EBITDA for the preceding four quarters) of less than 3.75 to 1.00, a Senior Secured Leverage Ratio (which was, generally, total senior secured debt over EBITDA for the preceding four quarters) of less than 2.50 to 1.00, Consolidated EBITDA of at least $50.0 million and Minimum Liquidity (which was, generally unrestricted cash and cash equivalents) of at least $100.0 million. As of December 31, 2014, the Company was in compliance with the various covenants contained in the Credit Agreement and the Security Agreement. Prior to the Company’s execution of the definitive agreement under which the Company will acquire Tower Holdings, Inc. and Lineage Therapeutics, Inc., the Company received the Administrative Agent’s consent that the execution of such agreement would not result in a breach of the covenants in the Credit Agreement.
		●	The Credit Agreement contained customary events of default (subject to customary grace periods, cure rights and materiality thresholds), including, among others, failure to pay principal, interest or fees, violation of covenants, material inaccuracy of representations and warranties, cross-default and cross-acceleration of material indebtedness and other obligations, certain bankruptcy and insolvency events, certain judgments, certain events related to the Employee Retirement Income Security Act of 1974, as amended, and a change of control.
		●	Following an event of default under the Credit Agreement, the Administrative Agent would be entitled to take various actions, including the acceleration of amounts due under the Credit Agreement and seek other remedies that may be taken by secured creditors.
	During the years ended December 31, 2014, 2013 and 2012, unused line fees incurred under the Credit Agreement were $124,000, $139,000 and $95,000, respectively.
	In connection with the Stock Purchase Agreement pursuant to which the Company will acquire Tower and Lineage, on January 2, 2015, the Company entered into a second amended and restated commitment letter (the “Commitment Letter”), which amended and restated the commitment letter dated as of October 8, 2014, as first amended and restated on October 22, 2014 with Barclays Bank plc (“Barclays”), Royal Bank of Canada (“Royal Bank”), Wells Fargo Bank, National Association (“Wells Fargo”) and Wells Fargo Securities, LLC (“Wells Fargo Securities” and together with Barclays, Royal Bank and Wells Fargo, the “Lenders”) pursuant to which the Lenders have severally but not jointly committed to provide a $50.0 million senior secured revolving credit facility and a $435.0 million senior secured term loan facility in an aggregate principal amount of up to $485.0 million for purposes of financing the Transaction and the related fees and expenses. The obligations of the Lender to provide debt financing under the Commitment Letter are subject to a number of customary conditions, including (i) absence of a Material Adverse Effect (as defined in the Stock Purchase Agreement) that would result in a failure of a condition under the Stock Purchase Agreement; (ii) execution and delivery by the Company of definitive documentation with respect to the debt financing consistent with the term sheet attached to the Commitment Letter; (iii) the accuracy of certain specified representations and warranties in the debt documents; (iv) concurrent consummation of the Transaction in accordance with the Stock Purchase Agreement; (v) delivery of certain customary closing documents (including, among others, a customary solvency certificate), specified items of collateral (where applicable) and certain Tower and Lineage financial statements; and (vi) payment of applicable costs, fees and expenses. The final termination date of the Commitment Letter is March 30, 2015.

Note_12_Alliance_and_Collabora

Note 12 - Alliance and Collaboration Agreements	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	12. ALLIANCE AND COLLABORATION AGREEMENTS
	The Company has entered into several alliance, collaboration, license and distribution agreements, and similar agreements with respect to certain of its products and services, with unrelated third-party pharmaceutical companies. The statement of operations includes revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform, revenue recognized under development agreements which generally obligate the Company to provide research and development services over multiple periods, and revenue recognized under a promotional services agreement which obligates the Company to provide physician detailing sales calls services to promote its promotional partner’s branded drug products over multiple periods.
	The Company’s alliance and collaboration agreements often include milestones and provide for milestone payments upon achievement of these milestones. Generally, the milestone events contained in the Company’s alliance and collaboration agreements coincide with the progression of the Company’s products and technologies from pre-commercialization to commercialization.
	The Company groups pre-commercialization milestones in its alliance and collaboration agreements into clinical and regulatory categories, each of which may include the following types of events:
	Clinical Milestone Events:
		●	Designation of a development candidate. Following the designation of a development candidate, generally, IND-enabling animal studies for a new development candidate take 12 to 18 months to complete.
		●	Initiation of a Phase I clinical trial. Generally, Phase I clinical trials take one to two years to complete.
		●	Initiation or completion of a Phase II clinical trial. Generally, Phase II clinical trials take one to three years to complete.
		●	Initiation or completion of a Phase III clinical trial. Generally, Phase III clinical trials take two to four years to complete.
		●	Completion of a bioequivalence study. Generally, bioequivalence studies take three months to one year to complete.
	Regulatory Milestone Events:
		●	Filing or acceptance of regulatory applications for marketing approval such as a New Drug Application in the United States or Marketing Authorization Application in Europe. Generally, it takes six to 12 months to prepare and submit regulatory filings and approximately two months for a regulatory filing to be accepted for substantive review.
		●	Marketing approval in a major market, such as the United States or Europe. Generally it takes one to three years after an application is submitted to obtain approval from the applicable regulatory agency.
		●	Marketing approval in a major market, such as the United States or Europe for a new indication of an already-approved product. Generally it takes one to three years after an application for a new indication is submitted to obtain approval from the applicable regulatory agency.
	Commercialization milestones in the Company’s alliance and collaboration agreements may include the following types of events:
		●	First commercial sale in a particular market, such as in the United States or Europe.
		●	Product sales in excess of a pre-specified threshold, such as annual sales exceeding $100 million. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.
	License and Distribution Agreement with Shire
	In January 2006, the Company entered into a License and Distribution Agreement with an affiliate of Shire Laboratories, Inc., which was subsequently amended (“Prior Shire Agreement”), under which the Company received a non-exclusive license to market and sell an authorized generic of Shire’s Adderall XR® product (“AG Product”) subject to certain conditions, but in any event by no later than January 1, 2010. The Company commenced sales of the AG Product in October 2009. On February 7, 2013, the Company entered into an Amended and Restated License and Distribution Agreement with Shire (the “Amended and Restated Shire Agreement”), which amended and restated the Prior Shire Agreement. The Amended and Restated Shire Agreement was entered into by the parties in connection with the settlement of the Company’s litigation with Shire relating to Shire’s supply of the AG Product to the Company under the Prior Shire Agreement. During 2013, the Company received a payment of $48,000,000 from Shire in connection with such litigation settlement, which was recorded in the first quarter of 2013 under the line item “Other Income” on the consolidated statement of operations. Under the Amended and Restated Shire Agreement Shire was required to supply the AG Product and Company was responsible for marketing and selling the AG Product subject to the terms and conditions thereof until the earlier of (i) the first commercial sale of the Company’s generic equivalent product to Adderall XR® and (ii) September 30, 2014 (the “Supply Term”), subject to certain continuing obligations of the parties upon expiration or early termination of the Supply Term, including Shire’s obligation to deliver AG Products still owed to the Company as of the end of the Supply Term. The Company is required to pay a profit share to Shire on sales of the AG Product, of which the Company owed a profit share payable to Shire of $21,089,000, $20,406,000 and $70,948,000 on sales of the AG Product during the years ended December 31, 2014, 2013 and 2012, respectively, with a corresponding charge included in the cost of revenues line in the consolidated statement of operations. Although the Supply Term expired on September 30, 2014, the Company is permitted to sell any AG Products in its inventory or owed to the Company by Shire under the Amended and Restated Shire Agreement until all such products are sold. The Company will continue to pay a profit share to Shire on sales of such products.
	Development, Supply and Distribution Agreement with TOLMAR, Inc.
	In June 2012, the Company entered into the Tolmar Agreement with Tolmar. Under the terms of the Tolmar Agreement, Tolmar granted to the Company an exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and manufacturing the products, and the Company is responsible for marketing and sale of the products. The Company is required to pay a profit share to Tolmar on sales of each product commercialized pursuant to the terms of the Tolmar Agreement. The Company paid Tolmar a $21,000,000 upfront payment upon signing of the agreement and a $1,000,000 milestone payment in the year ended December 31, 2012. During the fourth quarter ended December 31, 2013, the Company made a $12,000,000 payment to Tolmar upon Tolmar’s achievement of a regulatory milestone event in accordance with the terms of the agreement. The upfront payment for the Tolmar product rights has been allocated to the underlying topical products based upon the relative fair value of each product and will be amortized over the remaining estimated useful life of each underlying product, ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the second half of 2012. The amortization of the Tolmar product rights has been included as a component of cost of revenues on the consolidated statement of operations. The Company initially allocated $1,550,000 of the upfront payment to two products which are still in development and has recorded such amount as in-process research and development expense in its results of operations for the year ended December 31, 2012. The Company similarly recorded the $1,000,000 milestone paid in the year ended December 31, 2012 as a research and development expense. The Company is required to pay a profit share to Tolmar on sales of the topical products, of which the Company owed a profit share payable to Tolmar of $15,995,000, $3,905,000 and $551,000 during the years ended December 31, 2014, 2013 and 2012, respectively, with a corresponding charge included in the cost of revenues line in the Company’s consolidated statement of operations. Under the Tolmar Agreement, the Company has the potential to pay up to an aggregate of $10,000,000 in additional contingent milestone payments if certain commercialization events occur.
	Contingent milestone payments will be initially recognized in the period the triggering event occurs. Milestone payments which are contingent upon commercialization events will be accounted for as an additional cost of acquiring the product license rights. Milestone payments which are contingent upon regulatory approval events will be capitalized and amortized over the remaining estimated useful life of the approved product. As discussed in “Note 8 – Goodwill and Intangible Assets,” the Company recorded a $13.2 million intangible asset impairment charge to cost of revenues in the three month period ended September 30, 2013 related to the Tolmar product rights acquired under the Tolmar Agreement. During the fourth quarter of 2013, the Company made a $12.0 million payment to Tolmar upon Tolmar’s achievement of a regulatory milestone event in accordance with the terms of the Tolmar Agreement. During the fourth quarter of 2014, the Company paid a $2.0 million milestone related to the Diclofenac Sodium Gel 3% or Solaraze product to Tolmar pursuant to the Tolmar Agreement.
	The Company entered into a Loan and Security Agreement with Tolmar in March 2012 (the “Tolmar Loan Agreement”), under which the Company agreed to lend to Tolmar one or more loans through December 31, 2014, in an aggregate amount not to exceed $15,000,000. As of December 31, 2014, Tolmar borrowed $15,000,000 under the Tolmar Loan Agreement, which is included in “Other Assets” on the consolidated balance sheet. The outstanding principal amount of, including any accrued and unpaid interest on, the loans under the Tolmar Loan Agreement are payable by Tolmar beginning from March 31, 2017 through March 31, 2020 or the maturity date, in accordance with the terms therein. Tolmar may prepay all or any portion of the outstanding balance of the loans prior to the maturity date without penalty or premium.
	Strategic Alliance Agreement with Teva
	The Company entered into a Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited, in June 2001 (“Teva Agreement”). The Teva Agreement commits the Company to develop and manufacture, and Teva to distribute, a specified number controlled release generic pharmaceutical products (“generic products”), each for a 10-year period. The Company is required to develop the products, obtain FDA approval to market the products, and manufacture the products for Teva. The revenue the Company earns from the sale of product under the Teva Agreement consists of Teva’s reimbursement of the Company’s manufacturing costs plus a profit share on Teva’s sales of the product to its customers. The Company invoices Teva for the manufacturing costs or products it ships to Teva and payment is due within 30 days. Teva has the right to determine all terms and conditions of the product sales to its customers. Within 30 days of the end of each calendar quarter, Teva is required to provide the Company with a report of its net sales and profits during the quarter and to pay the Company its share of the profits resulting from those sales. Net sales are Teva’s gross sales less discounts, rebates, chargebacks, returns, and other adjustments, all of which are based upon fixed percentages, except chargebacks, which are estimated by Teva and subject to a true-up reconciliation.
	As of February 6, 2015, the Company was supplying Teva with Ditropan XL® 5,10 and 15 mg extended release tablets as the other products under the Teva Agreement have either been returned to the Company, are being manufactured by Teva at its election, were voluntarily withdrawn from the market, have not yet been approved by the FDA or the Company’s obligations to supply such product had expired or were terminated in accordance with the agreement.
	The following tables show the additions to and deductions from the deferred revenue under the Teva Agreement:
			For the Years Ended December 31,
	(in $000’s)
	Deferred revenue		2014			2013			2012
	Beginning balance		$	1,087		$	2,396		$	3,705
	Less amounts recognized			(1,087	)		(1,309	)		(1,309	)
	Ending deferred revenue		$	---		$	1,087		$	2,396
	OTC Partner Alliance Agreement
	In June 2002, the Company entered into a Development, License and Supply Agreement with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”), for a term of approximately 15 years, relating to the Company’s Loratadine and Pseudoephedrine Sulfate 5 mg/120 mg 12-hour Extended Release Tablets and Loratadine and Pseudoephedrine Sulfate 10 mg/240 mg 24-hour Extended Release Tablets for the OTC market. The Company previously developed the products, and is currently only responsible for manufacturing the products, and Pfizer is responsible for marketing and sale. The agreement included payments to the Company upon achievement of development milestones, as well as royalties paid to the Company by Pfizer on its sales of the product. Pfizer launched this product in May 2003 as Alavert® D-12 Hour. In February 2005, the agreement was partially cancelled with respect to the 24-hour Extended Release Product due to lower than planned sales volume. In December 2011, Pfizer and the Company entered into an agreement with L. Perrigo Company (“Perrigo”) whereby the parties agreed that the Company would supply the Company’s generic Claritin-D® 5 mg/120 mg 12-hour extended release product tablets to Perrigo in the United States and its territories. The agreements with Pfizer and Perrigo are no longer a core area of the Company’s business, and the over-the-counter pharmaceutical products the Company sells to Pfizer and Perrigo under the agreements are older products which are only sold to Pfizer and Perrigo. As noted above, the Company is currently only required to manufacture the products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
	Agreements with ValeantPharmaceuticalsInternational, Inc.
	In November 2008, the Company and Valeant Pharmaceuticals International, Inc., formerly Medicis Pharmaceutical Corporation (“Valeant”), entered into a Joint Development Agreement and a License and Settlement Agreement (“Joint Development Agreement”).
	Joint Development Agreement
	The Joint Development Agreement provides for the Company and Valeant to collaborate in the development of a total of five dermatology products, including four of the Company’s generic products and one branded advanced form of Valeant’s SOLODYN® product. Under the provisions of the Joint Development Agreement the Company received a $40,000,000 upfront payment, paid by Valeant in December 2008. The Company has also received an aggregate of $15,000,000 in milestone payments composed of two $5,000,000 milestone payments, paid by Valeant in March 2009 and September 2009, a $2,000,000 milestone payment paid by Valeant in December 2009, and a $3,000,000 milestone payment paid by Valeant in March 2011. The Company has the potential to receive up to an additional $8,000,000 of contingent regulatory milestone payments each of which the Company believes to be substantive, as well as the potential to receive royalty payments from sales, if any, by Valeant of its advanced form SOLODYN® brand product. Finally, to the extent the Company commercializes any of its four generic dermatology products covered by the Joint Development Agreement, the Company will pay to Valeant a gross profit share on sales of such products. The Company began selling one of the four generic dermatology products during the year ended December 31, 2011.
	The Joint Development Agreement results in three items of revenue for the Company, as follows:
	1.     Research & Development Services
	Revenue received from the provision of research and development services including the $40,000,000 upfront payment and the $12,000,000 of milestone payments received prior to January 1, 2011, have been deferred and are being recognized on a straight-line basis over the expected period of performance of the research and development services. During the three month period ended March 31, 2013, the Company extended the revenue recognition period for the Joint Development Agreement from the previous recognition period ending in November 2013 to December 2014, due to changes in the estimated timing of completion of certain research and development activities. This change was made on a prospective basis, and resulted in a reduced periodic amount of revenue recognized in current and future periods. Revenue from the remaining $8,000,000 of contingent milestone payments, including the $3,000,000 received from Valeant in March 2011, will be recognized using the Milestone Method of accounting. Deferred revenue is recorded as a liability captioned “Deferred revenue.” Revenue recognized under the Joint Development Agreement is included in “Note 20 - Supplementary Financial Information”, in the line item captioned “Other Revenues”. The Company determined the straight-line method better aligns revenue recognition with performance as the level of research and development services delivered under the Joint Development Agreement are expected to be provided on a relatively constant basis over the period of performance.
	2.     Royalty Fees Earned — Valeant’s Sale of Advanced Form SOLODYN® (Brand) Product
	Under the Joint Development Agreement, the Company granted Valeant a license for the advanced form of the SOLODYN® product, with the Company receiving royalty fee income under such license for a period ending eight years after the first commercial sale of the advanced form SOLODYN® product. Commercial sales of the new SOLODYN® product, if any, are expected to commence upon FDA approval of Valeant’s NDA. The royalty fee income, if any, from the new SOLODYN® product, will be recognized by the Company as current period revenue when earned.
	3.     Accounting for Sales of the Company’s Four Generic Dermatology Products
	Upon FDA approval of the Company’s ANDA for each of the four generic products covered by the Joint Development Agreement, the Company will have the right (but not the obligation) to begin manufacture and sale of its four generic dermatology products. The Company sells its manufactured generic products to all Global Division customers in the ordinary course of business through its Global Product sales channel. The Company accounts for the sale, if any, of the generic products covered by the Joint Development Agreement as current period revenue according to the Company’s revenue recognition policy applicable to its Global products. To the extent the Company sells any of the four generic dermatology products covered by the Joint Development Agreement, the Company pays Valeant a gross profit share, with such profit share payments accounted for as a current period cost of goods sold.
	The following table shows the additions to and deductions from deferred revenue under the Joint Development Agreement with Valeant:
	(in $000’s)		Years Ended December 31,
	Deferred revenue		2014			2013			2012
	Beginning balance		$	1,825		$	3,650		$	12,410
	Less amount recognized			(1,825	)		(1,825	)		(8,760	)
	Ending deferred revenue		$	---		$	1,825		$	3,650
	Development and Co-Promotion Agreement with Endo Pharmaceuticals Inc.
	In June 2010, the Company and Endo Pharmaceuticals, Inc. ("Endo") entered into a Development and Co-Promotion Agreement (“Endo Agreement”) under which the Company and Endo have agreed to collaborate in the development and commercialization of a next-generation advanced form of the Company’s lead branded product candidate ("Endo Agreement Product"). Under the provisions of the Endo Agreement, in June 2010, Endo paid to the Company a $10,000,000 upfront payment. The Company has the potential to receive up to an additional $30,000,000 of contingent milestone payments which includes $15,000,000 contingent upon the achievement of clinical events, $5,000,000 contingent upon the achievement of regulatory events, and $10,000,000 upon the achievement of commercialization events. The Company believes all milestones under the Endo Agreement are substantive. Upon commercialization of the Endo Agreement Product in the United States, Endo will have the right to co-promote such product to non-neurologists, which will require the Company to pay Endo a co-promotion service fee of up to 100% of the gross profits attributable to prescriptions for the Endo Agreement Product which are written by the non-neurologists.
	The Company is recognizing the $10,000,000 upfront payment as revenue on a straight-line basis over a period of 112 months, which is the estimated expected period of performance of research and development activities under the Endo Agreement, commencing with the June 2010 effective date of the Endo Agreement and ending in September 2019, the estimated date of FDA approval of the Company's NDA. The FDA approval of the Endo Agreement Product NDA represents the end of the Company’s expected period of performance, as the Company will have no further contractual obligation to perform research and development activities under the Endo Agreement, and therefore the earnings process will be completed. Deferred revenue is recorded as a liability captioned “Deferred revenue” on the consolidated balance sheet and deferred revenue under the Endo Agreement was $4,310,000 as of December 31, 2014. Revenue recognized under the Endo Agreement is reported on the consolidated statement of operations, in the line item captioned Research Partner. The Company determined the straight-line method aligns revenue recognition with performance as the level of research and development activities performed under the Endo Agreement are expected to be performed on a ratable basis over the Company’s estimated expected period of performance. Upon FDA approval of the Company’s Endo Agreement Product NDA, the Company will have the right (but not the obligation) to begin manufacture and sale of such product. The Company will sell its manufactured branded product to customers in the ordinary course of business through its Impax Pharmaceuticals Division. The Company will account for any sale of the product covered by the Endo Agreement as current period revenue. The co-promotion service fee paid to Endo, as described above, if any, will be accounted for as a current period selling expense as incurred.
	The Company and Endo also entered into a Settlement and License Agreement in June 2010 (the “Endo Settlement Agreement”) pursuant to which Endo agreed to make a payment to the Company should prescription sales of Opana® ER (as defined in the Endo Settlement Agreement) fall below a predetermined contractual threshold in the quarter immediately prior to the Company launching a generic version of Opana® ER. As a result of the Company’s launch of its generic version of Opana ER in January 2013 and Endo’s prescription sales of Opana ER during the fourth quarter of 2012, the Company recorded a $102,049,000 settlement gain during the three month period ended March 31, 2013, which is included in “Other Income” in the consolidated statement of operations. Payment of the $102,049,000 settlement was received from Endo in April 2013.
	License, Development and Commercialization Agreement with Glaxo Group Limited
	In December 2010, the Company entered into a License, Development and Commercialization Agreement with Glaxo Group Limited (“GSK”). Under the terms of the agreement with GSK, GSK received an exclusive license to develop and commercialize IPX066 (brand name RYTARY™ in the United States) throughout the world, except in the United States and Taiwan, and certain follow-on products at the option of GSK. Under the terms of the agreement, GSK paid an $11,500,000 upfront payment in December 2010, and the Company had the potential to receive up to $169,000,000 of contingent milestone payments. The upfront payment was recognized as revenue on a straight-line basis over the Company’s expected period of performance to provide research and development services which ended on December 31, 2012. In April 2013, the Company and GSK announced that they were terminating their collaboration for the development and commercialization of IPX066 outside the United States and Taiwan as a result of delays in the anticipated regulatory approval and launch dates in countries in which GSK had rights to commercialize the product and terminated the License, Development and Commercialization Agreement. At the end of July 2013, GSK’s rights to develop and commercialize IPX066 outside the United States and Taiwan were transferred back to the Company.
	Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited
	In January 2012, the Company entered into the AZ Agreement with AstraZeneca. Under the terms of the AZ Agreement, AstraZeneca granted to the Company an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on the Company’s behalf and AstraZeneca paid to the Company the gross profit on such Zomig® products. The Company is obligated to fulfill certain minimum requirements with respect to the promotion of currently approved Zomig® products as well as other dosage strengths of such products approved by the FDA in the future. The Company may, but has no obligation to, develop and commercialize additional products containing zolmitriptan and additional indications for Zomig®, subject to certain restrictions as set forth in the AZ Agreement. The Company will be responsible for conducting clinical studies and preparing regulatory filings related to the development of any such additional products and would bear all related costs. During the term of the AZ Agreement, AstraZeneca will continue to be the holder of the NDA for existing Zomig® products, as well as any future dosage strengths thereof approved by the FDA, and will be responsible for certain regulatory and quality-related activities for such Zomig® products. AstraZeneca will manufacture and supply Zomig® products to the Company and the Company will purchase its requirements of Zomig® products from AstraZeneca until a date determined in the AZ Agreement. Thereafter, AstraZeneca may terminate its supply obligations upon certain advance notice to the Company, in which case the Company would have the right to manufacture or have manufactured its own requirements for the applicable Zomig® product.
	Under the terms of the AZ Agreement, AstraZeneca was required to make payments to the Company representing 100% of the gross profit on sales of AstraZeneca-labeled Zomig® products during the specified transition period. The Company received transition payments from AstraZeneca aggregating $43,564,000 during 2012. The Company accounted for these payments as a reduction of the related receivable that was recorded in the initial purchase price allocation. The Company allocated $45,096,000 to an intangible asset, and the remaining $41,340,000 to prepaid royalty expense related to sales of Impax-labeled Zomig® products during 2012, with such royalty expense included in cost of revenues on the consolidated statement of operations. Beginning in January 2013, the Company was obligated to pay AstraZeneca tiered royalties on net sales of branded Zomig® products, depending on brand exclusivity and subject to customary reductions and other terms and conditions set forth in the AZ Agreement. The Company is also obligated to pay AstraZeneca royalties after a certain specified date based on gross profit from sales of authorized generic versions of the Zomig® products subject to certain terms and conditions set forth in the AZ Agreement. In May 2013, the Company’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and the Company launched authorized generic versions of those products in the United States.
	Co-Promotion Agreement with Pfizer
	In March 2010, the Company and Pfizer, Inc. (“Pfizer”) entered into the First Amendment to the Co-Promotion Agreement (originally entered into with Wyeth LLC, now a wholly owned subsidiary of Pfizer) ("Pfizer Co-Promotion Agreement"). The Company’s obligation to provide physician detailing sales calls under the Pfizer Co-Promotion Agreement ended on June 30, 2012. Prior to such time, the Company had received a fixed fee, effective January 1, 2010, for providing such physician detailing sales calls within a contractually defined range of an aggregate number of physician detailing sales calls rendered, determined on a quarterly basis. The Company recognized the physician detailing sales force fee revenue as the related services were performed and the performance obligations were met. The Company recognized $7,070,000 in the year ended December 31, 2012, which is included in the line item “Other Revenues” in “Note 20 - Supplementary Financial Information.”
	Agreement with DURECT Corporation
During the three month period ended March 31, 2014, the Company entered into an agreement with DURECT Corporation (“Durect”) granting the Company the exclusive worldwide rights to develop and commercialize DURECT’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia, referred to by the Company as IPX239. The Company paid Durect a $2,000,000 up-front payment upon signing of the agreement which was recognized immediately as research and development expense. The Company has the potential to pay up to $61,000,000 in additional contingent milestone payments upon the achievement of predefined development and commercialization milestones. If IPX239 is commercialized, Durect would also receive a tiered royalty on product sales.

Note_13_Employee_Benefit_Plans

Note 13 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Compensation and Employee Benefit Plans [Text Block]	13. EMPLOYEE BENEFIT PLANS
	401(k) Defined Contribution Plan
	The Company sponsors a 401(k) defined contribution plan covering all employees. Participants are permitted to contribute up to 25% of their eligible annual pre-tax compensation up to established federal limits on aggregate participant contributions. The Company matches 50% of the employee contributions up to a maximum of 6% of employee compensation. Effective January 1, 2015, the Company updated its 401(k) policy and will match 100% of the employee contributions up to a maximum of 5% of employee compensation. Discretionary profit-sharing contributions made by the Company, if any, are determined annually by the Board of Directors. Participants are 100% vested in discretionary profit-sharing and matching contributions made by the Company after three years of service, and are 25% and 50% vested after one and two years of service, respectively. There were $1,615,000, $1,501,000 and $1,428,000 in matching contributions and no discretionary profit-sharing contributions made under this plan for the years ended December 31, 2014, 2013 and 2012, respectively.
	Employee Stock Purchase Plan
	In February 2001, the Board of Directors of the Company approved the 2001 Non-Qualified Employee Stock Purchase Plan (“ESPP”), with a 500,000 share reservation. The purpose of the ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The ESPP provides the opportunity to purchase the Company’s common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. Under the ESPP plan, for the years ended December 31, 2014, 2013 and 2012, the Company sold shares of its common stock to its employees in the amount of 35,350, 39,748 and 44,731, respectively, for net proceeds of $788,000, $660,000 and $829,000, respectively.
	Deferred Compensation Plan
	In February 2002, the Board of Directors of the Company approved the Executive Non-Qualified Deferred Compensation Plan (“ENQDCP”) effective August 15, 2002 covering executive level employees of the Company as designated by the Board of Directors. Participants can defer up to 75% of their base salary and quarterly sales bonus and up to 100% of their annual performance based bonus. The Company matches 50% of employee deferrals up to 10% of base salary and bonus compensation. The maximum total match by the company cannot exceed 5% of total base and bonus compensation. Participants are vested in the employer match contribution at 20% each year, with 100% vesting after five years of employment. Participants can earn a return on their deferred compensation based on hypothetical investments in investment funds. Changes in the market value of the participant deferrals and earnings thereon are reflected as an adjustment to the liability for deferred compensation with an offset to compensation expense. There were $850,000, $764,000 and $717,000 in matching contributions under the ENQDCP for the years ended December 31, 2014, 2013 and 2012, respectively.
	The deferred compensation liability is a non-current liability recorded at the value of the amount owed to the ENQDCP participants, with changes in the value of such amounts recognized as a compensation expense in the consolidated statement of operations. The calculation of the deferred compensation obligation is derived from observable market data by reference to hypothetical investments selected by the participants and is included in the line item captioned “Other liabilities” on the consolidated balance sheet. The Company invests in corporate owned life insurance (“COLI”) policies, of which the cash surrender value is included in the line item captioned “Other assets” on the consolidated balance sheet. As of December 31, 2014 and 2013, the Company had a cash surrender value asset of $29,241,000 and $25,025,000, respectively, and a deferred compensation liability of $25,837,000 and $23,940,000, respectively, which approximated fair value. The asset representing the cash surrender value of the corporate owned life insurance and the deferred compensation liability are both Level 2 fair value measurements.

Note_14_Sharebased_Compensatio

Note 14 - Share-based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	14. SHARE-BASED COMPENSATION
	The Company recognizes the grant date fair value of each option and restricted share over its vesting period. Options and restricted shares granted under the Company’s Second Amended and Restated 2002 Equity Incentive Plan (“2002 Plan”) generally vest over a three or four year period and options have a term of ten years.
	Impax Laboratories, Inc. 1999 Equity Incentive Plan
	In October 2000, the Company’s stockholders approved an increase in the aggregate number of shares of common stock to be issued pursuant to the Company’s 1999 Equity Incentive Plan from 2,400,000 to 5,000,000 shares. Under the 1999 Equity Incentive Plan, 35,813, 50,312 and 115,785 stock options were outstanding at December 31, 2014, 2013 and 2012, respectively.
	Impax Laboratories, Inc. Amended and Restated 2002 Equity Incentive Plan
	Under the Company’s 2002 Plan, the aggregate number of shares of common stock for issuance pursuant to stock option grants and restricted stock awards was increased by the Company’s Board of Directors from 11,800,000 to 14,950,000 shares during 2013 and was approved by the Company’s stockholders. Under the 2002 Plan, stock options outstanding were 3,006,367, 3,720,593 and 4,061,436 at December 31, 2014, 2013 and 2012, respectively, and unvested restricted stock awards outstanding were 2,327,176, 2,123,835 and 1,954,570 at December 31, 2014, 2013 and 2012, respectively.
	The stock option activity for all of the Company’s equity compensation plans noted above is summarized as follows:
					Weighted-
					Average
					Exercise
		Number of Shares			Price
	Stock Options	Under Option			per Share
	Outstanding at December 31, 2011		5,073,097			11.76
	Options granted		278,500			20.9
	Options exercised		(1,060,746	)		11.16
	Options forfeited		(113,630	)		16.69
	Outstanding at December 31, 2012		4,177,221			12.72
	Options granted		506,000			18.06
	Options exercised		(814,177	)		9.28
	Options forfeited		(98,139	)		19.51
	Outstanding at December 31, 2013		3,770,905			14.01
	Options granted		386,600			25.27
	Options exercised		(778,112	)		13.76
	Options forfeited		(337,213	)		20.48
	Outstanding at December 31, 2014		3,042,180			14.78
	Options exercisable at December 31, 2014		2,458,207		$	12.89
	As of December 31, 2014, stock options outstanding and exercisable had average remaining contractual lives of 6.41 years and 5.45 years, respectively. Also, as of December 31, 2014, stock options outstanding and exercisable each had aggregate intrinsic values of $52,022,000 and $46,194,000, respectively and restricted stock awards outstanding had an aggregate intrinsic value of $73,724,936. As of December 31, 2014, the Company estimated 2,693,221 stock options and 2,060,233 restricted shares granted to employees which were vested or expected to vest.
	The Company grants restricted stock to certain eligible employees as a component of its long-term incentive compensation program. The restricted stock award grants are made in accordance with the Company’s 2002 Plan. A summary of the non-vested restricted stock awards is as follows:
		Non-Vested			Weighted-
		Restricted			Average
		Stock			Grant Date
	Restricted Stock Awards	Awards			Fair Value
	Non-vested at December 31, 2011		1,663,911			17.2
	Granted		1,015,937			23.41
	Vested		(585,392	)		14.72
	Forfeited		(139,886	)		19.08
	Non-vested at December 31, 2012		1,954,570			20.97
	Granted		1,032,924			19.92
	Vested		(617,302	)		18.8
	Forfeited		(246,357	)		20.69
	Non-vested at December 31, 2013		2,123,835			21.13
	Granted		1,449,585			25.35
	Vested		(796,966	)		21.36
	Forfeited		(449,278	)		21.47
	Non-vested at December 31, 2014		2,327,176		$	23.61
	Included in the 796,966 shares of restricted stock vested during the year ended December 31, 2014 are 284,842 shares with a weighted average fair value of $27.47 per share that were withheld for minimum withholding tax purposes upon vesting of such awards from stockholders who elected to net share settle such tax withholding obligation.
	As of December 31, 2014, the Company had 2,711,649 shares available for issuance of either stock options or restricted stock awards, including 2,298,203 shares from the 2002 Plan, 296,921 shares from the 1999 Plan, and 116,525 shares from the ESPP Plan.
	As of December 31, 2014, the Company had total unrecognized share-based compensation expense, net of estimated forfeitures, of $49,628,000 related to all of its share-based awards, which will be recognized over a weighted average period of 2.11 years. The intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $10,423,000, $8,780,000 and $12,380,000, respectively. The total fair value of restricted shares which vested during the years ended December 31, 2014, 2013 and 2012 was $16,959,000, $11,604,000 and $8,614,000, respectively.
	The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model with the following assumptions:
		For the Years Ended December 31,
		2014			2013			2012
	Volatility (range)		40.1%-41.7	%		41.7	%		48.5%-49.3	%
	Volatility (weighted average)		40.2	%		41.7	%		49.1	%
	Risk-free interest rate (range)		0.6%-1.9	%		1.1%-1.9	%		0.9%-1.0	%
	Risk-free interest rate (weighted average)		1.8	%		1.2	%		1	%
	Dividend yield		0	%		0	%		0	%
	Expected life (years)		6.07			6.19			6.19
	Weighted average grant date fair value	$	10.45		$	7.54		$	9.93
	The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility is based on historical volatility of the Company’s common stock. The expected term calculation is based on the “simplified” method described in SAB No. 107, Share-Based Payment and SAB No. 110, Share-Based Payment, as the result of the simplified method provides a reasonable estimate in comparison to actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield of zero is based on the fact that the Company has never paid cash dividends on its common stock, and has no present intention to pay cash dividends. Options granted under each of the above plans generally vest from three to four years and have a term of ten years.
	The amount of share-based compensation expense recognized by the Company is as follows:
		For the Years Ended December 31,
	(in $000’s)	2014			2013			2012
	Cost of revenues	$	2,494		$	2,035		$	2,405
	Research and development		5,072			4,885			4,658
Selling, general and administrative		13,317			10,724			9,240
Total	$	20,883		$	17,644		$	16,303
In June 2013, the Company announced that Dr. Larry Hsu planned to retire as President and Chief Executive Officer of Impax and in April 2014, Dr. Hsu retired from those positions at Impax. Pursuant to his Separation Agreement, all option grants and restricted stock grants expected to vest in the 12 month period following his retirement date were accelerated and vested as of the retirement date. As a result, during the three month period ended June 30, 2013, the Company recorded $2.3 million of accelerated expense related to Dr. Hsu’s outstanding stock options and restricted stock.
On April 21, 2014, the board of directors of the Company announced that it had appointed Fred Wilkinson as the Company’s new President and Chief Executive Officer effective as of April 29, 2014. In accordance with Mr. Wilkinson’s employment agreement, the Company granted 150,000 shares of the Company’s restricted stock with a grant date fair value of $3.9 million, which will vest as to one-third of the underlying shares on each of the first three six-month anniversaries of April 29, 2014, subject to Mr. Wilkinson’s continued employment with the Company on such vesting date. Further, Mr. Wilkinson also received an award of 375,000 shares of restricted stock that will vest in three tranches based upon continued service by Mr. Wilkinson to the Company and the achievement of certain performance criteria as set forth in his employment agreement. The Company valued these restricted stock awards using a Monte Carlo simulation and is recognizing the $7.6 million value of these awards over the longer of the derived or explicit service period, which is two years.
On October 22, 2014, the Company announced that Carole S. Ben-Maimon, M.D., President of the Company’s Global Pharmaceuticals Division, informed the Company of her decision to retire from her position effective November 3, 2014. Pursuant to her Separation Agreement, all option grants and restricted stock grants expected to vest in the 12 month period following her retirement date were accelerated and vested as of the retirement date. As a result, during the three month period ended December 31, 2014, the Company recorded $0.5 million of accelerated expense related to Dr. Ben-Maimon’s outstanding stock options and restricted stock.
The after tax impact of recognizing the share-based compensation expense related to FASB ASC Topic 718 on basic earnings per common share was $0.20, $0.19 and $0.18 for the years ended December 31, 2014, 2013 and 2012, respectively, and diluted earnings per common share was $0.20, $0.19 and $0.17 for the years ended December 31, 2014, 2013 and 2012, respectively. The Company recognized a deferred tax benefit of $6,880,000, $4,829,000 and $4,335,000 in 2014, 2013 and 2012, respectively, related to share-based compensation expense recorded for non-qualified employee stock options and restricted stock awards.
The Company’s policy is to issue new shares to satisfy stock option exercises and to grant restricted share awards. There were no modifications, other than discussed above, to any stock options during the years ended December 31, 2014, 2013 or 2012.

Note_15_Stockholders_Equity

Note 15 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	15. STOCKHOLDERS’ EQUITY
	Preferred Stock
	Pursuant to its certificate of incorporation, the Company is authorized to issue 2,000,000 shares, $0.01 par value per share, “blank check” preferred stock, which enables the Board of Directors of the Company, from time to time, to create one or more new series of preferred stock. Each series of preferred stock issued can have the rights, preferences, privileges and restrictions designated by the Company’s Board of Directors. The issuance of any new series of preferred stock could affect, among other things, the dividend, voting, and liquidation rights of the Company’s common stock. During the years ended December 31, 2014, 2013 and 2012, the Company did not issue any preferred stock.
	Common Stock
	The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue 90,000,000 shares of common stock with $0.01 par value.

Note_16_Earnings_per_Share

Note 16 - Earnings per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	16. EARNINGS PER SHARE
	Basic earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding for the period. Diluted earnings per common share is computed by dividing net income by the weighted average common shares outstanding adjusted for the dilutive effect of stock options, restricted stock awards, stock purchase warrants and convertible debt, excluding anti-dilutive shares.
	A reconciliation of basic and diluted earnings per share is as follows:
		For the Years Ended December 31,
	(in $000’s, except share and per share amounts)	2014		2013		2012
	Numerator:
	Net income	$	57,353	$	101,259	$	55,873
	Denominator:
	Weighted average common shares outstanding		68,185,552		66,921,181		65,660,271
	Effect of dilutive stock options and and restricted stock		2,344,797		1,733,857		2,744,280
	Diluted weighted average common shares outstanding		70,530,349		68,655,038		68,404,551
	Basic net income per share	$	0.84	$	1.51	$	0.85
	Diluted net income per share	$	0.81	$	1.47	$	0.82
	For the years ended December 31, 2014, 2013 and 2012, the Company excluded 946,288, 1,741,110 and 905,899, respectively, of stock options from the computation of diluted net income per common share as the effect of these options would have been anti-dilutive.

Note_17_Segment_Information

Note 17 - Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17. SEGMENT INFORMATION
	The Company has two reportable segments, the Global Division and the Impax Division. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products, primarily through the following sales channels: the Global Products sales channel for sales of generic prescription products directly to wholesalers, large retail drug chains, and others; the Private Label Product sales channel for generic over-the-counter and prescription products sold to unrelated third-party customers who, in turn, sell the products under their own label; the Rx Partner sales channel for generic prescription products sold through unrelated third-party pharmaceutical entities under their own label pursuant to alliance agreements; and the OTC Partner sales channel for over-the-counter products sold through unrelated third-party pharmaceutical entities under their own labels pursuant to alliance and supply agreements. Revenues from the “Global Products” sales channel and the “Private Label” sales channel are reported under the caption “Global Product sales, net” in “Note 20 – Supplementary Financial Information.” The Company also generates revenue in its Global Division from research and development services provided under a joint development agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.” Revenues from the “OTC Partner” sales channel are also reported under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.”
	The Impax Division is engaged in the development of proprietary brand pharmaceutical products that the Company believes represent improvements to already-approved pharmaceutical products addressing CNS disorders. The Impax Division currently has one internally developed branded pharmaceutical product, RYTARY™, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015. The Company has also filed the required documents for a Market Authorization Application to the European Medicines Agency (EMA) for IPX066 on November 5, 2014 and the filing was accepted by the EMA on November 26, 2014. The Company is also seeking to identify a licensing partner for the development and commercialization of IPX066 in countries outside of the U.S. The Impax Division is also engaged in the sale and distribution of branded Zomig® (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of the AZ Agreement with AstraZeneca in the United States and in certain U.S. territories. Revenues from Impax-labeled branded Zomig® products are reported under the caption “Impax Product sales, net” in “Note 20 – Supplementary Financial Information.” The Impax Division also has a number of product candidates that are in varying stages of development. Finally, the Company generates revenue in the Impax Division from research and development services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.”
	The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment income (loss) before income taxes. Items below income (loss) from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The accounting policies for the Company’s segments are the same as those described above in "Note 2 - Summary of Significant Accounting Policies – Revenue Recognition.” The Company has no inter-segment revenue.
	The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct research and development expenses, and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment:
	(in $000’s)	Global		Impax			Corporate			Total
	Year Ended December 31, 2014	Division		Division			and Other			Company
	Revenues, net	$	549,082	$	46,967		$	--		$	596,049
	Cost of revenues		260,459		22,937			--			283,396
	Research and development		40,927		38,187			--			79,114
	Patent litigation		5,333		--			--			5,333
	Selling, general and administrative		17,144		43,307			78,939			139,390
	Income (loss) before income taxes	$	225,219	$	(57,464	)	$	(77,196	)	$	90,559
		Global		Impax			Corporate			Total
	Year Ended December 31, 2013	Division		Division			and Other			Company
	Revenues, net	$	398,340	$	113,162		$	--		$	511,502
	Cost of revenues		253,836		58,366			--			312,202
	Research and development		41,384		27,470			--			68,854
	Patent litigation		16,545		--			--			16,545
	Selling, general and administrative		17,684		44,915			57,689			120,288
	Income (loss) before income taxes	$	68,891	$	(17,589	)	$	95,638		$	146,940
		Global		Impax			Corporate			Total
	Year Ended December 31, 2012	Division		Division			and Other			Company
	Revenues, net	$	448,682	$	133,010		$	--		$	581,692
	Cost of revenues		229,355		69,783			--			299,138
	Research and development		48,604		32,716			--			81,320
	Patent litigation		9,772		--			--			9,772
	Selling, general and administrative		15,377		37,896			55,197			108,470
	Income (loss) before income taxes	$	145,574	$	(7,385	)	$	(54,878	)	$	83,311
	Foreign Operations
	The Company’s wholly-owned subsidiary, Impax Laboratories (Taiwan) Inc., has constructed a facility in Taiwan which is utilized for manufacturing, research and development, warehouse, and administrative functions, with approximately $126,381,000 and $137,137,000 of net carrying value of assets, composed principally of a building and equipment, included in the Company's consolidated balance sheet at December 31, 2014 and 2013, respectively.

Note_18_Commitments_and_Contin

Note 18 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	18. COMMITMENTS AND CONTINGENCIES
	Leases
	The Company leases land, office, warehouse and laboratory facilities under non-cancelable operating leases expiring between June 2015 and January 2020. Rent expense for the years ended December 31, 2014, 2013 and 2012 was $2,162,000, $1,932,000 and $1,719,000, respectively. The Company recognizes rent expense on a straight-line basis over the lease period. The Company also leases certain equipment under various non-cancelable operating leases with various expiration dates between June 2015 and August 2019. Future minimum lease payments under the non-cancelable operating leases are as follows:
		Years Ended
	(in $000s)	December 31,
	2015		2,348
	2016		1,580
	2017		990
	2018		848
	2019		803
	Thereafter		2,584
	Total minimum lease payments	$	9,153
	Purchase Order Commitments
	As of December 31, 2014, the Company had approximately $42,627,000 of open purchase order commitments, primarily for raw materials. The terms of these purchase order commitments are generally less than one year in duration.
	Taiwan Facility
	The Company has entered into several contracts related to ongoing expansion activities at its Taiwan manufacturing facility. As of December 31, 2014, the Company had remaining obligations under these contracts of approximately $428,048.

Note_19_Legal_and_Regulatory_M

Note 19 - Legal and Regulatory Matters	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Legal Matters and Contingencies [Text Block]	19. LEGAL AND REGULATORY MATTERS
	Patent Infringement Litigation
	There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents typically cover most of the brand name controlled release products for which the Company is developing generic versions.
	Under federal law, when a drug developer files an ANDA for a generic drug seeking approval before expiration of a patent, which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45 day period, the FDA can review and approve the ANDA, but is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. Lawsuits have been filed against the Company in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation.
	Should a patent holder commence a lawsuit with respect to an alleged patent infringement by the Company, the uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. The delay in obtaining FDA approval to market the Company’s product candidates as a result of litigation, as well as the expense of such litigation, whether or not the Company is ultimately successful, could have a material adverse effect on the Company’s results of operations and financial position. In addition, there can be no assurance that any patent litigation will be resolved prior to the end of the 30-month period. As a result, even if the FDA were to approve a product upon expiration of the 30-month period, the Company may elect to not commence marketing the product if patent litigation is still pending.
	The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party.
	Although the outcome and costs of the asserted and unasserted claims is difficult to predict, the Company does not expect the ultimate liability, if any, for such matters to have a material adverse effect on its financial condition, results of operations, or cash flows.
	Takeda Pharmaceutical Co., Ltd, et al. v. Impax Laboratories, Inc. (Dexlansoprazole)
	In April 2011, Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, and Takeda Pharmaceuticals America, Inc. (collectively, “Takeda”) filed suit against the Company in the U.S. District Court for the Northern District of California (the “District Court”) alleging patent infringement based on the filing of the Company’s ANDA relating to Dexlansoprazole Delayed Release Capsules, 30 and 60 mg, generic to Dexilant®. The Company filed an answer and counterclaims. The trial court issued a claim construction ruling on April 11, 2012. In November 2012, the Company and Takeda filed cross motions for summary judgment regarding infringement and validity of the patents at issue. On April 8, 2013, the District Court ruled on the summary judgment motions as follows: (i) granted the Company’s motion for non-infringement of U.S. Patent No. 7,790,755, (ii) granted Takeda’s motion of infringement of U.S. Patent Nos. 6,664,276, 6,462,058 and 6,939,971 and (iii) denied the Company’s motion of invalidity for U.S. Patent No. 6,939,971. A bench trial was conducted beginning on June 5, 2013, and a decision was rendered on October 17, 2013, finding the asserted claims of U.S. Patent Nos. 6,462,058, 6,664,276, and 6,939,971 infringed and not invalid. The Company filed a notice of appeal of the District Court’s decision on the 6,462,058, 6,664,276, and 6,939,971 patents to the United States Court of Appeals for the Federal Circuit, and Takeda filed a notice of appeal of the District Court decision on the 7,790,755 patent to the Federal Circuit.
	In May 2013, Takeda filed another complaint against the Company in the District Court, alleging infringement of U.S. Patent No. 8,173,158 based on the filing of the Company’s ANDA relating to Dexlansoprazole Delayed Release Capsules, 30 and 60 mg, generic to Dexilant®. Takeda filed an amended complaint in July 2013, alleging infringement of another patent, U.S. Patent No. 8,461,187. The Company filed an answer and counterclaims. Following a hearing on claim construction on June 12, 2014, the Court issued a claim construction order on June 6, 2014. The parties agreed to settle the matters on October 14, 2014 and the District Court and Federal Circuit cases have been dismissed.
	Endo Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. and ThoRx Laboratories, Inc. (Oxymorphone hydrochloride); Endo Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. (Oxymorphone hydrochloride)
	In November 2012, Endo Pharmaceuticals, Inc. and Grunenthal GmbH (collectively, “Endo”) filed suit against ThoRx Laboratories, Inc., a wholly owned subsidiary of the Company (“ThoRx”), and the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the filing of ThoRx’s ANDA relating to Oxymorphone hydrochloride, Extended Release tablets, 5, 7.5, 10, 15, 20, 30 and 40 mg, generic to Opana ER®. In January 2013, Endo filed a separate suit against the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the filing of the Company’s ANDA relating to the same products. ThoRx and the Company filed an answer and counterclaims to the November 2012 suit and the Company filed an answer and counterclaims with respect to the January 2013 suit. Discovery is proceeding. Trial is currently scheduled to begin in March 2015.
	In November 2014, Endo Pharmaceuticals Inc. and Mallinckrodt LLC filed suit against the Company in the U.S. District Court for the District of Delaware making additional allegations of patent infringement based on the filing of the Company’s Oxymorphone hydrochloride ANDA described above. Also in November 2014, Endo and Mallinckrodt filed a separate suit in the U.S. District Court for the District of Delaware making additional allegations of patent infringement based on the filing of the ThoRx Oxymorphone hydrochloride ANDA described above. ThoRx and the Company filed an answer and counterclaim to those suits in which they are named as a defendant. The cases are currently pending.
	Pfizer Inc. and UCB Pharma GMBH v. Impax Laboratories, Inc. (Fesoterodine)
	In June 2013, Pfizer Inc. and UCB Pharma GMBH filed suit against the Company in the U.S. District Court for the District of Delaware alleging patent infringement based on the filing of the Company’s ANDA relating to Fesoterodine Fumarate Extended-Release Tablets, 4 and 8 mg, generic to Toviaz®. The Company filed its answer and counterclaims. On September 2, 2014, the District Court entered a stipulation of dismissal without prejudice as to both the complaint and the counterclaims.
	Impax Laboratories Inc., et al. v. Lannett Holdings, Inc. and Lannett Company
	In July 2014, the Company filed suit against Lannett Holdings, Inc. and Lannett Company (collectively, “Lannett”) in the United States District Court for the District of Delaware, alleging patent infringement based on the filing of the Lannett’s ANDA relating to Zolmitriptan Nasal Spray, 5mg, generic to Zomig® Nasal Spray. Lannett filed an answer and counterclaims alleging non-infringement and invalidity in September 2014, and the Company filed an answer to the counterclaims in October 2014. Discovery is proceeding, and trial is set for September 6, 2016.
	Other Litigation Related to the Company’s Business
	Civil Investigative Demand from the FTC (Minocycline Hydrochloride)
	On May 2, 2012, the Company received a Civil Investigative Demand (“CID”) from the United States Federal Trade Commission (“FTC”) concerning its investigation into the drug SOLODYN® and its generic equivalents. According to the FTC, the investigation relates to whether Medicis Pharmaceutical Corporation, now a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Medicis”), the Company, and six other companies have engaged or are engaged in unfair methods of competition in or affecting commerce by (i) entering into agreements regarding SOLODYN® or its generic equivalents and/or (ii) engaging in other conduct regarding the sale or marketing of SOLODYN® or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and witnesses in response to the investigation. To the knowledge of the Company, no FTC proceedings have been initiated against the Company to date, however no assurance can be given as to the timing or outcome of this investigation.
	Solodyn® Antitrust Class Actions
	From July 2013 to March 2014, 15 class action complaints were filed against manufacturers of the brand drug Solodyn® and its generic equivalents, including the Company.
	On July 22, 2013, Plaintiff United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On July 23, 2013, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 1, 2013, Plaintiff International Union of Operating Engineers Local 132 Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of California on behalf of itself and others similarly situated. On August 29, 2013, this Plaintiff withdrew its complaint from the United States District Court for the Northern District of California, and on August 30, 2013, re-filed the same complaint in the United States Court for the Eastern District of Pennsylvania, on behalf of itself and others similarly situated.
	On August 9, 2013, Plaintiff Local 274 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 12, 2013, Plaintiff Sheet Metal Workers Local No. 25 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 27, 2013, Plaintiff Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 29, 2013, Plaintiff Heather Morgan, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 30, 2013, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On September 9, 2013, Plaintiff Ahold USA, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On September 24, 2013, Plaintiff City of Providence, Rhode Island, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Arizona on behalf of itself and others similarly situated.
	On October 2, 2013, Plaintiff International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On October 7, 2013, Painters District Council No. 30 Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On October 25, 2013, Plaintiff Man-U Service Contract Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On March 13, 2014, Plaintiff Allied Services Division Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On March 19, 2014, Plaintiff NECA-IBEW Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On February 25, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the District of Massachusetts for coordinated pretrial proceedings, as In Re Solodyn (Minocycline Hydrochloride) Antitrust Litigation.
	The consolidated amended complaints allege that Medicis engaged in anticompetitive schemes by, among other things, filing frivolous patent litigation lawsuits, submitting frivolous Citizen Petitions, and entering into anticompetitive settlement agreements with several generic manufacturers, including the Company, to delay generic competition of Solodyn® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution.
	Civil Investigative Demand from the FTC (Oxymorphone Hydrochloride)
	On February 25, 2014, the Company received a CID from the FTC concerning its investigation into the drug Opana® ER and its generic equivalents. According to the FTC, the investigation relates to whether Endo Pharmaceuticals, Inc. (“Endo”) and the Company have engaged or are engaged in unfair methods of competition in or affecting commerce by (i) entering into agreements regarding Opana® ER or its generic equivalents and/or (ii) engaging in other conduct regarding the regulatory filings, sale or marketing of Opana® ER or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and witnesses in response to the CID. To the knowledge of the Company, no proceedings by the FTC have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
	Opana ER® Antitrust Class Actions
	From June 2014 to January 2015, eleven class action complaints were filed against the manufacturer of the brand drug Opana ER® and the Company.
	On June 4, 2014, Plaintiff Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On June 4, 2014, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On June 6, 2014, Plaintiff Value Drug Company, a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of California on behalf of itself and others similarly situated. On June 26, 2014, this Plaintiff withdrew its complaint from the United States District Court for the Northern District of California, and on July 16, 2014, re-filed the same complaint in the United States District Court for the Northern District of Illinois, on behalf of itself and others similarly situated.
	On June 19, 2014, Plaintiff Wisconsin Masons’ Health Care Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On July 17, 2014, Plaintiff Massachusetts Bricklayers, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 11, 2014, Plaintiff Pennsylvania Employees Benefit Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On September 19, 2014, Plaintiff Meijer Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On October 3, 2014, Plaintiff International Union of Operating Engineers, Local 138 Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On December 19, 2014, Plaintiff Kim Mahaffay, an indirect purchaser, filed a class action complaint in the Superior Court of the State of California, Alameda County, on behalf of herself and others similarly situated. On January 27, 2015, the Defendants removed the action to the United States District Court for the Northern District of California.
	On January 12, 2015, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On December 12, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the Northern District of Illinois for coordinated pretrial proceedings, as In Re Opana ER Antitrust Litigation.
	In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement agreement with the Company to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. Consolidated amended complaints have not yet been filed in the consolidated proceeding.
	Civil Investigation Demand from the Attorney General of the State of Alaska
	On February 10, 2015, the “Company received three CIDs from the Office of the Attorney General of the State of Alaska (“Alaska AG”) concerning its investigations into the drugs Adderall XR®, Effexor XR® and Opana® ER (each a “Product” and collectively, the “Products”) and their generic equivalents. According to the Alaska AG, the investigation is to determine whether the Company may have violated Alaskan state law by entering into settlement agreements with the respective brand name manufacturer for each of the foregoing Products that delayed generic entry of such Product into the marketplace.  The Company intends to cooperate with the Alaska AG in producing documents and information in response to the CIDs. To the knowledge of the Company, no proceedings have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
	Justice Department Subpoena to Company Sales Representative
	On November 3, 2014, a sales representative of the Company received a subpoena from the Justice Department’s Antitrust Division requesting the production of documents to and testimony before the grand jury of the Eastern District of Pennsylvania. The request relates to any communication or correspondence with any competitor (or an employee of any competitor) in the sale of generic prescription medications.
	Securities and Derivative Class Actions
	On March 7, 2013 and April 8, 2013, two class action complaints were filed against the Company and certain current and former officers and directors of the Company in the United States District Court for the Northern District of California by Denis Mulligan, individually and on behalf of others similarly situated, and Haverhill Retirement System, individually and on behalf of others similarly situated, respectively (“Securities Class Actions”), alleging that the Company and those named officers and directors violated the federal securities law by making materially false and misleading statements and/or failed to disclose material adverse facts to the public in connection with manufacturing deficiencies at the Hayward, California manufacturing facility, including but not limited to the impact the deficiencies would have on the Company’s ability to gain approval from the FDA for the Company’s branded product candidate, RYTARY™ and its generic version of Concerta®. These two Securities Class Actions were subsequently consolidated, assigned to the same judge, and lead plaintiff has been chosen. The plaintiff’s consolidated amended complaint was filed on September 13, 2013. The Company filed a motion to dismiss the consolidated amended complaint on November 14, 2013. On April 18, 2014, the Court denied the Company’s motion to dismiss. On September 22, 2014, the Company, together with certain current and former officers and directors of the Company, agreed to settle this consolidated securities class action, without any admission or concession of wrongdoing or liability by the Company or the other defendants. Pursuant to the settlement, the Company will pay $8.0 million for a full and complete release of all claims that were or could have been asserted against the Company or other defendants in this action. On January 16, 2015, the Court granted preliminary approval of the settlement. The Company will not be taking any charges for the settlement as the settlement amount will be paid for and covered by the Company's insurance policies. The settlement remains subject to final court approval and certain other conditions and does not resolve the related shareholder derivative litigations discussed below.
	On March 19, 2013, Virender Singh, derivatively on behalf of the Company, filed a state court action against certain current and former officers and directors for breach of fiduciary duty and unjust enrichment in the Superior Court of the State of California County of Santa Clara, asserting similar allegations as those in the Securities Class Actions. That action has been stayed pending resolution of the Securities Class Actions. On September 24, 2014, Nicholas Karant, derivatively on behalf of the Company, filed an action against certain current and former officers and directors in the United District Court for the Northern District of California, asserting similar allegations as those by Virender Singh. In addition, the Company is aware of two letters from stockholders demanding action by the Company’s board of directors, including to: (i) undertake an independent internal investigation into management’s alleged violations of Delaware and/or federal law; (ii) commence a civil action against members of management to recover damages sustained as a result of alleged breaches of fiduciary duties; and/or (iii) spearhead meaningful corporate reform to address alleged internal control inadequacies. Each letter further states that if such action is not commenced within a reasonable period of time, the stockholder will commence a stockholder’s derivative action on behalf of the Company.
	On August 13, 2014, a class action complaint was filed against the Company and certain current and former officers and directors of the Company in the United States District Court for the Northern District of California by Linus Aruliah, individually and on behalf of all others similarly situated. The complaint alleged that the Company and those named officers and directors violated the federal securities laws by making materially false and misleading statements and/or failed to disclose material adverse facts to the public in connection with manufacturing deficiencies at the Company’s Taiwan manufacturing facility, including but not limited to the impact the deficiencies would have on the Company’s ability to gain approval from the FDA for the Company’s then branded product candidate, RYTARY™ (which was subsequently approved by the FDA on January 7, 2015). On January 13, 2015, the Company, together with certain current and former officers and directors of the Company, agreed to settle this securities class action, without any admission or concession of wrongdoing or liability by the Company or the other defendants. Pursuant to the settlement, the Company will pay $4.75 million for a full and complete release of all claims that were or could have been asserted against the Company or other defendants in this action. The Company will not be taking any charges for the settlement as the settlement amount will be paid for and covered by the Company’s insurance policies. The settlement remains subject to preliminary and final court approval and certain other conditions and does not resolve the related shareholder derivative litigations.
	On September 22, 2014, Randall Wickey, derivatively on behalf of the Company, filed an action against certain current and former officers and directors of the Company in the United States District for the Northern District of California, alleging breaches of fiduciary duty in connection with the Company’s response to various FDA notices and warnings regarding problems in the manufacturing and quality control processes at the Company’s Hayward, California and Taiwan manufacturing facilities.
On November 10, 2014, International Union of Operating Engineers Local 478, derivatively on behalf of the Company, filed an action against certain current and former officers and directors of the Company in the United States District for the Northern District of California, asserting similar allegations as those by Randall Wickey.
Attorney General of the State of Connecticut Interrogatories and Subpoena Duces Tecum
On July 14, 2014, the Company received a subpoena and interrogatories (the “Subpoena”) from the State of Connecticut Attorney General (“Connecticut AG”) concerning its investigation into sales of the Company’s generic product, digoxin. According to the Connecticut AG, the investigation is to determine whether anyone engaged in a contract, combination or conspiracy in restraint of trade or commerce which has the effect of (i) fixing, controlling or maintaining prices or (ii) allocating or dividing customers or territories relating to the sale of digoxin in violation of Connecticut state antitrust law. The Company intends to cooperate with the Connecticut AG in producing documents and information in response to the Subpoena. To the knowledge of the Company, no proceedings by the Connecticut AG have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.

Note_20_Supplementary_Financia

Note 20 - Supplementary Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	20. SUPPLEMENTARY FINANCIAL INFORMATION (unaudited)
	Selected financial information for the quarterly periods noted is as follows:
		2014 Quarters Ended:
	(in $000’s except shares and per share amounts)	31-Mar		30-Jun			30-Sep			31-Dec
	Revenue:
	Global Product sales, gross	$	265,850	$	375,269		$	340,379		$	322,707
	Less:
	Chargebacks		95,714		110,518			115,419			131,882
	Rebates		52,054		74,079			64,442			66,685
	Product returns		1,294		5,140			3,494			993
	Other credits		10,671		21,571			13,449			8,288
	Global Product sales, net		106,117		163,961			143,575			114,859
	Rx Partner		2,435		9,204			1,447			1,028
	Other Revenues		589		3,229			611			2,028
	Global Division revenues, net		109,141		176,394			145,633			117,915
	Impax Product sales, gross		20,643		24,375			23,840			23,348
	Less:
	Chargebacks		8,230		10,107			8,787			6,720
	Rebates		1,070		938			469			1,010
	Product returns		181		216			223			475
	Other credits		1,853		1,654			2,261			2,074
	Impax Product sales, net		9,309		11,460			12,100			13,069
	Other Revenues		268		267			266			227
	Impax Division revenues, net		9,577		11,727			12,366			13,296
	Total net revenues		118,718		188,121			157,999			131,211
	Gross profit		57,622		109,772			84,438			60,821
	Net income	$	6,425	$	35,071		$	15,737		$	120
	Net income per share (basic)	$	0.09	$	0.52		$	0.23		$	0
	Net income per share (diluted)	$	0.09	$	0.5		$	0.22		$	0
	Weighted average:
	common shares outstanding:
	Basic		67,702,296		68,095,159			68,254,327			68,678,779
	Diluted		69,938,872		70,313,491			70,715,226			70,988,328
	Quarterly computations of net income per share amounts are made independently for each quarterly reporting period, and the sum of the per share amounts for the quarterly reporting periods may not equal the per share amounts for the year-to-date reporting period.
	Selected financial information for the quarterly periods noted is as follows:
		2013 Quarters Ended:
	(in $000’s except shares and per share amounts)	31-Mar		30-Jun			30-Sep			31-Dec
	Revenue:
	Global Product sales, gross	$	197,956	$	217,721		$	279,441		$	288,315
	Less:
	Chargebacks		64,345		82,013			98,449			111,903
	Rebates		30,572		35,649			54,530			68,363
	Product Returns		94		1,989			2,857			1,989
	Other credits		5,160		8,312			11,919			21,639
	Global Product sales, net		97,785		89,758			111,686			84,423
	Rx Partner		3,114		3,668			3,016			1,841
	Other Revenues		737		539			1,046			727
	Global Division revenues, net		101,636		93,965			115,748			86,991
	Impax Product sales, gross		69,292		48,300			22,849			21,244
	Less:
	Chargebacks		7,790		10,095			8,422			6,690
	Rebates		6,236		(1,735	)		(812	)		485
	Product Returns		1,490		2,197			175			224
	Other credits		7,255		2,409			(1,498	)		361
	Impax Product sales, net		46,521		35,334			16,562			13,484
	Other Revenues		332		332			331			266
	Impax Division revenues, net		46,853		35,666			16,893			13,750
	Total net revenues		148,489		129,631			132,641			100,741
	Gross profit		57,871		58,887			48,342			34,200
	Net income (loss)	$	105,442	$	5,619		$	(180	)	$	(9,622	)
	Net income (loss) per share (basic)	$	1.59	$	0.08		$	0		$	(0.14	)
	Net income (loss) per share (diluted)	$	1.55	$	0.08		$	0		$	(0.14	)
	Weighted average:
	common shares outstanding:
Basic		66,487,470		66,748,864			67,051,121			67,385,969
Diluted		68,178,355		68,287,948			67,051,121			67,385,969
Quarterly computations of net income (loss) per share amounts are made independently for each quarterly reporting period, and the sum of the per share amounts for the quarterly reporting periods may not equal the per share amounts for the year-to-date reporting period.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2014

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

SCHEDULE II, VALUATION AND QUALIFYING ACCOUNTS

For the Year Ended December 31, 2012

(in $000’s)

Column A

Column B

Column C

Column D

Column E

Description

Balance at

Charge to

Charge to

Deductions

Balance at

Beginning of

Costs and

Other

End of

Period

Expenses

Accounts

Period

Reserve for bad debts

$

612

---

---

(59

)

$

553

For the Year Ended December 31, 2013

(in $000’s)

Column A

Column B

Column C

Column D

Column E

Description

Balance at

Charge to

Charge to

Deductions

Balance at

Beginning of

Costs and

Other

End of

Period

Expenses

Accounts

Period

Reserve for bad debts

$

553

---

---

(14

)

$

539

For the Year Ended December 31, 2014

(in $000’s)

Column A

Column B

Column C

Column D

Column E

Description

Balance at

Charge to

Charge to

Deductions

Balance at

Beginning of

Costs and

Other

End of

Period

Expenses

Accounts

Period

Reserve for bad debts

$

539

---

---

(24

)

$

515

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the U.S. Securities & Exchange Commission (“SEC”) requires the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant judgments are employed in estimates used in determining values of tangible and intangible assets, legal contingencies, tax assets and tax liabilities, fair value of share-based compensation related to equity incentive awards issued to employees and directors, and estimates used in applying the Company’s revenue recognition policy including those related to accrued chargebacks, rebates, product returns, Medicare, Medicaid, and other government rebate programs, shelf-stock adjustments, and the timing and amount of deferred and recognized revenue and deferred and amortized product manufacturing costs related to alliance and collaboration agreements. Actual results may differ from estimated results. Certain prior year amounts have been reclassified to conform to the presentation for the year ended December 31, 2014.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of the operating parent company, Impax Laboratories, Inc., its wholly owned subsidiaries, including Impax Laboratories (Taiwan) Inc., and an equity investment in Prohealth Biotech, Inc. (“Prohealth”), in which the Company held a 57.54% majority ownership interest at December 31, 2014. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all short-term investments with maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which, for cash equivalents, approximates fair value due to their short-term maturity. The Company is potentially subject to financial instrument concentration of credit risk through its cash and cash equivalents. The Company maintains cash and cash equivalents with several major financial institutions. Such amounts frequently exceed Federal Deposit Insurance Corporation (“FDIC”) limits.
Investment, Policy [Policy Text Block]	Short-Term Investments
	Short-term investments represent investments in fixed rate financial instruments with maturities of greater than three months but less than 12 months at the time of purchase. The Company’s short-term investments are held in U.S. Treasury securities, corporate bonds, and high grade commercial paper, which are not insured by the FDIC. They are stated at amortized cost, which approximates fair value due to their short-term maturity, generally based upon observable market values of similar securities.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company’s deferred compensation liability is carried at the value of the amount owed to participants, and is derived from observable market data by reference to hypothetical investments. The carrying values of other financial assets and liabilities such as accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies
	In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, covering a wide range of matters, including, among others, patent litigation, stockholder lawsuits, and product and clinical trial liability. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards CodificationTM (“ASC”) Topic 450, "Contingencies", the Company records accruals for such loss contingencies when it is probable a liability will been incurred and the amount of loss can be reasonably estimated. The Company, in accordance with FASB ASC Topic 450, does not recognize gain contingencies until realized. The Company records an accrual for legal costs in the period incurred. A discussion of contingencies is included in the “Commitments and Contingencies,” and “Legal and Regulatory Matters” footnotes below.
Receivables, Policy [Policy Text Block]	Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers; these allowances are for specific amounts on certain accounts based on facts and circumstances determined on a case-by-case basis.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are cash, cash equivalents, short-term investments, and accounts receivable. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with high quality money market funds, corporate debt, and short-term commercial paper and in securities backed by the U.S. Government. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers.
	The following tables present the percentage of total accounts receivable and gross revenues represented by the Company’s five largest customers as of and for the years ended December 31, 2014, 2013 and 2012:
	Percent of Total Accounts Receivable		2014			2013			2012
	Customer #1			36.9	%		28.8	%		23.3	%
	Customer #2			28.2	%		35.1	%		31.9	%
	Customer #3			19.6	%		18.5	%		18.4	%
	Customer #4			1.8	%		2.9	%		--	%
	Customer #5			1.7	%		--	%		--	%
	Customer #6			--	%		--	%		3.7	%
	Customer #7			--	%		--	%		3.1	%
	Customer #8			--	%		1	%		--	%
	Total five largest customers			88.2	%		86.3	%		80.4	%
	Percent of Gross Revenues		2014			2013			2012
	Customer #1			36	%		30.6	%		21.8	%
	Customer #2			20.7	%		25.1	%		25.2	%
	Customer #3			19.3	%		20.3	%		15.1	%
	Customer #4			2.5	%		2.5	%		--	%
	Customer #5			1.9	%		--	%		--	%
	Customer #6			--	%		--	%		9.2	%
	Customer #7			--	%		2.4	%		2.9	%
	Total five largest customers			80.4	%		80.9	%		74.2	%
	During the years ended December 31, 2014, 2013 and 2012, the Company’s top ten generic products accounted for 62%, 68% and 70%, respectively, of Global Product sales, net. In the Impax Division, revenue from sales of branded Zomig® products pursuant to the AZ Agreement with AstraZeneca accounted for 100% of the Company’s Impax Product sales, net. Refer to “Note 20 - Supplemental Financial Information” for more information.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined using a standard cost method, and the cost flow assumption is first in, first out (“FIFO”) flow of goods. Standard costs are revised annually, and significant variances between actual costs and standard costs are apportioned to inventory and cost of goods sold based upon inventory turnover. Costs include materials, labor, quality control, and production overhead. Inventory is adjusted for short-dated, unmarketable inventory equal to the difference between the cost of inventory and the estimated value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Consistent with industry practice, the Company may build pre-launch inventories of certain products which are pending required approval from the FDA and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to prepare for the anticipated commercial launch and FDA approval is expected in the near term and/or the related litigation will be resolved in the Company’s favor. The Company accounts for all costs of idle facilities, excess freight and handling costs, and wasted materials (spoilage) as a current period charge in accordance with GAAP.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment
	Property, plant and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Costs incurred in connection with the construction or major renovation of facilities, including interest directly related to such projects, are capitalized as construction in progress. Depreciation is recognized using the straight-line method based on the estimated useful lives of the related assets, which are generally 40 years for buildings, 10 to 15 years for building improvements, eight to 10 years for equipment, and four to 10 years for office furniture and equipment. Land and construction-in-progress are not depreciated.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill
	In accordance with FASB ASC Topic 350, "Goodwill and Other Intangibles", rather than recording periodic amortization, goodwill is subject to an annual assessment for impairment by applying a fair value based test. Under FASB ASC Topic 350, if the fair value of the reporting unit exceeds the reporting unit’s carrying value, including goodwill, then goodwill is considered not impaired, making further analysis not required. The Company considers the Global Division and the Impax Division operating segments to each be a reporting unit. The Company attributes the entire carrying amount of goodwill to the Global Division.
	The Company concluded the carrying value of goodwill was not impaired as of December 31, 2014 and 2013 as the fair value of the Global Division exceeded its carrying value at each date. The Company performs its annual goodwill impairment test in the fourth quarter of each year. The Company estimated the fair value of the Global Division using a discounted cash flow model for both the reporting unit and the enterprise. In addition, on a quarterly basis, the Company performs a review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. If such events or changes in circumstances were deemed to have occurred, the Company would perform an interim impairment analysis, which may include the preparation of a discounted cash flow model, or consultation with one or more valuation specialists, to determine the impact, if any, on the Company’s assessment of the reporting unit’s fair value. The Company has not to date deemed there to have been any significant adverse changes in the legal, regulatory, or general economic environment in which the Company conducts its business operations.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company recognizes revenue when the earnings process is complete, which under SEC Staff Accounting Bulletin No. 104, Topic No. 13, “Revenue Recognition” (“SAB 104”), is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Company accounts for material revenue arrangements which contain multiple deliverables in accordance with FASB ASC Topic 605-25, revenue recognition for arrangements with multiple elements, which addresses the determination of whether an arrangement involving multiple deliverables contains more than one unit of accounting. A delivered item within an arrangement is considered a separate unit of accounting only if both of the following criteria are met:
		●	the delivered item has value to the customer on a stand-alone basis; and
		●	if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor.
	Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. Revenue recognition for arrangements with multiple deliverables constituting a single unit of accounting is recognized generally over the greater of the term of the arrangement or the expected period of performance, either on a straight-line basis or on a modified proportional performance method.
	The Company accounts for milestones related to research and development activities in accordance with FASB ASC Topic 605-28, milestone method of revenue recognition. FASB ASC Topic 605-28 allows for the recognition of consideration, which is contingent on the achievement of a substantive milestone, in its entirety in the period the milestone is achieved. A milestone is considered to be substantive if all of the following criteria are met: the milestone is commensurate with either: (1) the performance required to achieve the milestone, or (2) the enhancement of the value of the delivered items resulting from the performance required to achieve the milestone; the milestone relates solely to past performance; and, the milestone payment is reasonable relative to all of the deliverables and payment terms within the agreement.
	Global Product sales, net, and Impax Product sales, net:
	The Global Product sales, net and Impax Product sales, net include revenue recognized related to shipments of generic and branded pharmaceutical products to the Company’s customers, primarily drug wholesalers and retail chains. Gross sales revenue is recognized at the time title and risk of loss passes to the customer, which is generally when product is received by the customer. Global and Impax Product revenue, net may include deductions from the gross sales price related to estimates for chargebacks, rebates, distribution service fees, returns, shelf-stock, and other pricing adjustments. The Company records an estimate for these deductions in the same period when revenue is recognized. A summary of each of these deductions is as follows:
	Chargebacks
	The Company has agreements establishing contract prices for certain products with certain indirect customers, such as managed care organizations, hospitals and government agencies who purchase products from drug wholesalers. The contract prices are lower than the prices the customer would otherwise pay to the wholesaler, and the price difference is referred to as a chargeback, which generally takes the form of a credit memo issued by the Company to reduce the invoiced gross selling price charged to the wholesaler. An estimated accrued provision for chargeback deductions is recognized at the time of product shipment. The primary factors considered when estimating the provision for chargebacks are the average historical chargeback credits given, the mix of products shipped, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual chargebacks granted and compares them to the estimated provision for chargebacks to assess the reasonableness of the chargeback reserve at each quarterly balance sheet date.
	Rebates
	The Company maintains various rebate programs with its customers in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebates generally take the form of a credit memo to reduce the invoiced gross selling price charged to a customer for products shipped. An estimated accrued provision for rebate deductions is recognized at the time of product shipment. The primary factors the Company considers when estimating the provision for rebates are the average historical experience of aggregate credits issued, the mix of products shipped and the historical relationship of rebates as a percentage of total gross product sales, the contract terms and conditions of the various rebate programs in effect at the time of shipment, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual rebates granted and compares them to the estimated provision for rebates to assess the reasonableness of the rebate reserve at each quarterly balance sheet date.
	Distribution Service Fees
	The Company pays distribution service fees to several of its wholesaler customers related to sales of its Impax Products. The wholesalers are generally obligated to provide the Company with periodic outbound sales information as well as inventory levels of the Company’s Impax Products held in their warehouses. Additionally, the wholesalers have agreed to manage the variability of their purchases and inventory levels within specified days on hand limits. An accrued provision for distribution service fees is recognized at the time products are shipped to wholesalers.
	Returns
	The Company allows its customers to return product if approved by authorized personnel in writing or by telephone with the lot number and expiration date accompanying any request and if such products are returned within six months prior to or until twelve months following, the products’ expiration date. The Company estimates and recognizes an accrued provision for product returns as a percentage of gross sales based upon historical experience. The product return reserve is estimated using a historical lag period, which is the time between when the product is sold and when it is ultimately returned, and estimated return rates which may be adjusted based on various assumptions including changes to internal policies and procedures, changes in business practices, and commercial terms with customers, competitive position of each product, amount of inventory in the wholesaler supply chain, the introduction of new products, and changes in market sales information. The Company also considers other factors, including significant market changes which may impact future expected returns, and actual product returns. The Company monitors actual returns on a quarterly basis and may record specific provisions for returns it believes are not covered by historical percentages.
	Shelf-Stock Adjustments
	Based upon competitive market conditions, the Company may reduce the selling price of certain Global Division products. The Company may issue a credit against the sales amount to a customer based upon their remaining inventory of the product in question, provided the customer agrees to continue to make future purchases of product from the Company. This type of customer credit is referred to as a shelf-stock adjustment, which is the difference between the sales price and the revised lower sales price, multiplied by an estimate of the number of product units on hand at a given date. Decreases in selling prices are discretionary decisions made by the Company in response to market conditions, including estimated launch dates of competing products and declines in market price. The Company records an estimate for shelf-stock adjustments in the period it agrees to grant such a credit memo to a customer.
	Medicaidand Other Government Pricing Programs
	As required by law, the Company provides a rebate on drugs dispensed under the Medicaid program, Medicare Part D, TRICARE, and other U.S. government pricing programs. The Company determines its estimated government rebate accrual primarily based on historical experience of claims submitted by the various states and other jurisdictions and any new information regarding changes in the various programs which may impact the Company’s estimate of government rebates. In determining the appropriate accrual amount, the Company considers historical payment rates and processing lag for outstanding claims and payments. The Company records estimates for government rebates as a deduction from gross sales, with a corresponding adjustment to accrued liabilities.
	Cash Discounts
	The Company offers cash discounts to its customers, generally 2% of the gross selling price, as an incentive for paying within invoice terms, which generally range from 30 to 90 days. An estimate of cash discounts is recorded in the same period when revenue is recognized.
	Rx Partner and OTC Partner:
	The Rx Partner and OTC Partner contracts include revenue recognized under alliance and collaboration agreements between the Company and unrelated third-party pharmaceutical companies. The Company has entered into these alliance agreements to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform.
	The Rx Partners and OTC Partners alliance agreements obligate the Company to deliver multiple goods and/or services over extended periods. Such deliverables include manufactured pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development services. In exchange for these deliverables the Company receives payments from its agreement partners for product shipments and research and development services, and may also receive other payments including royalty, profit sharing, upfront, and periodic milestone payments. Revenue received from the alliance agreement partners for product shipments under these agreements is not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments. Royalty and profit sharing amounts the Company receives under these agreements are calculated by the respective agreement partner, with such royalty and profit share amounts generally based upon estimates of net product sales or gross profit which include estimates of deductions for chargebacks, rebates, product returns, and other adjustments the alliance agreement partners may negotiate with their respective customers. The Company records the agreement partner's adjustments to such estimated amounts in the period the agreement partner reports the amounts to the Company.
	The Company applies the updated guidance of ASC 605-25 “Multiple Element Arrangements” to the Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited (“Teva Agreement”). The Company looks to the underlying delivery of goods and/or services which give rise to the payment of consideration under the Teva Agreement to determine the appropriate revenue recognition. The Company initially defers consideration received as a result of research and development-related activities performed under the Teva Agreement. The Company recognizes deferred revenue on a straight-line basis over the expected period of performance for such services. Consideration received as a result of the manufacture and delivery of products under the Teva Agreement is recognized at the time title and risk of loss passes to the customer which is generally when product is received by Teva. The Company recognizes profit share revenue in the period earned.
	OTC Partner revenue is related to agreements with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”) and L. Perrigo Company (“Perrigo”) with respect to the supply of over-the-counter pharmaceutical products. The OTC Partner sales channel is no longer a core area of the business, and the over-the-counter pharmaceutical products the Company sells through this sales channel are older products which are only sold to Pfizer and Perrigo. The Company is currently only required to manufacture the over-the-counter pharmaceutical products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
	Research Partner:
	The Research Partner contract includes revenue recognized under development agreements with unrelated third-party pharmaceutical companies. The development agreements generally obligate the Company to provide research and development services over multiple periods. In exchange for this service, the Company received upfront payments upon signing of each development agreement and is eligible to receive contingent milestone payments, based upon the achievement of contractually specified events. Additionally, the Company may also receive royalty payments from the sale, if any, of a successfully developed and commercialized product under one of these development agreements. The Company recognizes revenue received from the achievement of contingent research and development milestones in the period such payment is earned. Royalty fee income, if any, will be recognized as current period revenue when earned.
	Promotional Partner:
	The Promotional Partner contract includes revenue recognized under a promotional services agreement with an unrelated third-party pharmaceutical company. The promotional services agreement obligated the Company to provide physician detailing sales calls services to promote certain of the unrelated third-party company’s branded drug products. The Company received service fee revenue in exchange for providing this service. The Company recognized revenue from providing physician detailing sales calls services as the services were provided. The Company’s obligation to provide physician detailing sales calls under the promotional services agreement ended on June 30, 2012.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Fees and Costs
	Shipping and handling fees related to sales transactions are recorded as selling expense. Shipping costs were $2,382,000, $1,890,000 and $1,425,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Research and development activities are expensed as incurred and consist of self-funded research and development costs and costs associated with work performed by other participants under collaborative research and development agreements.
Derivatives, Policy [Policy Text Block]	Derivatives
	The Company does not engage in hedging transactions for trading or speculative purposes or to hedge exposure to currency or interest rate fluctuations. From time to time, the Company may engage in transactions that result in embedded derivatives (e.g., convertible debt securities). In accordance with FASB ASC Topic 815, “Derivatives and Hedging”, the Company records the embedded derivative at fair value on the balance sheet and records any related gains or losses in current earnings in the statement of operations.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation
	The Company accounts for stock-based employee compensation arrangements in accordance with provisions of FASB ASC Topic 718, ”Stock Compensation”. Under FASB ASC Topic 718, the Company recognizes the grant date fair value of stock-based employee compensation as expense on a straight-line basis over the vesting period of the grant. The Company uses the Black Scholes option pricing model to determine the grant date fair value of employee stock options; the fair value of restricted stock awards is equal to the closing price of the Company’s stock on the date such award was granted.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company provides for income taxes using the asset and liability method as required by FASB ASC Topic 740, “Income Taxes”. This approach recognizes the amount of federal, state, local taxes, and foreign taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequences of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates in the period during which they are signed into law. Under FASB ASC Topic 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.
	FASB ASC Topic 740, Sub-topic 10, ”Tax Positions”, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with generally accepted accounting principles. Under FASB ASC Topic 740, Sub-topic 10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not the tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Additionally, FASB ASC Topic 740, Sub-topic 10 provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. In accordance with the disclosure requirements of FASB ASC Topic 740, Sub-topic 10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.
Earnings Per Share, Policy [Policy Text Block]	Earnings per Share
	Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares adjusted for the dilutive effect of common stock equivalents outstanding during the period.
Comprehensive Income, Policy [Policy Text Block]	Other Comprehensive Income
	The Company follows the provisions of FASB ASC Topic 220, ”Comprehensive Income”, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive income is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company recorded foreign currency translation gains and losses, which are reported as comprehensive income. Foreign currency translation gains (losses) for the years ended December 31, 2014, 2013 and 2012 were $(7,149,000), $(4,104,000) and $3,520,000 respectively.
Deferred Charges, Policy [Policy Text Block]	Deferred Financing Costs
	The Company capitalizes direct costs incurred with obtaining debt financing, which are included in other assets on the consolidated balance sheet. Deferred financing costs, including costs incurred in obtaining debt financing, are amortized to interest expense over the term of the underlying debt on a straight-line basis, which approximates the effective interest method. The Company recognized amortization of $30,000, $30,000 and $30,000 in the years ended December 31, 2014, 2013 and 2012, respectively.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation
	The Company translates the assets and liabilities of the Taiwan dollar functional currency of its majority-owned affiliate Prohealth Biotech, Inc. and its wholly-owned subsidiary Impax Laboratories (Taiwan), Inc. into the U.S. dollar reporting currency using exchange rates in effect at the end of each reporting period. The revenue and expense of these entities are translated using an average of the rates in effect during the reporting period. Gains and losses from these translations are recorded as currency translation adjustments included in the consolidated statements of comprehensive income and the consolidated statements of changes in stockholders’ equity.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]		Years Ended December 31,
		2014		2013		2012
	(in $000s)
	Cash paid for interest	$	17	$	89	$	546
	Cash paid for income taxes, net	$	72,174	$	34,272	$	55,356

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Percent of Total Accounts Receivable	2014			2013			2012
	Customer #1		36.9	%		28.8	%		23.3	%
	Customer #2		28.2	%		35.1	%		31.9	%
	Customer #3		19.6	%		18.5	%		18.4	%
	Customer #4		1.8	%		2.9	%		--	%
	Customer #5		1.7	%		--	%		--	%
	Customer #6		--	%		--	%		3.7	%
	Customer #7		--	%		--	%		3.1	%
	Customer #8		--	%		1	%		--	%
	Total five largest customers		88.2	%		86.3	%		80.4	%
	Percent of Gross Revenues	2014			2013			2012
	Customer #1		36	%		30.6	%		21.8	%
	Customer #2		20.7	%		25.1	%		25.2	%
	Customer #3		19.3	%		20.3	%		15.1	%
	Customer #4		2.5	%		2.5	%		--	%
	Customer #5		1.9	%		--	%		--	%
	Customer #6		--	%		--	%		9.2	%
	Customer #7		--	%		2.4	%		2.9	%
	Total five largest customers		80.4	%		80.9	%		74.2	%

Note_4_Investments_Tables

Note 4 - Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Held-to-maturity Securities [Table Text Block]				Gross		Gross
	(in $000’s)	Amortized		Unrecognized		Unrecognized			Fair
	31-Dec-14	Cost		Gains		Losses			Value
	Commercial paper	$	68,972	$	17	$	--		$	68,989
	Corporate bonds		131,011		--		(101	)		130,910
	Total short-term investments	$	199,983	$	17	$	(101	)	$	199,899
				Gross		Gross
	(in $000’s)	Amortized		Unrecognized		Unrecognized			Fair
	31-Dec-13	Cost		Gains		Losses			Value
	Commercial paper	$	91,480	$	26	$	--		$	91,506
	Corporate bonds		137,041		13		(21	)		137,033
	Total short-term investments	$	228,521	$	39	$	(21	)	$	228,539

Note_5_Accounts_Receivable_Tab

Note 5 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]		December 31,			December 31,
	(in $000’s)	2014			2013
	Gross accounts receivable	$	287,362		$	246,319
	Less: Rebate reserve		(88,812	)		(88,449	)
	Less: Chargeback reserve		(43,125	)		(37,066	)
	Less: Other deductions		(8,935	)		(7,811	)
	Accounts receivable, net	$	146,490		$	112,993
Allowance for Credit Losses on Financing Receivables [Table Text Block]	(in $000’s)	December 31,			December 31,			December 31,
	Rebate reserve	2014			2013			2012
	Beginning balance	$	88,449		$	46,011		$	29,164
	Provision recorded during the period		260,747			193,288			111,099
	Credits issued during the period		(260,384	)		(150,850	)		(94,252	)
	Ending balance	$	88,812		$	88,449		$	46,011
	(in $000’s)	December 31,			December 31,			December 31,
	Chargeback reserve	2014			2013			2012
	Beginning balance	$	37,066		$	18,410		$	22,161
	Provision recorded during the period		487,377			389,707			209,452
	Credits issued during the period		(481,318	)		(371,051	)		(213,203	)
	Ending balance	$	43,125		$	37,066		$	18,410

Note_6_Inventory_Tables

Note 6 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		December 31,		December 31,
	(in $000’s)	2014		2013
	Raw materials	$	34,681	$	27,981
	Work in process		2,447		1,434
	Finished goods		55,102		47,416
	Total inventory		92,230		76,831
	Less: Non-current inventory		11,660		6,724
	Total inventory-current	$	80,570	$	70,107

Note_7_Property_Plant_and_Equi1

Note 7 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		December 31,			December 31,
	(in $000’s)	2014			2013
	Land	$	5,773		$	5,773
	Buildings and improvements		154,374			139,657
	Equipment		122,184			114,950
	Office furniture and equipment		12,623			11,523
	Construction-in-progress		9,404			15,910
	Property, plant and equipment, gross	$	304,358		$	287,813
	Less: Accumulated depreciation		(116,189	)		(99,622	)
	Property, plant and equipment, net	$	188,169		$	188,191

Note_8_Goodwill_and_Intangible1

Note 8 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(in $000’s)	Initial		Accumulated						Carrying
	31-Dec-14	Cost		Amortization			Impairment			Value
	Intangible assets:
	Zomig® product rights	$	41,783	$	(31,561	)	$	---		$	10,222
	Tolmar product rights		33,450		(10,801	)		(16,032	)		6,617
	Perrigo product rights		1,000		(297	)		---			703
	Ursodiol product rights		3,000		(331	)		---			2,669
	Other product rights		7,250		---			(750	)		6,500
	Total intangible assets	$	86,483	$	(42,990	)	$	(16,782	)	$	26,711
	(in $000’s)	Initial		Accumulated						Carrying
	31-Dec-13	Cost		Amortization			Impairment			Value
	Intangible assets:
	Zomig® product rights	$	41,783	$	(28,641	)	$	---		$	13,142
	Tolmar product rights		31,450		(3,266	)		(13,156	)		15,028
	Other product rights		2,250		---			(750	)		1,500
	Total intangible assets	$	75,483	$	(31,907	)	$	(13,906	)	$	29,670
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]		Amortization
	(in $000’s)	Expense
	2015	$	5,846
	2016		4,618
	2017		4,230
	2018		2,625
	2019		1,005
	Thereafter		1,887
	Total	$	20,211

Note_9_Accrued_Expenses_Tables

Note 9 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	(in $000’s)	December 31,			December 31,
		2014			2013
	Payroll-related expenses	$	33,812		$	27,985
	Product returns		27,174			28,089
	Government rebates		18,272			23,351
	Legal and professional fees		9,497			3,162
	Income taxes payable		40			21,186
	Physician detailing sales force fees		2,336			1,512
	Litigation accrual		12,750			--
	Other		6,589			6,238
	Total accrued expenses	$	110,470		$	111,523
Schedule of Product Warranty Liability [Table Text Block]	(in $000's)	December 31,			December 31,			December 31,
	Returns Reserve	2014			2013			2012
	Beginning balance	$	28,089		$	23,440		$	24,101
	Provision related to sales recorded in the period		12,016			11,015			3,003
	Credits issued during the period		(12,931	)		(6,366	)		(3,664	)
	Ending balance	$	27,174		$	28,089		$	23,440

Note_10_Income_Taxes_Tables

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		For the Years Ended December 31,
	(in $000’s)	2014			2013			2012
	Current:
	Federal taxes	$	42,635		$	67,407		$	49,636
	State taxes		2,467			2,569			1,721
	Foreign taxes		832			742			453
	Total current tax expense		45,934			70,718			51,810
	Deferred:
	Federal taxes	$	(9,039	)	$	(21,050	)	$	(21,650	)
	State taxes		(3,597	)		(1,965	)		(2,537	)
	Foreign taxes		(92	)		(2,022	)		(185	)
	Total deferred tax (benefit) expense		(12,728	)		(25,037	)		(24,372	)
	Provision for income taxes	$	33,206		$	45,681		$	27,438
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		For the Years Ended December 31,
	(in $000’s)	2014						2013					2012
	Income before income taxes	$	90,559					$	146,940				$	83,311
	Tax provision at the federal statutory rate		31,696			35	%		51,429		35	%		29,159		35	%
	Increase (decrease) in tax rate resulting from:
	Tax rate differential and permanent items on foreign income		2,285			2.5	%		383		0.3	%		(1,259	)	(1.5	)%
	State income taxes, net of federal benefit		887			1	%		1,616		1.1	%		1,906		2.3	%
	State research and development credits		(2,133	)		(2.4	)%		(1,787	)	(1.2	)%		(1,560	)	(1.9	)%
	Federal research and development credits		(2,401	)		(2.6	)%		(1,900	)	(1.3	)%		---		--	%
	Share-based compensation		189			0.2	%		92		0.1	%		326		0.4	%
	Executive compensation		1,552			1.7	%		336		0.2	%		825		1	%
	Domestic manufacturing deduction		(679	)		(0.7	)%		(1,666	)	(1.1	)%		(2,010	)	(2.4	)%
	Other permanent book/tax differences		170			0.2	%		(967	)	(0.7	)%		(185	)	(0.2	)%
	Provision for uncertain tax positions		952			1.1	%		1,718		1.1	%		801		0.9	%
	Revision of prior years’ estimates		664			0.7	%		(1,150	)	(0.8	)%		(392	)	(0.5	)%
	Prior year Federal research and development credits		---			--	%		(1,950	)	(1.3	)%		---		--	%
	Other, net		24			0	%		(473	)	(0.3	)%		(173	)	(0.2	)%
	Provision for income taxes	$	33,206			36.7	%	$	45,681		31.1	%	$	27,438		32.9	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
	(in $000’s)	2014			2013
	Deferred tax assets:
	Deferred revenues	$	1,550		$	2,961
	Accrued expenses		46,206			44,404
	Inventory reserves		10,223			6,681
	Net operating loss carryforwards		46			61
	Depreciation and amortization		284			275
	Acquired product rights and intangibles		18,788			15,147
	Capitalized legal fees		12,829			11,245
	R&D credit carryforwards		4,331			3,238
	Share based compensation expense		4,397			4,786
	Other		1,048			745
	Deferred tax assets	$	99,702		$	89,543
	Deferred tax liabilities:
	Tax depreciation and amortization in excess of book amounts	$	1,028		$	2,592
	Deferred manufacturing costs		65			65
	Other		1,947			2,172
	Deferred tax liabilities	$	3,040		$	4,829
	Deferred tax assets, net	$	96,662		$	84,714
		December 31,
	(in $000’s)	2014			2013
	Current deferred tax assets	$	56,772		$	52,959
	Current deferred tax liabilities		(1,947	)		(2,171	)
	Current deferred tax assets, net		54,825			50,788
	Non-current deferred tax assets		42,930			36,583
	Non-current deferred tax liabilities		(1,093	)		(2,657	)
	Non-current deferred tax assets, net		41,837			33,926
	Deferred tax assets, net	$	96,662		$	84,714
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		For the Years Ended December 31,
	(in $000’s)	2014			2013			2012
	Unrecognized tax benefits beginning of year	$	5,292		$	2,920		$	1,791
	Gross change for current year positions		1,089			797			249
	Gross change for prior period positions		310			1,575			1,231
	Decrease due to settlements and payments		(174	)		--			(351	)
	Unrecognized tax benefits end of year	$	6,517		$	5,292		$	2,920

Note_12_Alliance_and_Collabora1

Note 12 - Alliance and Collaboration Agreements (Tables)	12 Months Ended
	Dec. 31, 2014
Teva Pharmaceutical Industries Limited [Member]
Note 12 - Alliance and Collaboration Agreements (Tables) [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]		For the Years Ended December 31,
	(in $000’s)
	Deferred revenue	2014			2013			2012
	Beginning balance	$	1,087		$	2,396		$	3,705
	Less amounts recognized		(1,087	)		(1,309	)		(1,309	)
	Ending deferred revenue	$	---		$	1,087		$	2,396
Valeant [Member]
Note 12 - Alliance and Collaboration Agreements (Tables) [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	(in $000’s)	Years Ended December 31,
	Deferred revenue	2014			2013			2012
	Beginning balance	$	1,825		$	3,650		$	12,410
	Less amount recognized		(1,825	)		(1,825	)		(8,760	)
	Ending deferred revenue	$	---		$	1,825		$	3,650

Note_14_Sharebased_Compensatio1

Note 14 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]					Weighted-
					Average
					Exercise
		Number of Shares			Price
	Stock Options	Under Option			per Share
	Outstanding at December 31, 2011		5,073,097			11.76
	Options granted		278,500			20.9
	Options exercised		(1,060,746	)		11.16
	Options forfeited		(113,630	)		16.69
	Outstanding at December 31, 2012		4,177,221			12.72
	Options granted		506,000			18.06
	Options exercised		(814,177	)		9.28
	Options forfeited		(98,139	)		19.51
	Outstanding at December 31, 2013		3,770,905			14.01
	Options granted		386,600			25.27
	Options exercised		(778,112	)		13.76
	Options forfeited		(337,213	)		20.48
	Outstanding at December 31, 2014		3,042,180			14.78
	Options exercisable at December 31, 2014		2,458,207		$	12.89
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]		Non-Vested			Weighted-
		Restricted			Average
		Stock			Grant Date
	Restricted Stock Awards	Awards			Fair Value
	Non-vested at December 31, 2011		1,663,911			17.2
	Granted		1,015,937			23.41
	Vested		(585,392	)		14.72
	Forfeited		(139,886	)		19.08
	Non-vested at December 31, 2012		1,954,570			20.97
	Granted		1,032,924			19.92
	Vested		(617,302	)		18.8
	Forfeited		(246,357	)		20.69
	Non-vested at December 31, 2013		2,123,835			21.13
	Granted		1,449,585			25.35
	Vested		(796,966	)		21.36
	Forfeited		(449,278	)		21.47
	Non-vested at December 31, 2014		2,327,176		$	23.61
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		For the Years Ended December 31,
		2014			2013			2012
	Volatility (range)		40.1%-41.7	%		41.7	%		48.5%-49.3	%
	Volatility (weighted average)		40.2	%		41.7	%		49.1	%
	Risk-free interest rate (range)		0.6%-1.9	%		1.1%-1.9	%		0.9%-1.0	%
	Risk-free interest rate (weighted average)		1.8	%		1.2	%		1	%
	Dividend yield		0	%		0	%		0	%
	Expected life (years)		6.07			6.19			6.19
	Weighted average grant date fair value	$	10.45		$	7.54		$	9.93
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		For the Years Ended December 31,
	(in $000’s)	2014			2013			2012
	Cost of revenues	$	2,494		$	2,035		$	2,405
	Research and development		5,072			4,885			4,658
	Selling, general and administrative		13,317			10,724			9,240
	Total	$	20,883		$	17,644		$	16,303

Note_16_Earnings_per_Share_Tab

Note 16 - Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		For the Years Ended December 31,
	(in $000’s, except share and per share amounts)	2014		2013		2012
	Numerator:
	Net income	$	57,353	$	101,259	$	55,873
	Denominator:
	Weighted average common shares outstanding		68,185,552		66,921,181		65,660,271
	Effect of dilutive stock options and and restricted stock		2,344,797		1,733,857		2,744,280
	Diluted weighted average common shares outstanding		70,530,349		68,655,038		68,404,551
	Basic net income per share	$	0.84	$	1.51	$	0.85
	Diluted net income per share	$	0.81	$	1.47	$	0.82

Note_17_Segment_Information_Ta

Note 17 - Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	(in $000’s)	Global		Impax			Corporate			Total
	Year Ended December 31, 2014	Division		Division			and Other			Company
	Revenues, net	$	549,082	$	46,967		$	--		$	596,049
	Cost of revenues		260,459		22,937			--			283,396
	Research and development		40,927		38,187			--			79,114
	Patent litigation		5,333		--			--			5,333
	Selling, general and administrative		17,144		43,307			78,939			139,390
	Income (loss) before income taxes	$	225,219	$	(57,464	)	$	(77,196	)	$	90,559
		Global		Impax			Corporate			Total
	Year Ended December 31, 2013	Division		Division			and Other			Company
	Revenues, net	$	398,340	$	113,162		$	--		$	511,502
	Cost of revenues		253,836		58,366			--			312,202
	Research and development		41,384		27,470			--			68,854
	Patent litigation		16,545		--			--			16,545
	Selling, general and administrative		17,684		44,915			57,689			120,288
	Income (loss) before income taxes	$	68,891	$	(17,589	)	$	95,638		$	146,940
		Global		Impax			Corporate			Total
	Year Ended December 31, 2012	Division		Division			and Other			Company
	Revenues, net	$	448,682	$	133,010		$	--		$	581,692
	Cost of revenues		229,355		69,783			--			299,138
	Research and development		48,604		32,716			--			81,320
	Patent litigation		9,772		--			--			9,772
	Selling, general and administrative		15,377		37,896			55,197			108,470
	Income (loss) before income taxes	$	145,574	$	(7,385	)	$	(54,878	)	$	83,311

Note_18_Commitments_and_Contin1

Note 18 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]		Years Ended
	(in $000s)	December 31,
	2015		2,348
	2016		1,580
	2017		990
	2018		848
	2019		803
	Thereafter		2,584
	Total minimum lease payments	$	9,153

Note_20_Supplementary_Financia1

Note 20 - Supplementary Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]		2014 Quarters Ended:
	(in $000’s except shares and per share amounts)	31-Mar		30-Jun			30-Sep			31-Dec
	Revenue:
	Global Product sales, gross	$	265,850	$	375,269		$	340,379		$	322,707
	Less:
	Chargebacks		95,714		110,518			115,419			131,882
	Rebates		52,054		74,079			64,442			66,685
	Product returns		1,294		5,140			3,494			993
	Other credits		10,671		21,571			13,449			8,288
	Global Product sales, net		106,117		163,961			143,575			114,859
	Rx Partner		2,435		9,204			1,447			1,028
	Other Revenues		589		3,229			611			2,028
	Global Division revenues, net		109,141		176,394			145,633			117,915
	Impax Product sales, gross		20,643		24,375			23,840			23,348
	Less:
	Chargebacks		8,230		10,107			8,787			6,720
	Rebates		1,070		938			469			1,010
	Product returns		181		216			223			475
	Other credits		1,853		1,654			2,261			2,074
	Impax Product sales, net		9,309		11,460			12,100			13,069
	Other Revenues		268		267			266			227
	Impax Division revenues, net		9,577		11,727			12,366			13,296
	Total net revenues		118,718		188,121			157,999			131,211
	Gross profit		57,622		109,772			84,438			60,821
	Net income	$	6,425	$	35,071		$	15,737		$	120
	Net income per share (basic)	$	0.09	$	0.52		$	0.23		$	0
	Net income per share (diluted)	$	0.09	$	0.5		$	0.22		$	0
	Weighted average:
	common shares outstanding:
	Basic		67,702,296		68,095,159			68,254,327			68,678,779
	Diluted		69,938,872		70,313,491			70,715,226			70,988,328
		2013 Quarters Ended:
	(in $000’s except shares and per share amounts)	31-Mar		30-Jun			30-Sep			31-Dec
	Revenue:
	Global Product sales, gross	$	197,956	$	217,721		$	279,441		$	288,315
	Less:
	Chargebacks		64,345		82,013			98,449			111,903
	Rebates		30,572		35,649			54,530			68,363
	Product Returns		94		1,989			2,857			1,989
	Other credits		5,160		8,312			11,919			21,639
	Global Product sales, net		97,785		89,758			111,686			84,423
	Rx Partner		3,114		3,668			3,016			1,841
	Other Revenues		737		539			1,046			727
	Global Division revenues, net		101,636		93,965			115,748			86,991
	Impax Product sales, gross		69,292		48,300			22,849			21,244
	Less:
	Chargebacks		7,790		10,095			8,422			6,690
	Rebates		6,236		(1,735	)		(812	)		485
	Product Returns		1,490		2,197			175			224
	Other credits		7,255		2,409			(1,498	)		361
	Impax Product sales, net		46,521		35,334			16,562			13,484
	Other Revenues		332		332			331			266
	Impax Division revenues, net		46,853		35,666			16,893			13,750
	Total net revenues		148,489		129,631			132,641			100,741
	Gross profit		57,871		58,887			48,342			34,200
	Net income (loss)	$	105,442	$	5,619		$	(180	)	$	(9,622	)
	Net income (loss) per share (basic)	$	1.59	$	0.08		$	0		$	(0.14	)
	Net income (loss) per share (diluted)	$	1.55	$	0.08		$	0		$	(0.14	)
	Weighted average:
	common shares outstanding:
	Basic		66,487,470		66,748,864			67,051,121			67,385,969
	Diluted		68,178,355		68,287,948			67,051,121			67,385,969

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Cash Flow Elements [Abstract]
Accrued Vendor Invoices	$1,932,000	$6,210,000	$10,017,000

Supplemental_Cash_Flow_Informa3

Supplemental Cash Flow Information (Details) - Supplemental Disclosure of Non-cash Investing and Financing Activities (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Disclosure of Non-cash Investing and Financing Activities [Abstract]
Cash paid for interest	$17	$89	$546
Cash paid for income taxes, net	$72,174	$34,272	$55,356

Note_1_The_Company_Details

Note 1 - The Company (Details) (USD $)	0 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Oct. 30, 2014	Jun. 04, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2014	Oct. 08, 2014	Oct. 22, 2014	Jun. 30, 2014
Note 1 - The Company (Details) [Line Items]
Number of Reportable Segments				2
Number Of Channels				4	4
Number of Internally Developed Branded Pharmaceutical Product Candidate				1
Restructuring and Related Cost, Number of Positions Eliminated	41	110
Restructuring and Related Cost, Incurred Cost			$3
Research and Development Services [Member]
Note 1 - The Company (Details) [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated	35
Employee Severance [Member]
Note 1 - The Company (Details) [Line Items]
Restructuring Charges	2.1
Payments for Restructuring					1.8
Tower Holdings, Inc [Member]
Note 1 - The Company (Details) [Line Items]
Business Combination, Consideration Transferred						700
Separation Pay and Benefits [Member] | President and CEO [Member]
Note 1 - The Company (Details) [Line Items]
Employee-related Liabilities			2.7
Accelerated Expense Outstanding Options and Restricted Stock [Member] | President and CEO [Member]
Note 1 - The Company (Details) [Line Items]
Employee-related Liabilities			2.3
Severance Charges and Accelerated Equity Expense [Member] | Senior Vice President [Member]
Note 1 - The Company (Details) [Line Items]
Employee-related Liabilities								0.9
Termination Benefits and Payments [Member] | Carole S. Ben-Maimon [Member]
Note 1 - The Company (Details) [Line Items]
Other Labor-related Expenses							1.9
President and CEO [Member]
Note 1 - The Company (Details) [Line Items]
Employee-related Liabilities			$5
California [Member]
Note 1 - The Company (Details) [Line Items]
Number Of Properties				5	5
Hayward California [Member]
Note 1 - The Company (Details) [Line Items]
Number Of Leased Properties				3

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Number of Largest Customers	5	5	5
Number Of Products	10	10	10
Cash Discount Discount Rate	2.00%
Shipping, Handling and Transportation Costs (in Dollars)	$2,382,000	$1,890,000	$1,425,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax (in Dollars)	-7,149,000	-4,104,000	3,520,000
Amortization of Financing Costs (in Dollars)	$30,000	$30,000	$30,000
Period Prior to Expiration Date [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Product Return Period	6 months
Period Following Expiration Date [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Product Return Period	12 months
Building [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Building Improvements [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Building Improvements [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Equipment [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	8 years
Equipment [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office Furniture and Equipment [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Office Furniture and Equipment [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Global Division [Member] | Top 10 Generic Products [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	62.00%	68.00%	70.00%
Impax Division [Member] | Zomig Products [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	100.00%
Prohealth Biotech [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	57.54%
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Cash Discount Invoice Terms	30 days
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Cash Discount Invoice Terms	90 days

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Percentage of Total Accounts Receivable and Gross Revenues (Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Customer 1 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	36.90%	28.80%	23.30%
Customer 1 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	36.00%	30.60%	21.80%
Customer 2 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	28.20%	35.10%	31.90%
Customer 2 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	20.70%	25.10%	25.20%
Customer 3 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	19.60%	18.50%	18.40%
Customer 3 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	19.30%	20.30%	15.10%
Customer 4 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	1.80%	2.90%
Customer 4 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	2.50%	2.50%
Customer 5 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	1.70%
Customer 5 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	1.90%
Customer 6 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer			3.70%
Customer 6 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer			9.20%
Customer 7 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer			3.10%
Customer 7 [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer		2.40%	2.90%
Customer 8 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer		1.00%
Total 5 Largest Customers [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	88.20%	86.30%	80.40%
Total 5 Largest Customers [Member] | Gross Revenues [Member]
Concentration Risk [Line Items]
Customer	80.40%	80.90%	74.20%

Note_3_Recent_Accounting_Prono1

Note 3 - Recent Accounting Pronouncements (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	$0.70

Note_4_Investments_Details_Sum

Note 4 - Investments (Details) - Summary of Short-term Investments (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$199,983	$228,521
Gross Unrecognized Gains	17	39
Gross Unrecognized Losses	-101	-21
Fair Value	199,899	228,539
Commercial Paper [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	68,972	91,480
Gross Unrecognized Gains	17	26
Fair Value	68,989	91,506
Corporate Bonds [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	131,011	137,041
Gross Unrecognized Gains		13
Gross Unrecognized Losses	-101	-21
Fair Value	$130,910	$137,033

Note_5_Accounts_Receivable_Det

Note 5 - Accounts Receivable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Receivables [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$515,000	$539,000

Note_5_Accounts_Receivable_Det1

Note 5 - Accounts Receivable (Details) - Composition of Accounts Receivable, Net (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Composition of Accounts Receivable, Net [Abstract]
Gross accounts receivable	$287,362	$246,319
Less: Rebate reserve	-88,812	-88,449
Less: Chargeback reserve	-43,125	-37,066
Less: Other deductions	-8,935	-7,811
Accounts receivable, net	$146,490	$112,993

Note_5_Accounts_Receivable_Det2

Note 5 - Accounts Receivable (Details) - Roll Forward of the Rebate and Chargeback Reserves Activity (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Financing Receivable, Allowance for Credit Losses [Line Items]
Ending balance	$43,125	$37,066
Ending balance	88,812	88,449
Rebate Reserve [Member]
Financing Receivable, Allowance for Credit Losses [Line Items]
Beginning balance	88,449	46,011	29,164
Provision recorded during the period	260,747	193,288	111,099
Credits issued during the period	-260,384	-150,850	-94,252
Ending balance	88,812	88,449	46,011
Chargeback Reserve [Member]
Financing Receivable, Allowance for Credit Losses [Line Items]
Provision recorded during the period	487,377	389,707	209,452
Credits issued during the period	-481,318	-371,051	-213,203
Ending balance	43,125	37,066	18,410
Beginning balance	$37,066	$18,410	$22,161

Note_6_Inventory_Details

Note 6 - Inventory (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
Note 6 - Inventory (Details) [Line Items]
Inventory Valuation Reserves	25,639,000	$17,702,000
Finished and Unfinished Inventory Related to Discontinued Products [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Valuation Reserves			6,700,000
Impact of Expected Delay of FDA Approval [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Valuation Reserves			5,000,000
Additional Pre-launch Inventory of Product Manufactured for Third-Party [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Valuation Reserves			6,400,000
Unapproved Inventory [Member]
Note 6 - Inventory (Details) [Line Items]
Unapproved Product Inventory Net	7,312,000	$6,462,000
Raw Materials [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Turnover Period Minimum	3 years
Inventory Turnover Period Maximum	5 years
Finished Goods [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Turnover Period Maximum	2 years

Note_6_Inventory_Details_Inven

Note 6 - Inventory (Details) - Inventory, Net of Carrying Value Reserves (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net of Carrying Value Reserves [Abstract]
Raw materials	$34,681	$27,981
Work in process	2,447	1,434
Finished goods	55,102	47,416
Total inventory	92,230	76,831
Less: Non-current inventory	11,660	6,724
Total inventory-current	$80,570	$70,107

Note_7_Property_Plant_and_Equi2

Note 7 - Property, Plant and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation	$20,353,000	$16,782,000	$15,982,000

Note_7_Property_Plant_and_Equi3

Note 7 - Property, Plant and Equipment (Details) - Property, Plant and Equipment, Net (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment, Net [Abstract]
Land	$5,773	$5,773
Buildings and improvements	154,374	139,657
Equipment	122,184	114,950
Office furniture and equipment	12,623	11,523
Construction-in-progress	9,404	15,910
Property, plant and equipment, gross	304,358	287,813
Less: Accumulated depreciation	-116,189	-99,622
Property, plant and equipment, net	$188,169	$188,191

Note_8_Goodwill_and_Intangible2

Note 8 - Goodwill and Intangible Assets (Details) (USD $)	3 Months Ended	12 Months Ended			3 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Jun. 30, 2012	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2014
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill		$27,574,000	$27,574,000				$27,574,000
Number Of Products		10	10	10
Impairment of Intangible Assets (Excluding Goodwill)		2,876,000	13,906,000
Impairment of Intangible Assets (Excluding Goodwill), Percent of Carrying Value	100.00%
Amortization of Intangible Assets		11,083,000	13,061,000	18,846,000
Cost of Sales [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	2,900,000				13,200,000
Research and Development Expense [Member] | Abbreviated New Drug Applications [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)					800,000
Products Approved [Member] | Tolmar Incorporated [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products		10				10
Product Pending Approval [Member] | Tolmar Incorporated [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products		1				1
Tolmar Incorporated [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products		11				11
Zomig Product Rights Tablet [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		14 months
Zomig Product Rights Orally Disintegrating Tablet [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		11 months
Zomig Product Rights Nasal Spray [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		72 months
Tolmar Product Rights [Member] | Minimum [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		5 years
Tolmar Product Rights [Member] | Maximum [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		12 years
Tolmar Product Rights [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Period Increase (Decrease)							2,000,000
Perrigo Product Rights [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Period Increase (Decrease)								1,000,000
Actavis Product Rights [Member]
Note 8 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life									8 years
Finite-lived Intangible Assets Acquired									$8,000,000

Note_8_Goodwill_and_Intangible3

Note 8 - Goodwill and Intangible Assets (Details) - Intangible Assets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible assets:
Initial cost	$86,483	$75,483
Accumulated amortization	-42,990	-31,907
Impairment	-16,782	-13,906
Carrying value	26,711	29,670
Other Product Rights [Member]
Intangible assets:
Initial cost	7,250	2,250
Impairment	-750	-750
Carrying value	6,500	1,500
Zomig Product Rights [Member]
Intangible assets:
Initial cost	41,783	41,783
Accumulated amortization	-31,561	-28,641
Carrying value	10,222	13,142
Tolmar Product Rights [Member]
Intangible assets:
Initial cost	33,450	31,450
Accumulated amortization	-10,801	-3,266
Impairment	-16,032	-13,156
Carrying value	6,617	15,028
Perrigo Product Rights [Member]
Intangible assets:
Initial cost	1,000
Accumulated amortization	-297
Carrying value	703
Ursodiol Product Rights [Member]
Intangible assets:
Initial cost	3,000
Accumulated amortization	-331
Carrying value	$2,669

Note_8_Goodwill_and_Intangible4

Note 8 - Goodwill and Intangible Assets (Details) - Expected Amortization Expense (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Expected Amortization Expense [Abstract]
2015	$5,846
2016	4,618
2017	4,230
2018	2,625
2019	1,005
Thereafter	1,887
Total	$20,211

Note_9_Accrued_Expenses_Detail

Note 9 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]
Payroll-related expenses	$33,812	$27,985
Product returns	27,174	28,089
Government rebates	18,272	23,351
Legal and professional fees	9,497	3,162
Income taxes payable	40	21,186
Physician detailing sales force fees	2,336	1,512
Litigation accrual	12,750
Other	6,589	6,238
Total accrued expenses	$110,470	$111,523

Note_9_Accrued_Expenses_Detail1

Note 9 - Accrued Expenses (Details) - Roll Forward of Product Return Reserve (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 9 - Accrued Expenses (Details) - Roll Forward of Product Return Reserve [Line Items]
Ending balance	$27,174	$28,089
Returns Reserve [Member]
Note 9 - Accrued Expenses (Details) - Roll Forward of Product Return Reserve [Line Items]
Beginning balance	28,089	23,440	24,101
Provision related to sales recorded in the period	12,016	11,015	3,003
Credits issued during the period	-12,931	-6,366	-3,664
Ending balance	$27,174	$28,089	$23,440

Note_10_Income_Taxes_Details

Note 10 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 10 - Income Taxes (Details) [Line Items]
Unrecognized Tax Benefits	$6,517,000	$5,292,000	$2,920,000	$1,791,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	5,000,000	4,100,000	2,300,000
Unrecognized Tax Benefits, Interest on Income Taxes Expense	5,000	299,000
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	597,000	602,000
Deferred Tax Liabilities, Undistributed Foreign Earnings	0
Domestic Tax Authority [Member]
Note 10 - Income Taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$2,401,000	$1,900,000	$0

Note_10_Income_Taxes_Details_P

Note 10 - Income Taxes (Details) - Provision for Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal taxes	$42,635	$67,407	$49,636
State taxes	2,467	2,569	1,721
Foreign taxes	832	742	453
Total current tax expense	45,934	70,718	51,810
Deferred:
Federal taxes	-9,039	-21,050	-21,650
State taxes	-3,597	-1,965	-2,537
Foreign taxes	-92	-2,022	-185
Total deferred tax (benefit) expense	-12,728	-25,037	-24,372
Provision for income taxes	$33,206	$45,681	$27,438

Note_10_Income_Taxes_Details_E

Note 10 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation [Line Items]
Income before income taxes	$90,559,000	$146,940,000	$83,311,000
Tax provision at the federal statutory rate	31,696,000	51,429,000	29,159,000
Tax provision at the federal statutory rate	35.00%	35.00%	35.00%
Increase (decrease) in tax rate resulting from:
Tax rate differential and permanent items on foreign income	2,285,000	383,000	-1,259,000
Tax rate differential and permanent items on foreign income	2.50%	0.30%	-1.50%
State income taxes, net of federal benefit	887,000	1,616,000	1,906,000
State income taxes, net of federal benefit	1.00%	1.10%	2.30%
Share-based compensation	189,000	92,000	326,000
Share-based compensation	0.20%	0.10%	0.40%
Executive compensation	1,552,000	336,000	825,000
Executive compensation	1.70%	0.20%	1.00%
Domestic manufacturing deduction	-679,000	-1,666,000	-2,010,000
Domestic manufacturing deduction	-0.70%	-1.10%	-2.40%
Other permanent book/tax differences	170,000	-967,000	-185,000
Other permanent book/tax differences	0.20%	-0.70%	-0.20%
Provision for uncertain tax positions	952,000	1,718,000	801,000
Provision for uncertain tax positions	1.10%	1.10%	0.90%
Other, net	24,000	-473,000	-173,000
Other, net	0.00%	-0.30%	-0.20%
Provision for income taxes	33,206,000	45,681,000	27,438,000
Provision for income taxes	36.70%	31.10%	32.90%
State and Local Jurisdiction [Member]
Increase (decrease) in tax rate resulting from:
Research and development credits	-2,133,000	-1,787,000	-1,560,000
Research and development credits	-2.40%	-1.20%	-1.90%
Domestic Tax Authority [Member]
Increase (decrease) in tax rate resulting from:
Research and development credits	-2,401,000	-1,900,000	0
Research and development credits	-2.60%	-1.30%
Prior Years' Estimated [Member]
Increase (decrease) in tax rate resulting from:
Revision of prior yearsb estimates	664,000	-1,150,000	-392,000
Revision of prior yearsb estimates	0.70%	-0.80%	-0.50%
Prior Year Federal R and D Credits [Member]
Increase (decrease) in tax rate resulting from:
Revision of prior yearsb estimates		($1,950,000)
Revision of prior yearsb estimates		-1.30%

Note_10_Income_Taxes_Details_C

Note 10 - Income Taxes (Details) - Components of Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Deferred revenues	$1,550	$2,961
Accrued expenses	46,206	44,404
Inventory reserves	10,223	6,681
Net operating loss carryforwards	46	61
Depreciation and amortization	284	275
Acquired product rights and intangibles	18,788	15,147
Capitalized legal fees	12,829	11,245
R&D credit carryforwards	4,331	3,238
Share based compensation expense	4,397	4,786
Other	1,048	745
Deferred tax assets	99,702	89,543
Deferred tax liabilities:
Tax depreciation and amortization in excess of book amounts	1,028	2,592
Deferred manufacturing costs	65	65
Other	1,947	2,172
Deferred tax liabilities	3,040	4,829
Deferred tax assets, net	96,662	84,714
Current deferred tax assets	56,772	52,959
Current deferred tax liabilities	-1,947	-2,171
Current deferred tax assets, net	54,825	50,788
Non-current deferred tax assets	42,930	36,583
Non-current deferred tax liabilities	-1,093	-2,657
Non-current deferred tax assets, net	$41,837	$33,926

Note_10_Income_Taxes_Details_R

Note 10 - Income Taxes (Details) - Rollforward of Unrecognized Tax Benefits (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Rollforward of Unrecognized Tax Benefits [Abstract]
Unrecognized tax benefits beginning of year	$5,292	$2,920	$1,791
Unrecognized tax benefits end of year	6,517	5,292	2,920
Gross change for current year positions	1,089	797	249
Gross change for prior period positions	310	1,575	1,231
Decrease due to settlements and payments	($174)		($351)

Note_11_Revolving_Line_of_Cred1

Note 11 - Revolving Line of Credit (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 02, 2015
Subsequent Event [Member] | Revolving Credit Facility and Term Loan [Member] | Tower Holdings, Inc [Member] | Barclays, Royal Bank, Wells Fargo, and Wells Fargo Securities [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount				$485,000,000
Subsequent Event [Member] | Term Loan [Member] | Tower Holdings, Inc [Member] | Barclays, Royal Bank, Wells Fargo, and Wells Fargo Securities [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Long-term Debt				435,000,000
Subsequent Event [Member] | Revolving Credit Facility [Member] | Tower Holdings, Inc [Member] | Barclays, Royal Bank, Wells Fargo, and Wells Fargo Securities [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				50,000,000
Revolving Credit Facility [Member] | Alternate Base Rate [Member] | Minimum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Revolving Credit Facility [Member] | Alternate Base Rate [Member] | Maximum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Revolving Credit Facility [Member] | Minimum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Revolving Credit Facility [Member] | Maximum [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.45%
Revolving Credit Facility [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	50,000,000
Minimum Unrestricted Cash as Defined in Credit Agreement	100,000,000
Letter of Credit [Member] | Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000
Wells Fargo Bank, N.A. [Member]
Note 11 - Revolving Line of Credit (Details) [Line Items]
Equity Interest Pledged As Collateral	65.00%
Long-term Line of Credit	0
Total Net Leverage Ratio	3.75
Senior Secured Leverage Ratio	2.5
Minimum Consolidated EBITDA	50,000,000
Minimum Liquidity	100,000,000
Debt Instrument, Unused Borrowing Capacity, Fee	124,000	$139,000	$95,000

Note_12_Alliance_and_Collabora2

Note 12 - Alliance and Collaboration Agreements (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

25 Months Ended

1 Months Ended

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Mar. 31, 2011

Dec. 31, 2009

Mar. 31, 2009

Dec. 31, 2011

Dec. 31, 2008

Jun. 30, 2010

Dec. 31, 2010

Mar. 31, 2011

Jun. 30, 2012

Apr. 30, 2013

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

10

10

10

Research and Development Expense

$79,114,000

$68,854,000

$81,320,000

Impairment of Intangible Assets (Excluding Goodwill)

2,876,000

13,906,000

Receivable Collection Period

30 days

Period after the First Commercial Sale of the Advanced Form of SOLODYN Product the Company Is Receiving Royalty Fee Income

8 years

Gain (Loss) Related to Litigation Settlement

102,049,000

Cost of Sales [Member] | Tolmar Product Rights [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Impairment of Intangible Assets (Excluding Goodwill)

13,200,000

Cost of Sales [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Impairment of Intangible Assets (Excluding Goodwill)

13,200,000

2,900,000

Milestone Payments [Member] | Diclofenac Sodium Gel [Member] | Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Required Payment Net

2,000,000

Milestone Payments [Member] | Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Required Payment Net

1,000,000

12,000,000

Research and Development Expense

1,000,000

Collaborative Arrangement Maximum Contingent Payments Amount

10,000,000

Milestone Payments [Member] | Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

8,000,000

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

3,000,000

2,000,000

5,000,000

12,000,000

Milestone Payments [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

30,000,000

Milestone Payments [Member] | Glaxo Group Limited [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

169,000,000

Up-front Payment Arrangement [Member] | Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

40,000,000

Up-front Payment Arrangement [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Deferred Revenue, Additions

10,000,000

Up-front Payment Arrangement [Member] | Glaxo Group Limited [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Deferred Revenue, Additions

11,500,000

Milestone Payment Arrangement [Member] | Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

15,000,000

Clinical Milestone Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

15,000,000

Regulatory Milestone Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

5,000,000

Commercialization Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

10,000,000

Products Approved [Member] | Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

10

10

Product Pending Approval [Member] | Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

1

1

Products in Development [Member] | Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

2

Research and Development Expense

1,550,000

Generic Products [Member] | Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

4

1

Branded Advanced Form of Solodyn Product [Member] | Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

1

Tolmar Product Rights [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

5 years

Tolmar Product Rights [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

Specified Threshold [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Product Sales

100,000,000

Shire Laboratories Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Litigation Settlement, Amount

48,000,000

Increase (Decrease) in Other Accrued Liabilities

21,089,000

20,406,000

70,948,000

Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Increase (Decrease) in Other Accrued Liabilities

15,995,000

3,905,000

551,000

Number Of Products

11

11

Collaborative Arrangement Up Front Payment

21,000,000

Teva Pharmaceutical Industries Limited [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Service Agreement Term

10 years

Profit Share Collection Period

30 days

Valeant [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

5

Endo Pharmaceuticals Incorporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Litigation Settlement, Amount

102,049,000

Collaborative Arrangement Copromotion Service Fee Percentage

100.00%

100.00%

Deferred Revenue Estimated Period Of Recognition

112 months

Deferred Revenue

4,310,000

4,310,000

OTC Partners Alliance Agreement [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Transition Payment Percentage Of Gross Profit

100.00%

Astra Zeneca [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Quarterly Payments Made

43,564,000

Finite-Lived Intangible Assets, Gross

45,096,000

Prepaid Royalties

41,340,000

Pfizer Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Sales Revenue, Services, Net

7,070,000

DURECT Corporation [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Up Front Payment

2,000,000

Collaborative Arrangement Maximum Contingent Payments Amount

61,000,000

IND-enabling Animal Studies for New Development Candidate [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

12 months

IND-enabling Animal Studies for New Development Candidate [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

18 months

Phase 1 Trials [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Phase 1 Trials [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 years

Phase 2 Trials [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Phase 2 Trials [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Phase 3 Trials [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 years

Phase 3 Trials [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

4 years

Bioequivalence Studies [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 months

Bioequivalence Studies [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Preparation And Submission Of Regulatory Filings [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

6 months

Preparation And Submission Of Regulatory Filings [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

12 months

Acceptance Of Regulatory Filings For Substantive Review [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 months

Potential Marketing Approval One [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Potential Marketing Approval One [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Potential Marketing Approval Two [Member] | Minimum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Potential Marketing Approval Two [Member] | Maximum [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Tolmar Incorporated [Member]

Note 12 - Alliance and Collaboration Agreements (Details) [Line Items]

Maximum Loan Amount Pursuant to Loan and Security Agreement

15,000,000

15,000,000

Loans Receivable, Net

$15,000,000

$15,000,000

Note_12_Alliance_and_Collabora3

Note 12 - Alliance and Collaboration Agreements (Details) - Additions To And Deductions From The Deferred Revenue Under The Teva Agreement (Teva Pharmaceutical Industries Limited [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Teva Pharmaceutical Industries Limited [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Beginning balance	$1,087,000	$2,396,000	$3,705,000
Less amounts recognized	-1,087,000	-1,309,000	-1,309,000
Ending deferred revenue		$1,087,000	$2,396,000

Note_12_Alliance_and_Collabora4

Note 12 - Alliance and Collaboration Agreements (Details) - Additions To And Deductions From Deferred Revenue Under The Joint Development Agreement With Valeant (Valeant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valeant [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Beginning balance	$1,825,000	$3,650,000	$12,410,000
Less amount recognized	-1,825,000	-1,825,000	-8,760,000
Ending deferred revenue		$1,825,000	$3,650,000

Note_13_Employee_Benefit_Plans1

Note 13 - Employee Benefit Plans (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 01, 2015	Feb. 28, 2001
Note 13 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	25.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan Employers Discretionary Profit Sharing and Matching Contributions Vesting Period	3 years
Defined Contribution Plan, Cost Recognized (in Dollars)	$1,615,000	$1,501,000	$1,428,000
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)					500,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	15.00%
Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)	3,270,000	3,552,000	7,764,000
Deferred Compensation Arrangement with Individual Contributions by Plan Participants Percentage of Salary Maximum	75.00%
Deferred Compensation Arrangement with Individual Contributions by Plan Participants Percentage of Bonus Maximum	100.00%
Deferred Compensation Arrangement with Individual Employer Contribution Percentage	50.00%
Deferred Compensation Arrangement with Individual Employer Contribution Percentage of Eligible Salary	10.00%
Deferred Compensation Arrangement with Individual Employer Match Contributions Vesting Period	5 years
Deferred Compensation Arrangement with Individual, Employer Contribution (in Dollars)	850,000	764,000	717,000
Cash Surrender Value of Life Insurance (in Dollars)	29,241,000	25,025,000
Deferred Compensation Liability, Classified, Noncurrent (in Dollars)	25,837,000	23,940,000
Annually for First 5 Years of Employment [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Deferred Compensation Arrangement With Individual, Percentage Vested	20.00%
After 5 Years of Employment [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Deferred Compensation Arrangement With Individual, Percentage Vested	100.00%
Subsequent Event [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match				100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay				5.00%
Minimum [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Deferred Compensation Arrangement with Individual Employer Contribution Percentage of Eligible Salary	5.00%
After 3 Years of Service [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	100.00%
After 1 Year of Service [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	25.00%
After 2 Year of Service [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	50.00%
The ESPP Plan [Member]
Note 13 - Employee Benefit Plans (Details) [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	35,350	39,748	44,731
Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)	$788,000	$660,000	$829,000

Note_14_Sharebased_Compensatio2

Note 14 - Share-based Compensation (Details) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended			0 Months Ended
	Jun. 30, 2013	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 29, 2014	Dec. 31, 2011	Oct. 31, 2000	Sep. 30, 2000
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		3,042,180		3,042,180	3,770,905	4,177,221		5,073,097
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				6 years 149 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term				5 years 164 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)		$52,022,000		$52,022,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)		46,194,000		46,194,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		2,693,221		2,693,221
Share Based Compensation Arrangement by Share-based Payment Award Equity Instruments Other ThanOptions Vested and Expected to Vest Outstanding, Number		2,060,233		2,060,233
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,711,649		2,711,649
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)		49,628,000		49,628,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 40 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)				10,423,000	8,780,000	12,380,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%	0.00%
Period Following The Retirement Date For Grants Expected To Vest Which Will Vest As Of The Chief Executive Officer's Retirement Date	12 months
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost (in Dollars)	2,300,000
After Tax Share-based Compensation Effect on Earnings Per Share, Basic (in Dollars per share)		$0.20			$0.19	$0.18
After Tax Share-based Compensation Effect on Earnings Per Share, Diluted				0.2	0.19	0.17
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense (in Dollars)				6,880,000	4,829,000	4,335,000
Stock Options and Restricted Stock Awards [Member] | Minimum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Stock Options and Restricted Stock Awards [Member] | Maximum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Stock Options and Restricted Stock Awards [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Restricted Stock Awards [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		2,327,176		2,327,176	2,123,835	1,954,570		1,663,911
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding (in Dollars)		73,724,936		73,724,936
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				796,966	617,302	585,392
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value (in Dollars per share)				$21.36	$18.80	$14.72
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars)				16,959,000	11,604,000	8,614,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,449,585	1,032,924	1,015,937
Restricted Stock [Member] | Withheld for Minimum Withholding Tax Purposes [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				284,842
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value (in Dollars per share)				$27.47
Restricted Stock [Member] | President and CEO [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							150,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Fair Value (in Dollars)							3,900,000
Restricted Stock [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				796,966
Performance Shares [Member] | President and CEO [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							375,000
Minimum [Member] | President and CEO [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years
President and CEO [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)							7,600,000
President [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost (in Dollars)		$500,000
The 1999 Equity Incentive Plan [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									5,000,000	2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		35,813		35,813	50,312	115,785
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		296,921		296,921
Amended and Restated 2002 Equity Incentive Plan [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					14,950,000	11,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		3,006,367		3,006,367	3,720,593	4,061,436
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		2,327,176		2,327,176	2,123,835	1,954,570
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,298,203		2,298,203
The ESPP Plan [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		116,525		116,525

Note_14_Sharebased_Compensatio3

Note 14 - Share-based Compensation (Details) - Summary of Stock Option Activity (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of Stock Option Activity [Abstract]
Number of Shares, Options Outstanding	3,770,905	4,177,221	5,073,097
Weighted-Average Exercise Price per Share, Options Outstanding	$14.01	$12.72	$11.76
Options exercisable at December 31, 2014	2,458,207
Options exercisable at December 31, 2014	$12.89
Number of Shares, Options granted	386,600	506,000	278,500
Weighted-Average Exercise Price per Share, Options granted	$25.27	$18.06	$20.90
Number of Shares, Options exercised	-778,112	-814,177	-1,060,746
Weighted-Average Exercise Price per Share, Options exercised	$13.76	$9.28	$11.16
Number of Shares, Options forfeited	-337,213	-98,139	-113,630
Weighted-Average Exercise Price per Share, Options forfeited	$20.48	$19.51	$16.69
Number of Shares, Options Outstanding	3,042,180	3,770,905	4,177,221
Weighted-Average Exercise Price per Share, Options Outstanding	$14.78	$14.01	$12.72

Note_14_Sharebased_Compensatio4

Note 14 - Share-based Compensation (Details) - Summary of Non-vested Restricted Stock Awards (Restricted Stock Awards [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Awards [Member]
Note 14 - Share-based Compensation (Details) - Summary of Non-vested Restricted Stock Awards [Line Items]
Restricted Stock Awards, Non-vested	2,123,835	1,954,570	1,663,911
Weighted-Average Grant Date Fair Value, Non-vested	$21.13	$20.97	$17.20
Restricted Stock Awards, Granted	1,449,585	1,032,924	1,015,937
Weighted-Average Grant Date Fair Value, Granted	$25.35	$19.92	$23.41
Restricted Stock Awards, Vested	-796,966	-617,302	-585,392
Weighted-Average Grant Date Fair Value, Vested	$21.36	$18.80	$14.72
Restricted Stock Awards, Forfeited	-449,278	-246,357	-139,886
Weighted-Average Grant Date Fair Value, Forfeited	$21.47	$20.69	$19.08
Restricted Stock Awards, Non-vested	2,327,176	2,123,835	1,954,570
Weighted-Average Grant Date Fair Value, Non-vested	$23.61	$21.13	$20.97

Note_14_Sharebased_Compensatio5

Note 14 - Share-based Compensation (Details) - Stock Option Valuation Assumptions (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option Valuation Assumptions [Abstract]
Volatility (range)	40.10%		48.50%
Volatility (range)	41.70%	41.70%	49.30%
Volatility (weighted average)	40.20%	41.70%	49.10%
Risk-free interest rate (range)	0.60%	1.10%	0.90%
Risk-free interest rate (range)	1.90%	1.90%	1.00%
Risk-free interest rate (weighted average)	1.80%	1.20%	1.00%
Dividend yield	0.00%	0.00%	0.00%
Expected life (years)	6 years 25 days	6 years 69 days	6 years 69 days
Weighted average grant date fair value (in Dollars per share)	$10.45	$7.54	$9.93

Note_14_Sharebased_Compensatio6

Note 14 - Share-based Compensation (Details) - Share-based Compensation Expense (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Compensation	$20,883	$17,644	$16,303
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Compensation	2,494	2,035	2,405
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Compensation	5,072	4,885	4,658
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Compensation	$13,317	$10,724	$9,240

Note_15_Stockholders_Equity_De

Note 15 - Stockholders' Equity (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$0.01	$0.01
Preferred Stock, Shares Issued	0	0	0
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.01	$0.01

Note_16_Earnings_per_Share_Det

Note 16 - Earnings per Share (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	946,288	1,741,110	905,899

Note_16_Earnings_per_Share_Det1

Note 16 - Earnings per Share (Details) - Reconciliation of Basic and Diluted Earnings per Share (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Basic and Diluted Earnings per Share [Abstract]
Net income (in Dollars)	$120	$15,737	$35,071	$6,425	($9,622)	($180)	$5,619	$105,442	$57,353	$101,259	$55,873
Weighted average common shares outstanding	68,678,779	68,254,327	68,095,159	67,702,296	67,385,969	67,051,121	66,748,864	66,487,470	68,185,552	66,921,181	65,660,271
Effect of dilutive stock options and and restricted stock									2,344,797	1,733,857	2,744,280
Diluted weighted average common shares outstanding	70,988,328	70,715,226	70,313,491	69,938,872	67,385,969	67,051,121	68,287,948	68,178,355	70,530,349	68,655,038	68,404,551
Basic net income per share (in Dollars per share)	$0	$0.23	$0.52	$0.09	($0.14)	$0	$0.08	$1.59	$0.84	$1.51	$0.85
Diluted net income per share (in Dollars per share)	$0	$0.22	$0.50	$0.09	($0.14)	$0	$0.08	$1.55	$0.81	$1.47	$0.82

Note_17_Segment_Information_De

Note 17 - Segment Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 17 - Segment Information (Details) [Line Items]
Number of Reportable Segments	2
Number of Internally Developed Branded Pharmaceutical Product Candidate	1
Assets	$1,079,197,000	$996,923,000
Taiwan Facility [Member]
Note 17 - Segment Information (Details) [Line Items]
Assets	$126,381,000	$137,137,000

Note_17_Segment_Information_De1

Note 17 - Segment Information (Details) - Segment Information Reconciled to Consolidated Financial Results (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues, net	$131,211,000	$157,999,000	$188,121,000	$118,718,000	$100,741,000	$132,641,000	$129,631,000	$148,489,000	$596,049,000	$511,502,000	$581,692,000
Cost of revenues									283,396,000	312,202,000	299,138,000
Research and development									79,114,000	68,854,000	81,320,000
Patent litigation expense									5,333,000	16,545,000	9,772,000
Selling, general and administrative									139,390,000	120,288,000	108,470,000
Income (loss) before provision for income taxes									90,559,000	146,940,000	83,311,000
Global Division [Member]
Segment Reporting Information [Line Items]
Revenues, net	117,915,000	145,633,000	176,394,000	109,141,000	86,991,000	115,748,000	93,965,000	101,636,000	549,082,000	398,340,000	448,682,000
Cost of revenues									260,459,000	253,836,000	229,355,000
Research and development									40,927,000	41,384,000	48,604,000
Patent litigation expense									5,333,000	16,545,000	9,772,000
Selling, general and administrative									17,144,000	17,684,000	15,377,000
Income (loss) before provision for income taxes									225,219,000	68,891,000	145,574,000
Impax Division [Member]
Segment Reporting Information [Line Items]
Revenues, net	13,296,000	12,366,000	11,727,000	9,577,000	13,750,000	16,893,000	35,666,000	46,853,000	46,967,000	113,162,000	133,010,000
Cost of revenues									22,937,000	58,366,000	69,783,000
Research and development									38,187,000	27,470,000	32,716,000
Selling, general and administrative									43,307,000	44,915,000	37,896,000
Income (loss) before provision for income taxes									-57,464,000	-17,589,000	-7,385,000
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative									78,939,000	57,689,000	55,197,000
Income (loss) before provision for income taxes									($77,196,000)	$95,638,000	($54,878,000)

Note_18_Commitments_and_Contin2

Note 18 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 18 - Commitments and Contingencies (Details) [Line Items]
Operating Leases, Rent Expense	$2,162,000	$1,932,000	$1,719,000
Purchase Commitment, Remaining Minimum Amount Committed	42,627,000
Purchase Commitment Period	1 year
Taiwan Facility [Member]
Note 18 - Commitments and Contingencies (Details) [Line Items]
Contractual Obligation	$428,048

Note_18_Commitments_and_Contin3

Note 18 - Commitments and Contingencies (Details) - Future Minimum Lease Payments under Non-cancelable Operating Leases (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Lease Payments under Non-cancelable Operating Leases [Abstract]
2015	$2,348
2016	1,580
2017	990
2018	848
2019	803
Thereafter	2,584
Total minimum lease payments	$9,153

Note_19_Legal_and_Regulatory_M1

Note 19 - Legal and Regulatory Matters (Details) (USD $)	9 Months Ended	8 Months Ended	9 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Jan. 31, 2015	Mar. 31, 2014	Jan. 13, 2015	Apr. 08, 2013	Dec. 31, 2014
Note 19 - Legal and Regulatory Matters (Details) [Line Items]
Loss Contingency Patent Infringement Litigation Period Within Which Patent Holder May File Suit For Patent Infringement	45 days
Loss Contingency Patent Infringement Litigation Maximum Stay Period For Approval Of Abbreviated New Drug Application	30 months
Subsequent Event [Member] | Opana ER [Member]
Note 19 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints		11
Solodyn [Member]
Note 19 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints			15
Securities Class Actions [Member]
Note 19 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints					2
Litigation Settlement, Amount (in Dollars)				($4,750,000)		($8,000,000)

Note_20_Supplementary_Financia2

Note 20 - Supplementary Financial Information (unaudited) (Details) - Selected Financial Information (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Less:
Revenues	$131,211	$157,999	$188,121	$118,718	$100,741	$132,641	$129,631	$148,489	$596,049	$511,502	$581,692
Gross profit	60,821	84,438	109,772	57,622	34,200	48,342	58,887	57,871	312,653	199,300	282,554
Net income	120	15,737	35,071	6,425	-9,622	-180	5,619	105,442	57,353	101,259	55,873
Net income per share (basic) (in Dollars per share)	$0	$0.23	$0.52	$0.09	($0.14)	$0	$0.08	$1.59	$0.84	$1.51	$0.85
Net income per share (diluted) (in Dollars per share)	$0	$0.22	$0.50	$0.09	($0.14)	$0	$0.08	$1.55	$0.81	$1.47	$0.82
common shares outstanding:
Basic (in Shares)	68,678,779	68,254,327	68,095,159	67,702,296	67,385,969	67,051,121	66,748,864	66,487,470	68,185,552	66,921,181	65,660,271
Diluted (in Shares)	70,988,328	70,715,226	70,313,491	69,938,872	67,385,969	67,051,121	68,287,948	68,178,355	70,530,349	68,655,038	68,404,551
Global Division [Member] | Chargeback Reserve [Member]
Less:
Sales allowances goods	131,882	115,419	110,518	95,714	111,903	98,449	82,013	64,345
Global Division [Member] | Rebate Reserve [Member]
Less:
Sales allowances goods	66,685	64,442	74,079	52,054	68,363	54,530	35,649	30,572
Global Division [Member] | Other Credits [Member]
Less:
Sales allowances goods	8,288	13,449	21,571	10,671	21,639	11,919	8,312	5,160
Global Division [Member] | Rx Partner [Member]
Less:
Sales revenue net	1,028	1,447	9,204	2,435	1,841	3,016	3,668	3,114
Global Division [Member] | Other Revenues [Member]
Less:
Sales revenue net	2,028	611	3,229	589	727	1,046	539	737
Global Division [Member]
Revenue:
Sales revenue goods gross	322,707	340,379	375,269	265,850	288,315	279,441	217,721	197,956
Less:
Product returns	993	3,494	5,140	1,294	1,989	2,857	1,989	94
Sales revenue goods net	114,859	143,575	163,961	106,117	84,423	111,686	89,758	97,785
Revenues	117,915	145,633	176,394	109,141	86,991	115,748	93,965	101,636	549,082	398,340	448,682
Impax Division [Member] | Chargeback Reserve [Member]
Less:
Sales allowances goods	6,720	8,787	10,107	8,230	6,690	8,422	10,095	7,790
Impax Division [Member] | Rebate Reserve [Member]
Less:
Sales allowances goods	1,010	469	938	1,070	485	-812	-1,735	6,236
Impax Division [Member] | Other Credits [Member]
Less:
Sales allowances goods	2,074	2,261	1,654	1,853	361	-1,498	2,409	7,255
Impax Division [Member]
Revenue:
Sales revenue goods gross	23,348	23,840	24,375	20,643	21,244	22,849	48,300	69,292
Less:
Product returns	475	223	216	181	224	175	2,197	1,490
Sales revenue goods net	13,069	12,100	11,460	9,309	13,484	16,562	35,334	46,521
Sales revenue net	227	266	267	268	266	331	332	332
Revenues	13,296	12,366	11,727	9,577	13,750	16,893	35,666	46,853	46,967	113,162	133,010
Chargeback Reserve [Member]
Less:
Sales allowances goods									487,377	389,707	209,452
Rebate Reserve [Member]
Less:
Sales allowances goods									$260,747	$193,288	$111,099

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) - Valuation And Qualifying Accounts (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Valuation Allowance [Line Items]
Balance at beginning of period	$539	$553	$612
Deductions	-24	-14	-59
Balance at end of period	$515	$539	$553